1. What Arrowhead reported this morning

On September 15, Arrowhead released interim topline results from the Phase 1/2a study of ARO-DIMER-PA. The numbers below are from that release and nothing else has been presented. Fuller detail goes to a medical congress later.

ARO-DIMER-PA is one molecule carrying two payloads. One switches off PCSK9, which governs how much LDL cholesterol the blood clears. The other switches off APOC3, which governs triglycerides. Both targets are reachable through hepatic delivery, and both have been silenced before, separately, by separate drugs.

Putting two independent triggers on one conjugate, and showing that both stay active in a person, is the novel part.

The obvious reading of this morning’s release is a convenience story. Two mechanisms, one injection, a large and undertreated market. That reading is correct and it is the smaller half of what happened.

2. The number to look at is the gap

Arrowhead reported mean maximal single-dose reductions of 72 percent for PCSK9 and 88 percent for APOC3.

A sixteen point spread sounds lopsided. The right question is not whether the two numbers match each other. It is whether each one is close to what a drug built for that job alone would have delivered.

Figure 1. Reductions as reported. Comparisons to other drugs are across different trials and populations and should be held loosely.

On that test both halves did their work. APOC3 fell 88 percent, which sits in the range a dedicated APOC3 drug produces. PCSK9 fell 72 percent. Downstream, LDL cholesterol fell 54 percent from a single dose, in the range of the roughly 50 percent LDL-C lowering reported with inclisiran on its established regimen. Nothing in those numbers suggests either trigger became pharmacologically irrelevant because it traveled with the other.

Whatever competition may exist between them, neither trigger was functionally crowded out. That was the thing worth finding out, and it is the thing the release does not spell out.

Had one looked strong while the other barely moved, Arrowhead would still have had a lipid drug. What it would not have had is clean evidence that two payloads can share the architecture without one becoming materially compromised. Future dimers will still be engineering projects. They no longer begin with the unanswered question of whether two functional triggers can coexist on the architecture at all.

3. What the lipid numbers say

Downstream of the gene silencing, the numbers a cardiologist cares about came out well.

LDL cholesterol down 54 percent. Triglycerides down 73 percent. Non-HDL cholesterol down 61 percent. ApoB down 50 percent.

James Hamilton pointed at the last one and he was right to. Because each atherogenic lipoprotein particle carries one ApoB molecule, ApoB estimates the total burden of those particles rather than the cholesterol sitting inside one class of them. In a patient whose problem is both high cholesterol and high triglycerides, treating one number can leave much of that burden intact. Fifty percent off ApoB from a single injection is the number that shows most clearly how broadly the treatment reduced that burden.

The comment from Steven Nissen in the release is worth reading for what it highlights. Even with intensive statins and a PCSK9 inhibitor, substantial risk remains in these patients, and the triglyceride-rich remnants may be part of what is left. That is a cardiologist saying the current standard of care does not finish the job.

4. Why one to two is the expensive jump

Here is why this matters beyond a lipid drug, and it comes down to where the difficulty sits.

Going from zero triggers to one was solved years ago and every approved siRNA drug does it. Going from one to two asks something genuinely new. Does a single conjugate carry two different payloads to the same cells. Do both get loaded into the silencing machinery. Does one crowd out the other. Does the molecule survive being twice as complicated.

Going from two to three still raises engineering questions. A third trigger could bring new competition for the silencing machinery, new potency or chemistry constraints, new manufacturing problems. It is a different kind of question now, though. Before this morning, the open issue was whether two triggers could share one architecture and both stay functional.

That first multiplexing boundary looks crossed. The next one has not been tested.

5. What this does to a pipeline

Many of the diseases medicine struggles with are not single-target problems. They are networks, with several genes or pathways contributing at once. Building one small molecule that precisely modulates several chosen targets is extraordinarily hard. Giving a patient a separate biologic for each is technically possible and quickly becomes an exercise in dosing, toxicity, manufacturing and cost.

Worth being precise about what that does and does not mean. This is not polygenic risk in the genetic sense, where hundreds of common variants each make small contributions and there is no practical way to address the whole distributed signal with a drug. It is the narrower case where a handful of known targets in the same tissue, reachable through the same delivery chemistry, each matter, and treating one leaves the others running.

RNAi offers a different possibility. Target recognition is encoded largely in sequence, and if multiple sequences can share one delivery architecture without losing activity, multiplexing starts to look less like combination therapy and more like molecular programming. Until this morning that proposition rested on chemistry and preclinical work. Now there is a human dataset behind it.

Which makes the interesting question not what ARO-DIMER-PA does for mixed hyperlipidemia. It is which combinations Arrowhead nominates next, and whether the patent estate already tells you.

It does, partly. US-20260176631-A1 is directed to hepatic delivery platforms carrying multiple RNAi agents on one conjugate. US-20250376688-A1 is directed to PCSK9. US-12365899-B2 covers APOC3. A further filing covers dual inhibition of both targets together, which the company lists in its annual report as its APOC3 and PCSK9 dimer group. Arrowhead did not discover this morning that dimers might work and then go looking for protection. The architecture was mapped first.

6. What got de-risked, and what did not

The biological question, whether both targets can be knocked down at the same time, looks answered. The architectural question, whether two triggers can share one conjugate and both stay active, now has human evidence behind it. The major product questions remain open: dose, durability, repeat dosing, safety at the intended regimen, and eventually whether any of it prevents a heart attack.

The biggest de-risking this morning was architectural, not commercial.

Four things, and they matter more than the ones being quoted.

No time points. Mean maximal reduction is the deepest number reached, not the number three months later. For a drug meant to be given quarterly, the trough matters more than the nadir and it is not in this release.

No dose attribution. Escalation completed through 400 mg. Whether 72 and 88 came from the same dose, or whether the best PCSK9 number and the best APOC3 number came from different cohorts, changes how you read the symmetry.

No numbers per cohort. The study enrolls up to 78 subjects across single and multiple dose portions. Early cohorts are small and these are means.

The multiple dose portion is still running. Which is where a quarterly regimen actually gets defined. A single-dose result tells you the architecture works. It does not tell you what the product looks like.

One thing the release does report and this note has otherwise passed over. The most common adverse events were injection site reactions and headaches, with no drug-related serious adverse events, and escalation completed through 400 mg. That is reassuring for this stage. A small single-dose dataset cannot establish the safety profile of the repeat-dose regimen the drug would actually be given on.

Additional detail goes to a medical congress, which is where these questions get answered.

7. What I would watch from here

Whether a second dimer gets nominated in the months ahead, and what it pairs. That will be the first test of whether Arrowhead treats this morning as a one-off product or a reusable capability.

Whether the durability supports quarterly dosing when the multiple-dose data arrives.

Then whether anybody else attempts it. Arrowhead now has a human result and a patent estate around the architecture. The interesting signal over the next year is how many other companies start talking about multi-target RNAi, because that tells you whether the field thinks this generalizes.

A drug that lowers two lipids is a product. A molecular architecture that can silence two independent targets at once is a capability.

Arrowhead reported the product this morning. The capability may end up worth more.

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This note is published by BioBoyScout and is intended for informational and educational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss. All financial projections, acquisition price estimates, and valuation analyses herein are hypothetical frameworks for analytical purposes and do not represent predictions of actual outcomes. Readers should conduct their own due diligence and consult a registered investment advisor before making investment decisions. All ARO-DIMER-PA figures are from the company release of September 15, 2026, which reports interim single-dose topline results. Comparisons to inclisiran and to APOC3-targeting drugs are across separate trials with different populations and designs. Patent filings referenced are as published. The framing of the architectural problem is the author's own.

About the Author

BioBoyScout is the publishing name for Robert Toczycki, an independent biotech investment research writer based in Chicago. The BioBoyScout series publishes institutional-grade analysis of structural dynamics in RNA-class therapeutics, with particular focus on Arrowhead Pharmaceuticals’ TRiM platform and the broader competitive landscape. Robert is a registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

1. The trade nobody remembers

In July 2008 Roche bought a small Madison company called Mirus Bio for $125 million. Mirus had spun out of University of Wisconsin research in 1995 and had spent more than a decade on nucleic acid delivery, work that predates therapeutic RNAi entirely. That expertise turned out to be unusually valuable once RNAi arrived and the field ran into its defining problem, which was getting the molecule into the right cell.

The year before, Roche had paid Alnylam $331 million for access to the field. Add the milestones and the development spending and Roche had committed something close to half a billion dollars to becoming a leader in RNAi.

In 2010 they changed their minds and exited the field entirely.

Figure 1. Transaction figures as reported at the time. The 2026 market capitalization is approximate.

In October 2011 Arrowhead acquired Roche’s Madison operation. Not the technology alone, but an operating research site, its equipment, the intellectual property, the licenses from Tekmira and Alnylam, and a team of more than forty scientists.

Those figures are not comparable purchase prices and I do not want to present them as such. What they show is the scale of what Roche spent assembling a capability Arrowhead ended up inheriting.

Arrowhead paid no cash at closing. Roche took a promissory note of fifty thousand dollars and an equity stake of just under ten percent. Arrowhead subsequently recorded total purchase consideration for the transaction at roughly $5.27 million, comprising about $5.13 million in shares, the note, and a small amount assigned to contingent consideration.

That is not the same as paying nothing, and it is worth being precise. Roche also kept rights to negotiate for certain future products, milestone payments that trigger only after regulatory approval, and low single-digit royalties on some sales. The consideration was real. Much of what Roche stood to receive was contingent on success that had not happened yet, which meant Arrowhead committed very little cash at a moment when it had very little cash to commit.

Arrowhead’s own document explaining the deal said it more plainly than I could. “Fortunate to stand on these broad shoulders.”

2. The part that actually mattered

Everyone focuses on the price, which was remarkable. The more interesting question is why the team was still there to acquire.

Picture the same thing happening in Cambridge. Roche announces it is shutting its RNAi site. Forty scientists with deep delivery expertise hit the market on a Tuesday. By Friday they have offers from Alnylam, from Dicerna, from half a dozen startups, from whatever startup raised a Series A that month. The building gets subleased. The knowledge scatters across the ecosystem and stops being a platform.

Now picture it in Madison in 2011. Roche announces the same thing. Where does a delivery chemist go?

This is not a place without scientists. It is a place without competing employers, and those are entirely different problems.

There was almost nowhere local for an RNAi delivery team to go, and that may be the most important part of the story. Isolation did not make the team cheap. It made the team intact.

When Arrowhead arrived with stock and a plan, they were not recruiting forty individuals. They were acquiring a group that had worked together for years and would have been difficult to reassemble anywhere.

The handoff shows up in the personnel records. Within a month of closing, Arrowhead named David Lewis and David Rozema to run biology and chemistry in Madison. Both had held those functions under Roche, Lewis as site head and director of research, Rozema as director of delivery chemistry. The company also granted inducement options to thirty-seven selected new employees at the Madison facility. The intellectual property changed owners and a good deal of the operating organization crossed the bridge with it.

The conventional model treats talent density as the asset. Arrowhead’s history suggests the inverse can also hold. When the product is a platform rather than a molecule, talent stickiness is worth something too.

There is a way of framing that which I think generalizes beyond this company. A patent makes knowledge harder for a competitor to appropriate. Geography can make a team harder for a competitor to take apart.

The moat was never that the scientists could not leave. It was that leaving usually meant changing cities rather than changing badges, and friction is what lets an advantage last long enough to compound.

Geography did not create the capability. It gave the capability time to compound.

3. Why continuity is what compounds

A delivery platform is not a molecule and it is not a patent. It is accumulated knowledge about what works, what fails, and why, most of which never gets written down properly.

Which linker survives the bloodstream. What happens when you change the sugar. Why the third version worked and the second did not. That kind of understanding lives in the people who generated it, and it only compounds if those people keep working on the same problem together.

Boston is optimized for talent liquidity. You can staff a program in a month. You can also lose it in a month. That trade works perfectly well when the value sits in an asset. It works much less well when the value sits in accumulated organizational knowledge.

The Madison lineage was doing the reverse. Decades on the same underlying problem, across three different owners. Under Arrowhead alone, fifteen years of iteration carried that work from liver to lung, muscle, fat and brain, each step informed by the chemistry and delivery work that came before it.

For that kind of company, the ability to hire quickly matters far less than the difficulty of being raided.

4. The same distance, opposite value

Roche’s RNAi effort was spread across Madison, Kulmbach and Nutley inside a global company headquartered in Basel. Madison was not an afterthought, and it is worth correcting the easy version of this story. Roche itself described Madison and Kulmbach as centers of excellence for RNA therapeutics.

What distance did do was put the decision somewhere else. When Roche made a portfolio-level judgment to leave the field, the fate of the Madison organization was settled by people who were not in Wisconsin, and the sites in Germany and New Jersey went the same way.

Under Arrowhead the same geography produced the opposite effect. Madison went from being one node inside a global pharmaceutical company to being a core scientific operation inside a much smaller one, while the thin local labor market likely helped hold the group together long enough for that to happen.

One property, opposite effects, depending entirely on who controls the capital allocation.

5. Building outside the cluster

In December 2021 Arrowhead bought thirteen acres in the Verona Technology Park for just under three million dollars. On that land it built a GMP manufacturing plant and a lab and office building, together running to roughly three hundred thousand square feet. The investment was estimated at two hundred to two hundred fifty million at announcement. By the end of 2025, with the build-out substantially complete, Arrowhead reported costs incurred of approximately $298.5 million.

Figure 2. Figures from company announcements and the Wisconsin Economic Development Corporation.

Look at the land number again. Thirteen acres for under three million dollars. There is effectively no comparable transaction available in Cambridge or South San Francisco at anything resembling those economics.

The other half of the ledger is the direction the money flows. Verona authorized up to sixteen million in tax increment financing toward site improvements, repayable out of future tax increment. The state offered up to two and a half million in refundable credits contingent on job creation and capital spending. Neither is a check handed over at closing. Both are public money pointed at a campus Arrowhead owns.

In a place where everybody wants to be, you pay a premium to get in. In a place that wants you, they pay you to stay.

Arrowhead also owns the plant rather than renting capacity from a contract manufacturer. For a company whose platform advantage depends heavily on chemistry and delivery, having the people who make the molecule in the same organization as the people who design it is not a cost saving. It is a feedback loop.

6. The university nobody mentions

The weakest objection to Madison is that there is no talent there, and it is worth taking apart because it is simply wrong.

The University of Wisconsin has been doing serious nucleic acid science for most of a century. Har Gobind Khorana did the work there that helped crack how the genetic code turns RNA into protein, and won a Nobel for it. Howard Temin discovered reverse transcriptase there, which rewrote what everyone thought they knew about how genetic information moves, and won a Nobel for that. James Thomson derived the first human embryonic stem cell lines there.

None of that is a direct lineage into siRNA delivery and I would not pretend otherwise. What it establishes is narrower and sufficient. Madison is not a scientific wilderness, and it has not been one for a very long time.

The university also runs one of the oldest and most successful technology transfer operations in the country, the Wisconsin Alumni Research Foundation (WARF), founded in 1925. The blood thinner warfarin is named after it. Mirus Bio itself spun out of university research in 1995, which is how the delivery expertise that later became central to RNAi took root in Madison.

The state development agency put Arrowhead’s Madison research headcount at roughly two hundred ten in 2022, in a hundred and eleven thousand square foot facility, with intern and trainee pipelines into local institutions. Arrowhead has also disclosed research use of a primate colony housed at the Wisconsin National Primate Research Center, a university affiliate. That is not a company scraping for staff in a scientific vacuum. It is a company sitting inside an ecosystem.

Chris Anzalone talks about the place in the language of a relationship rather than a location decision. “A dedicated member of the biotech community in the greater Madison area” for more than a decade. “Strong local relationships.” A “productive and mutually beneficial relationship” with the local business community for many years.

That is the vocabulary of somebody who has been somewhere long enough for it to matter, which is the asset this whole paper is about.

7. The costs, which are real

None of which makes this free.

Arrowhead is a split company. The executive office is in Pasadena, the delivery chemistry and manufacturing in Wisconsin, more research in San Diego. That is a genuine organizational cost and anyone who has worked across time zones knows it.

Senior recruiting is harder. An accomplished executive who has built a life in the Bay Area will not casually move to Dane County, and Arrowhead has to pay up or wait longer to fill those roles.

The informal information flow is thinner too. In Cambridge you learn what a competitor is doing because somebody’s spouse works there. Arrowhead does not get that, which cuts both ways since nobody learns what Arrowhead is doing either.

8. What a buyer would actually be getting

This is where the argument starts mattering to anybody modeling a bid for this company.

Platform acquisitions carry a peculiar risk. The buyer can acquire every asset and still slowly lose the platform. A large company buys a small one for its capability, integrates it, moves reporting lines, folds the labs into an existing structure, and over a couple of years the people who actually held the capability in their heads take their payout and go. What is left is buildings, patents and an org chart.

Every acquirer of a platform company is really buying a bet that the people stay. The question is not what Arrowhead owns. It is what walks out the door on the Monday after closing.

In Cambridge that bet is a retention package, and retention packages have a known expiry. In Madison the bet is a fact about the map.

There is also an unusually clean natural experiment here, of a kind few platform companies can point to. The Madison organization has already been through one of the harsher versions of what an acquisition can do. Roche bought Mirus in 2008, ran the Madison organization for a little over two years, then reversed strategy and walked away from the field.

The transfer to Arrowhead did not happen until late 2011, and that gap may be the most telling part. The owner had already abandoned the field, and enough of the organization stayed coherent that somebody could still acquire it as an operating group. That is a change of ownership followed by abandonment, which is the failure mode buyers worry about, and the group came out the other side intact enough that Arrowhead retained dozens of them and put two of Roche’s own site leaders back in charge.

Most teams have never been tested. This one has been acquired, abandoned, transferred, and is still working on the same underlying problem in the same city nearly two decades on.

The corporate structure helps too, in a way that looks accidental and is worth noticing. Arrowhead keeps its executive office in Pasadena, its manufacturing and delivery chemistry in Wisconsin, and further research in San Diego. In almost any acquisition the synergies come from eliminating duplicate corporate functions, and those sit in California. A core part of what a buyer would want to preserve sits two thousand miles from the corporate functions it might want to cut.

You can take out a headquarters without anybody in a lab noticing. That is not true of a company where finance and chemistry share a cafeteria.

Which means the geography that looks inefficient in a standalone company becomes unusually efficient in an acquisition. A buyer would not need to relocate the Madison delivery organization or work out where manufacturing should live. Those questions have already been answered by the map, and the answer is Wisconsin.

Then there is the plant. Dedicated GMP capacity for this class of medicine is not easy to come by, and companies without their own remain dependent on outside manufacturers and their schedules. A buyer acquiring Arrowhead gets roughly a hundred and sixty thousand square feet of owned manufacturing built for exactly this chemistry, plus the process development group that knows how to run it. For anybody planning to launch more than one product, that is not a real estate line. It is control over a critical part of the launch schedule.

Roche had already written the playbook, which makes the Madison story stranger rather than simpler. When it acquired the rest of Genentech in 2009 it deliberately kept research and early development as an independent center in South San Francisco, explicitly to preserve the culture that had produced the pipeline. Roche understood the value of organizational continuity. A year later it simply concluded that RNAi itself no longer justified the investment, and Madison went with the decision.

The cheapest way to avoid breaking the factory is to buy one that is already standing somewhere you were never going to move it to.

9. The outpost

Chess has a square worth understanding here.

An outpost is a square deep in the opponent’s half where you can plant a knight and no enemy pawn can ever attack it. Put a knight there and it sits for the rest of the game, controlling squares, impossible to dislodge, growing more valuable with every piece that gets traded off.

The square itself is nothing special. It is a square. What makes it an outpost is that nothing can drive the piece away.

Madison is not a better place to do science than Cambridge. It is a place where a team that is already good is hard to dislodge, and over fifteen years of Arrowhead ownership that may have turned out to be the more valuable property.

The scientific lineage running through Madison can be traced through Arrowhead’s expansion out of the liver and into everything after it. The chemistry that reaches liver cells. The ligand that reaches the airway. A molecule given as a shot under the skin, now being tested in people for whether it can reach the central nervous system and silence tau.

Roche bought the team, funded it, and gave up on the field. Arrowhead took the square and never moved the piece.

Boston and South San Francisco are where you go to hire quickly. Nobody planned Madison as an alternative to either. It simply turned out that a company trying to accumulate one capability for the better part of two decades needed somewhere that would hold still.

Talent density is worth a great deal if you are building a drug. It is worth much less than continuity if you are building a factory that makes them.

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this white paper accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this white paper; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This note is provided for informational and analytical purposes only. It does not constitute investment advice, financial advice, legal advice, or a recommendation to buy, sell, or hold any security, and it is not a recommendation as to any corporate course of action. The author holds a long position in Arrowhead common stock. Past performance is not indicative of future results, and forward-looking analysis is inherently uncertain. The author and BioBoyScout are not registered investment advisors. The author assumes no obligation to update this paper. Transaction details are from contemporaneous reporting and from Arrowhead’s own disclosures and filings at the time of the 2011 acquisition. The consideration comprised a promissory note, restricted common stock, negotiation rights, post-approval milestones and royalties rather than cash at closing, recorded by the company at approximately $5.27 million. Verona campus figures reflect the single project announced in 2021, with costs incurred through December 2025 as reported by the company; incentive amounts are authorized maximums contingent on performance rather than payments received. Arrowhead also operates research facilities in San Diego and its corporate office in Pasadena. The characterization of why the Madison team remained available is the author’s interpretation and not a claim about any individual’s decisions.

About the Author

BioBoyScout is the publishing name for Robert Toczycki, an independent biotech investment research writer based in Chicago. The BioBoyScout series publishes institutional-grade analysis of structural dynamics in RNA-class therapeutics, with particular focus on Arrowhead Pharmaceuticals’ TRiM platform and the broader competitive landscape. Robert is a registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

1. Three notes, one week

Morgan Stanley, Stifel and Bank of America all published fresh commentary on Arrowhead within days of the ESC presentations. All three are positive. All three carried price objectives set earlier in the summer, at $120, $104, and $100, and none of them moved.

I read all three looking for what they disagreed about. What struck me instead was what they had in common, and it is not a disagreement at all. It is a shared limit in the tool.

2. What each of them does

Morgan Stanley runs a single discounted cash flow. That means projecting the company’s future cash and discounting it back to today, in their case at 10 percent a year with 1 percent growth after that. There is no breakdown by drug and no disclosure of what odds are being assigned to any of them. The $120 is one number produced by one model, and a reader cannot see which assumption is carrying it.

Stifel says the quiet part out loud and then does it anyway. Condulis writes that the market gives the brain program, the dual-target molecule and the two obesity assets essentially no credit. He is right. He then builds a valuation that gives those same programs what he describes as highly risk-adjusted credit, which is a polite way of saying not much. He identifies the mispricing and then only partly corrects for it.

Bank of America shows its work, which is why its note is the most useful of the three. Gerberry breaks the valuation into pieces. The APOC3 franchise, meaning the approved drug plus the wider patient population it is applying to sell into, carries about half the entire company. The partnered liver program carries 9 percent. The two obesity programs carry 6 percent.

Everything else sits in one bucket worth about a quarter of the company, marked down on the assumption that each program has less than a 30 percent chance of working.

Figure 1. Composition as described in the published note. Percentages are approximate.

Look at what is inside that quarter. The brain platform, a systemically delivered route into the central nervous system with extensive primate data and its first human clinical readout arriving this month, with a patent listing thirty-four targets behind it. The dual-target molecule reading out this month. Two inhaled antiviral programs. Whatever else has not been announced.

More than twenty clinical programs spanning liver, lung, muscle, adipose and now the central nervous system, on a delivery platform with an unusually broad tissue footprint. Half the value sits in one drug and the brain program shares a quarter-slice with everything the company has not announced yet.

3. Why this happens, and it is not carelessness

These three notes do not all use the same method, and that is part of the point. What they share is a modeling convention: value what can be modeled, discount it for risk and for time, and leave out what cannot be modeled.

The most common implementation is called risk-adjusted net present value, where you value each drug separately. Morgan Stanley instead runs one company-wide cash flow. Different arithmetic, same convention underneath.

The idea is simple and it is sound.

You take each drug, estimate the cash it would generate if it works, multiply by the odds it works, and discount the result back to today. Add up all the drugs and you have a company. A cancer drug in Phase 1 might get 10 percent odds. An approved drug gets close to 100. It is disciplined, it makes you say out loud what you are assuming, and for most biotech companies it is exactly the right tool.

The trouble starts when a company’s biggest asset is not a drug at all.

Every discount in that calculation gets applied to something that already exists. A molecule with a name, a trial running, a date on a calendar. Conventional practice has no line for the thing that produced those molecules and will produce the next twenty. An analyst could create one. Nothing in the arithmetic forbids a line for the platform, for how productively it generates candidates, or for what people call optionality, meaning the value of being able to do something you have not committed to yet. It is simply that doing so requires assumptions that are hard to defend in print. The line therefore does not get created, and the ability to invent the next drug carries no explicit value at all.

As conventionally built, risk-adjusted valuation prices the inventory and not the factory. For most biotech companies that distinction does not matter, because there is no factory.

4. Undrilled acreage

There is an industry that built a language for exactly this problem decades ago, and I think the comparison is worth walking through.

Nobody values an oil company by adding up the cash from wells that are pumping today. That would be absurd. It would price a company sitting on an enormous untapped field exactly the same as one that has already pumped its last barrel.

The industry built categories instead:

1. Wells that are producing.

2. Reserves that have been found but not yet developed, where you know the oil is there and have not built the infrastructure.

3. Prospects, which are locations the seismic work has identified as worth drilling but where nobody has drilled.

4. Then undrilled acreage, which is land you hold and have not yet surveyed.

Each of those categories can carry value, and acreage itself regularly changes hands at a price per acre. Companies pay real money for the right to drill holes that may find nothing, because the option to find something is worth something before you know.

Now put Arrowhead into those buckets.

Figure 2. Categories adapted from oil and gas reserve reporting. The mapping is illustrative.

Plozasiran is producing. Approved in five geographies and generating commercial revenue. A valuation counts it, and it should.

The clinical pipeline is discovered but not yet developed. ARO-MAPT, the dual-target molecule, the two obesity programs, zodasiran. Real trials, real timelines, with delivery demonstrated clinically for the lipid and obesity programs and preclinically for the brain one. A valuation counts these too, heavily discounted, which is reasonable.

Then it stops counting.

Here is the part I think gets missed. Arrowhead holds a patent listing thirty-four specific targets its brain delivery system is designed to carry. Not a vague ambition to work in neurology. Thirty-four named genes, written into a filing, covering Huntington’s disease, three genetic forms of ALS, four inherited ataxias, prion disease, Parkinson’s, chronic pain and more.

That number, however, is easy to run away with. A list of targets in a patent tells you what a company thinks its technology could be pointed at. It does not tell you there are thirty-four drugs sitting in a drawer somewhere. Nobody has shown that each of those genes can actually be drugged, that a molecule against it works, or that the resulting medicine would sell.

What it does establish is that somebody has done the survey work. In oil terms these are mapped prospects: locations identified as worth drilling, written down with coordinates, sitting behind a delivery route whose first human data arrive this month. That is not raw land.

They should not be valued as thirty-four drugs. Treating thirty-four identified applications of a heavily validated preclinical delivery system as carrying no explicit value today is also an assumption, and it is the one conventional modeling effectively makes.

The patent estate is the map. The brain patent is the one I have read closely. It is not the only one of its kind, and once you look at the whole estate the structure is unmistakable. It maps onto the oil categories almost exactly.

Arrowhead reports roughly 643 issued patents and 833 pending applications worldwide, across more than a hundred patent families. For the purposes of this analogy, two recurring kinds of filing matter most.

One kind claims a route into a tissue. GalNAc sugar clusters for liver. αvβ6 integrin ligands for inhaled delivery to the lung. Antibodies against the transferrin receptor, TfR1, for the central nervous system, which is the door ARO-MAPT walks through. Then skeletal muscle delivery platforms and lipid conjugates for adipose tissue, where the published titles name the tissue rather than the chemistry.

Five tissues, five dedicated delivery families, each with its own filings. That is the acreage side of the portfolio. Arrowhead is staking out the routes it intends to protect.

The second kind is target-specific. Filings aimed at a particular gene, or a defined combination of them, appearing as individual programs emerge. APOC3, ANGPTL3, alpha-1 antitrypsin, PNPLA3, HSD17B13, Lp(a), complement C3, complement factor B, XDH, factor XII, MARC1, PCSK9, INHBE and more in the liver. Alpha-ENaC, beta-ENaC, MUC5AC, RAGE, MMP7 and TSLP in the lung. DUX4 in muscle. ALK7 in adipose. MAPT in the brain. Influenza A and coronavirus for the inhaled antivirals.

Better than thirty named genes with their own filings, across five tissues plus the antiviral work.

Somebody should push back here, because listing targets in a patent is what patent attorneys do. The marginal cost of adding another contemplated target to a broad disclosure is tiny next to the cost of actually developing it. Broad biotech target lists can reflect lawyering as much as development intent, and treating one as a pipeline would be foolish.

What makes this one different is the conversion record. Arrowhead has done the same thing in tissue after tissue. Liver now has more than a dozen targets with dedicated patent filings. Lung has six. Adipose has ALK7, where the company has already shown direct knockdown in human fat tissue, and there is no obvious reason a working route stops at one gene. Arrowhead does not stake out a route and then work a single target in it. It works the ground.

That is the difference between a list and a record. A list tells you what somebody thought to write down. A demonstrated history of turning names into programs makes it reasonable to expect that at least some of the remaining names will become programs too.

Those are the wells. The brain estate is where you can actually watch one get drilled.

Several of the thirty-four have already made that trip. SOD1 sits on the brain delivery target list and has its own dedicated filings. Worth stating that ARO-SOD1 was discontinued before the planned Phase 1 study enrolled, so this is not a success story. It still progressed from a name on the platform map to dedicated IP and a clinical-stage program, which is the conversion I am pointing at. Huntingtin has made the same trip, the gene behind Huntington’s disease. MAPT has as well, which is the one reading out this month. Prospects on a map became locations somebody decided were worth drilling, and the paperwork followed them across.

That is the machine, visible in the filings. Delivery patents stake out ground. Target patents get filed as the company works through it. Better than thirty genes now have filings of their own, and the brain list still holds most of its thirty-four.

The dual-target molecule reading out this month is visible in the estate too, though the filings did not arrive in a tidy conceptual order. APOC3 had its own target filings years ago. PCSK9 came later. A separate family covers hepatic delivery platforms carrying multiple RNAi agents on one conjugate. Then a dedicated filing for dual inhibition of both targets at once, which the company lists in its annual report as its APOC3 and PCSK9 dimer group. Which patent came first is not the point. The point is that the estate holds all three layers: the individual targets, the architecture for carrying more than one at a time, and eventually the specific combined drug.

A conventional valuation counts the wells. It does not count the ground, and it does not count the fact that the company keeps walking across it.

Nearly nineteen years of assembling all of it, and little of that capability appears explicitly in a conventional valuation, because there is no individual drug to attach a probability to.

5. The best argument against me

There is a serious case on the other side.

Platform value is exactly the sort of claim that gets abused. Every biotech with two molecules calls itself a platform company. Most of them are not. The graveyard is full of delivery technologies that worked once and never again, and an analyst who declined to pay for optionality was right far more often than wrong.

Analysts cannot model what does not exist. Refusing to assign value to an unnamed future drug is not a failure of imagination. It is discipline, and the alternative is a valuation that can be justified at any number you like.

Optionality is also unfalsifiable. If I say the platform is worth several billion dollars and you disagree, neither of us can settle it. If every unnamed future target can be invoked to justify today’s price, platform analysis stops being valuation and becomes storytelling. That is a genuinely bad property for a valuation input, and I understand entirely why a professional putting their name on a published number would rather leave it out.

6. What survives that

Three things.

The blind spot comes from the convention, not from a judgment that the platform is worthless. Three firms took different routes and arrived in the same neighborhood. That is not three analysts independently concluding the pipeline is worth little. It is a shared convention that tends to arrive there by construction, because standard practice gives the arithmetic nowhere to put platform optionality unless an analyst deliberately builds a separate category for it.

The analysts themselves know it. Stifel wrote that the market gives these programs no credit. That is not a stray observation. His own model then gives them some heavily risk-adjusted value, but only partly repairs the gap he had just identified. When somebody identifies a pricing failure and then only partly corrects for it in the same document, the constraint is more likely in the framework than in the analyst.

There is a third thing, and I hold it more loosely. Acquirers run these calculations too, so the difference is not that they use a different arithmetic. It is that a strategic buyer can pay for things a published asset-by-asset model has no room for, including competitive position, what the target denies a rival, and what the organization might produce next. When Roche bought the rest of Genentech it paid roughly $46.8 billion for the 44 percent it did not own, implying a total above $100 billion.

Genentech had enormous approved products by then, so I would not claim Roche was paying purely for the engine. What is more suggestive is what Roche chose to preserve after buying the rest. Genentech research and early development continued as an independent center inside Roche, explicitly to protect the culture and the research approach that had generated the pipeline. Roche bought the products. It also took unusual steps not to break the factory.

Everything described so far is public. A pharmaceutical company can pull the same patents, study the same conversion record and reach its own view about what the remaining ground is worth. The asymmetry does not require privileged information.

What differs is the burden of explanation. A buyer can debate a platform premium internally. An analyst who lets the same assumption materially move a published price target has to explain it to clients and live with it in the model months later.

The buyer still faces diligence, return hurdles, integration risk and internal approval, and a serious bidder may later see things public investors never do. None of that is needed to notice the optionality in the first place.

That is the strange part. The value does not have to be concealed to be hard to express. It can simply sit in a category that published research handles awkwardly and a private strategic judgment handles more comfortably.

7. What better would look like

Not a bigger number. A visible one.

If a note showed each asset separately with its own probability of success attached, a reader could argue with the pieces. If it carried a line, even a small one, for programs the company has demonstrated it can generate but has not yet named, a reader could argue with that too. The number might come out lower than $100. That would be fine.

Somebody is going to ask what a platform line would even be built out of, and that is a fair question. It does not require pretending thirty-four drugs already exist. It could start with things that are actually observable: how often this company has produced a clinical candidate, how long each one took, how reliably its delivery chemistry has carried from one target to the next inside a tissue, and what a program has historically been worth once it reaches the clinic.

Then discount all of it heavily, because the targets are unnamed and most of them will fail.

The point is not the number that comes out. The point is that zero is a number too, and for programs that have not yet been named and modeled, it is the one conventional practice uses by default.

The problem is not that the resulting values are too low. It is that when half the value sits in one drug and the entire brain franchise is inside a bucket labelled everything else, there is nothing specific to disagree with.

That standard should apply to my own work as much as anybody’s. When I put a number on Arrowhead in an acquisition context, I showed three possible buyers, what each could afford, what holds each of them back, and how a contested sale would end up setting the price. Anyone who thinks I am wrong can say which of those is wrong. That is the bar, and I would rather be visibly wrong than opaquely right.

8. Why this matters right now

Two readouts land this month. One asks whether a single molecule can switch off two genes at once. The other asks whether a shot under the skin can switch off a gene inside a living human brain.

Both of those sit inside the 25 percent bucket.

If they work, the thing that changed is not that two drugs got better odds. DIMER working tells you something about DIMER and something about whether Arrowhead can build molecules that hit two targets at once as a general matter. MAPT working tells you something about MAPT and something about whether a shot under the skin can produce meaningful target knockdown in the human central nervous system at all.

A drug readout updates the probability of one drug. A platform readout updates the probability distribution of drugs that do not exist yet. Conventional models naturally register the first and usually leave the second implicit.

The market finds out this month whether the land has oil under it. The question is whether the models treat that as information about two wells, or as information about the field.

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This note is published by BioBoyScout and is intended for informational and educational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss. All financial projections, acquisition price estimates, and valuation analyses herein are hypothetical frameworks for analytical purposes and do not represent predictions of actual outcomes. Readers should conduct their own due diligence and consult a registered investment advisor before making investment decisions. Patent counts reflect the author's review of Arrowhead patent families, with each target family counted once regardless of jurisdiction or continuation. Valuation methodologies and composition figures are as described in published research notes from Morgan Stanley, Stifel and Bank of America following the ESC Congress, and percentages are approximate. Nothing here should be read as a criticism of any individual analyst's competence or integrity. The Genentech transaction value is as reported at the time.

About the Author

BioBoyScout is the publishing name for Robert Toczycki, an independent biotech investment research writer based in Chicago. The BioBoyScout series publishes institutional-grade analysis of structural dynamics in RNA-class therapeutics, with particular focus on Arrowhead Pharmaceuticals’ TRiM platform and the broader competitive landscape. Robert is a registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

1. What happened

Novartis announced this afternoon that its big Lp(a) trial failed. Across 8,323 patients with established cardiovascular disease and high Lp(a), pelacarsen failed to reduce the combined risk of cardiovascular death, heart attack, stroke and urgent coronary procedures versus placebo.

Read the next sentence of their release carefully, because it is the whole story. Lower Lp(a) levels were achieved with pelacarsen.

The drug did exactly what it was designed to do. It lowered the thing. Lowering the thing did not improve outcomes in the overall study population.

2. Why this is a hypothesis failure and not a modality failure

The distinction matters and it is going to get blurred in the coverage over the next few days.

Pelacarsen is an antisense drug, which is a different chemistry from Arrowhead’s RNAi but aimed at the same job of silencing a gene’s message. Ionis discovered it and licensed it to Novartis. Nothing here says either chemistry is broken. The molecule got to the liver, reduced production of apolipoprotein(a) and kept Lp(a) low in thousands of people for years.

What failed is narrower than the target itself. HORIZON refuted the proposition that the depth and duration of Lp(a) lowering pelacarsen achieved, in this treated secondary prevention population, produces a detectable cardiovascular benefit. That is a specific claim and it is now dead. Whether Lp(a) is a viable target at all is a wider question this trial does not fully settle.

Twenty years of genetic evidence said Lp(a) causes cardiovascular disease. That evidence appears to have been right about causation and wrong about reversibility, at least in this population and at this level of lowering.

Genetics measures what happens to somebody who carries elevated Lp(a) from birth. HORIZON asked something different. It asked whether lowering it late, after atherosclerosis is already built and while statins and blood pressure drugs are doing their work, undoes enough of that accumulated history to change what happens next.

Those are not the same experiment, and causation does not guarantee reversibility. The industry has spent a long time treating them as though it did.

3. What it costs Arrowhead directly

Olpasiran is Arrowhead’s own Lp(a) drug. Arrowhead built it and licensed it to Amgen back in 2016, and Amgen is now running OCEAN(a)-Outcomes, which tests the same idea with Arrowhead’s chemistry instead of Ionis’s.

The economics are less exposed than they look, because of a decision made four years ago.

Figure 1. Amounts as disclosed in company filings and the November 2022 agreement.

In November 2022 Arrowhead sold its entire olpasiran royalty interest to Royalty Pharma for $250 million in cash, plus up to $160 million in milestones payable back to Arrowhead. The first of those, $50 million on completion of OCEAN Phase 3 enrollment, was collected in 2024.

That means $300 million has been received. The filings state plainly that Arrowhead is not obligated to repay it.

What is now in doubt is the remaining $110 million from Royalty Pharma, since both remaining triggers require an approved and selling drug, and much of the roughly $375 million in Amgen milestones still outstanding, particularly the regulatory and sales portions, which Arrowhead retained when it sold the royalty.

Arrowhead sold a royalty stream in 2022 for $250 million it never has to give back, four years before anybody knew whether the drug worked. Royalty Pharma bought the risk. This afternoon that looks like one of the better capital allocation decisions this management team has made.

I would not oversell it as foresight. Monetizing a partnered royalty to fund your own pipeline is a reasonable thing to do regardless of how the trial turns out. The trade was available to be made badly, though, and it was not made badly.

4. What happens to OCEAN(a)

Amgen almost certainly finishes. Enrollment closed in 2024, the trial runs to roughly seven thousand patients, it is event-driven, and the money is spent. Companies do not stop trials at this stage because a competitor missed.

The probability of success dropped hard this afternoon, though, and anyone telling you otherwise is selling something.

OCEAN(a) is not a carbon copy, and the differences deserve a fair hearing. It enrolled 7,297 patients at a higher Lp(a) threshold. Olpasiran produces substantially deeper suppression, above 95 percent at the higher doses in Phase 2 against roughly 80 percent for pelacarsen. Its primary composite is not identical to HORIZON. Novartis also wrote that the findings did not demonstrate reduced risk in the overall study population, which leaves the prespecified 90 mg/dL subgroup unaddressed.

Those differences are enough to keep the experiment worth running. They are not enough to pretend the prior probability has not moved. The surviving argument is that the effect needs sicker patients or deeper suppression than pelacarsen delivered, which is not absurd and is also what every program in this position says. I would want the subgroup data from the congress before giving it much weight.

5. The part that matters more than the money

Set the milestones aside. They are small against a twelve billion dollar company.

What happened this afternoon is the most expensive demonstration available that moving a biomarker is not the same as helping a patient.

Eight thousand three hundred and twenty-three people. Years of follow-up. A drug that unambiguously lowered the marker it was built to lower, in a target with two decades of human genetic evidence behind it, in a population where the marker is present in roughly one person in five. Then no demonstrated benefit.

Chess has a word for this. A refutation is a concrete demonstration that a line which looked perfectly sound actually loses. It does not mean the opening is bad or the pieces are wrong. It means that particular sequence has been worked out to the end and does not hold. Theory gets rewritten and everybody stops playing it.

This version of Lp(a) lowering was theory. Eight thousand patients was the refutation. The pieces are fine. That line is not.

6. What this should do to how you read September

Arrowhead reports first human data on ARO-MAPT at the end of this quarter or early next. The number everybody will trade on is tau reduction in cerebrospinal fluid.

That number tells you the drug got where it was going and reduced production of the protein it was built to target. That would demonstrate something RNAi has not previously established clinically, which is systemic delivery to the human central nervous system from a simple shot under the skin.

It is also exactly the kind of number pelacarsen produced.

I wrote earlier this week that a drug readout updates the probability of one drug while a platform readout updates the probability of drugs that do not exist yet. Both of those are still true. What this afternoon adds is the other half of the same idea. A biomarker readout establishes target engagement, not patient benefit, until somebody connects the two.

That connection is exactly what CELIA has begun to suggest for tau without yet establishing it. Diranersen lowered cerebrospinal tau by 50 to 65 percent and produced a clinical signal, and it missed its primary dose-response endpoint because higher doses did not produce greater benefit. For neurofilament in ALS, the FDA accepted a reduction as reasonably likely to predict clinical benefit, which is a regulatory judgment rather than a proven link. For Lp(a), Novartis has just spent eight thousand patients failing to establish that connection in the overall population.

If September delivers deep tau knockdown, that is a delivery result and it is worth a great deal to the platform. It is not, by itself, evidence that ARO-MAPT helps anybody with Alzheimer’s disease. Today is a reminder of how expensive it is to learn the difference.

7. Where that leaves things

For Arrowhead, a modest financial hit against milestones that were never in the base case, and a partnered program whose odds just got materially worse.

For Ionis, a harder afternoon. They lose the pelacarsen economics on top of already competing against plozasiran in severe hypertriglyceridemia.

For Novartis, worth watching. They face the largest patent expiry in their history and just lost a cardiovascular asset that was meant to help fill it. That does not reduce their need to buy something. It sharpens it.

For anybody holding this stock into a first-in-human CNS readout, a well-timed reminder that the number in the headline and the question that matters are not always the same number.

A Note on Supporting Independent Research

If this white paper has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,500 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this white paper accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this white paper; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This paper is provided for informational and analytical purposes only. It does not constitute investment advice, financial advice, legal advice, or a recommendation to buy, sell, or hold any security, and it is not a recommendation as to any corporate course of action. The author holds a long position in Arrowhead common stock. Past performance is not indicative of future results, and forward-looking analysis is inherently uncertain. The author and BioBoyScout are not registered investment advisors. The author assumes no obligation to update this paper. Lp(a)HORIZON details are from the Novartis release of September 4, 2026. Olpasiran deal terms are from the November 2022 Royalty Pharma agreement and Arrowhead's subsequent quarterly filings. Full Lp(a)HORIZON results have not been presented and the analysis here is based on topline disclosure only.

About the Author

BioBoyScout is the publishing name for Robert Toczycki, an independent biotech investment research writer based in Chicago. The BioBoyScout series publishes institutional-grade analysis of structural dynamics in RNA-class therapeutics, with particular focus on Arrowhead Pharmaceuticals’ TRiM platform and the broader competitive landscape. Robert is a registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

1. The presentation nobody went to

Nine in the morning on Monday, in a session called Beyond statins, a physician from Peking Union Medical College Hospital in Beijing presented the first Phase 3 results anywhere in the world for zodasiran.

It appeared in the program under Visirna’s development code, VSA003, rather than zodasiran or ARO-ANG3, the name most Arrowhead investors know it by. Arrowhead mentioned it in one sentence on its investor call an hour later. As far as I can tell, almost nobody wrote about it.

The disease is homozygous familial hypercholesterolemia (HoFH). About as rare as diseases get, somewhere between one in 170,000 and one in 300,000 people.

Here is what these patients are dealing with. Your liver clears cholesterol out of your blood using a receptor on the surface of its cells. These patients inherit defects that leave that receptor pathway severely impaired, in some cases close to nonfunctional. Statins work largely by making the liver produce more of those receptors, so in this disease there is much less receptor function to work with. Untreated, patients develop heart disease as children.

The trial enrolled 46 people in China, 30 on drug and 16 on placebo. Average starting LDL cholesterol was around 390 milligrams per deciliter. A normal number is under 100.

2. The number, and who to measure it against

LDL cholesterol dropped 44.8 percent from where patients started, and 43.9 percentage points more than placebo, at six months. ANGPTL3, the protein the drug is designed to suppress, fell 89.4 percent from baseline, which is 86.2 points more than placebo.

Two comparisons make that number mean something, and neither is obvious from the press coverage.

The first is Arrowhead’s own earlier study. A Phase 2 called GATEWAY, run in a similar population, produced a 35.7 percent LDL reduction at this same dose. The China Phase 3 beat it by about nine points.

That should get your attention. It would have been reasonable to expect some fade in a larger, properly blinded Phase 3, particularly coming off an open-label Phase 2 where everybody knew who was getting the drug. GATEWAY was open-label. This one was blinded. The effect got bigger anyway.

The second is the drug this would compete with. Evinacumab is an approved antibody for this disease, it hits the same target, and in its pivotal trial it lowered LDL by 47.1 percent from baseline. It is given by intravenous infusion, once every four weeks.

Zodasiran came in at 44.8 percent on the same measure. Roughly two points apart. It is a shot under the skin, once every three months.

Figure 1. Both figures are reduction from baseline. They come from separate trials in different populations and are not directly comparable.

3. Why those two points are worth giving up

Thirteen infusions a year against four injections. That sounds like a convenience argument until you think about who is receiving them.

This disease gets diagnosed in childhood. Treatment never stops. Plenty of these patients are also on apheresis, which is a procedure that filters cholesterol out of the blood mechanically, and it means hours hooked to a machine every week or two on top of everything else. The average patient in this trial was in their thirties. Four of them were teenagers.

An evinacumab infusion needs a clinic, an appointment, a nurse, an IV line and most of a morning, every four weeks. A quarterly injection is a fundamentally smaller procedure. Even if every zodasiran dose were given in a clinic rather than at home, that is four brief visits a year instead of thirteen infusions. Spread across forty or fifty years of treatment, that stops being about convenience.

Chess has a name for this kind of trade. Giving up the exchange means handing your opponent a rook, the more valuable piece, in return for a bishop or a knight and a better position. On the scoresheet you have lost material. Tigran Petrosian built a world championship partly on these, and for years both computers and commentators undervalued them, because material is easy to count and position is not.

Zodasiran gives up roughly two points of cholesterol lowering. It gets back nine infusion visits a year, every year, for the rest of somebody’s life. Anyone scoring this on the efficacy number alone is counting material and ignoring the position.

Worth adding: two thirds of the patients in this trial were already on a PCSK9 inhibitor, and the drug worked on top of it.

4. What the slides left out

Two things are missing from the presentation, and I think both are informative rather than sinister.

The responder rate stops at 30 percent. The trial design slide says they planned to report the share of patients who cut LDL by at least 30 percent and by at least 50 percent. The results give you the 30 percent number, which was 83.3 percent of treated patients. The 50 percent number never appears. In a deck built to show a drug at its best, the omission suggests that number was not the headline.

Goal attainment is missing too. The presentation does not report how many patients reached a specific LDL target, and a group average cannot answer that question, because patients did not all start in the same place or respond by the same amount. What the average does tell you is how brutal this disease is. The treated group started around 383 milligrams per deciliter, and even a 45 percent cut leaves the average patient well above what guidelines want for an adult with this condition. Some individuals may well have reached goal. The slides do not say how many.

This should eventually get a real answer. The global Phase 3, called YOSEMITE, lists the proportion of patients getting below 100 milligrams per deciliter as a secondary objective. It is fully enrolled at 70 patients with completion expected around the middle of 2027.

5. The liver signal

Start with the context. Overall side-effect rates were essentially identical, 76.7 percent on drug against 75.0 percent on placebo, and there were no drug-related serious adverse events at all. Against that backdrop, one thing stands out.

Three patients on drug had liver-related adverse events flagged. None on placebo did.

Two were mild elevations in a liver enzyme called AST, three to five times the normal ceiling. One was moderate, above five times, and the investigator judged it probably unrelated to the drug. All three cleared up within six weeks. Total bilirubin stayed below twice the normal ceiling in every case, and that matters: a substantial bilirubin rise alongside those enzyme elevations would raise considerably more concern for clinically significant drug-induced liver injury.

The slide separately notes two moderate drug-related events in patients whose liver enzymes were already abnormal before they started. Both were still unresolved when the database closed.

Three events in thirty patients is a small number and a real one. I would watch it rather than worry about it, and I would want the imaging. An earlier zodasiran study measured liver fat directly by MRI and found it moved in the favorable direction. This trial did no imaging at all, and that is a gap I would want closed somewhere in the broader zodasiran safety package.

One detail says somebody was paying attention. Worsening blood sugar in diabetic patients was written into the protocol in advance as something to watch for specifically. Zero events, both arms.

There was one death, sudden cardiac death in a 61-year-old woman with several risk factors, judged unrelated to treatment. In a population carrying extreme lifetime cardiovascular risk, a sudden cardiac death is unfortunately not unexpected. Somebody will still quote it without the context.

6. The number worth watching

Lipoprotein(a) came in 28.9 percentage points lower than placebo, with a p-value of 0.0016. Lp(a) is set by your genes, barely responds to anything, and independently drives cardiovascular risk. A reduction that size from a drug not designed to touch it would be genuinely interesting.

I would hold it loosely. The placebo group started with much higher Lp(a) than the treatment group, 148.8 against 116.5, which is a real imbalance in a 46-person trial. The spread around the estimate is wide. The pivotal antibody data against this same target did not show anything close to this magnitude of Lp(a) lowering.

Worth watching in the global study. Not worth building anything on yet.

7. The pattern, which is the actual story

This is the second time in two days that Arrowhead presented a Phase 3 result resting on the same foundation.

Sunday: plozasiran matched or beat an approved competitor on triglyceride lowering and offered four injections a year against that competitor’s twelve.

Monday: zodasiran came within roughly two points of an approved competitor on LDL lowering and offered four injections a year against that competitor’s thirteen intravenous infusions.

Different disease, different target, different competitor, different continent. One sentence describes both. Comparable efficacy, radically better delivery.

That is what a platform looks like when it is working. Raw potency is not the common denominator here. Efficient delivery and durability are. Arrowhead is getting a molecule where it needs to go and producing gene silencing durable enough to dose on a schedule a patient can actually live with, which is the thing that has always been hardest in this field.

8. What it is actually worth

Very little directly. Quite a lot indirectly.

The direct commercial opportunity is not the point. China has roughly 5,000 patients with this condition, and only about four percent of them are on any cholesterol-lowering therapy at all. Greater China rights are licensed to Visirna, which is Arrowhead’s majority-owned regional vehicle rather than an unrelated partner, so the economics are not entirely someone else’s. Even so, nobody should be modeling meaningful revenue off a few thousand Chinese patients.

What it buys is a positive, blinded Phase 3, run separately by Visirna in China, on the same molecule in the same indication as the global YOSEMITE program. Zodasiran has had a complicated history, and in this disease specifically, until Monday it was an asset with encouraging open-label Phase 2 data and an open question about the liver. It is now an asset with a blinded Phase 3 that beat its own Phase 2.

That does not make zodasiran approved in Arrowhead’s major commercial markets. It changes what it is reasonable to assume about the trial that would.

9. The chair

Strip out the endpoints and it comes down to something simple.

Somebody with this disease will spend their life in treatment. The question Monday answered was not whether a new drug lowers cholesterol, because the approved antibody already does that, and slightly better. The question was how much of that life has to be spent sitting in a clinic.

Arrowhead did not present a better cholesterol drug on Monday. It presented one that is nearly as good and asks for a fraction of the patient’s life. That has been the argument all week.

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This note is published by BioBoyScout and is intended for informational and educational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Trial figures come from the presentation delivered at the ESC Congress on August 31, 2026. Comparisons to GATEWAY and to evinacumab are across separate trials in different populations and are directional only. Zodasiran is investigational and has not been approved by any regulatory authority for this indication. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss. All financial projections, acquisition price estimates, and valuation analyses herein are hypothetical frameworks for analytical purposes and do not represent predictions of actual outcomes. Readers should conduct their own due diligence and consult a registered investment advisor before making investment decisions.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

1. What was actually new

The headline numbers came out on July 22. Triglycerides down 79 and 81 percent in the two studies, pancreatitis events down 78 percent, both trials hitting every goal they had set. The market has had six weeks to think about that.

Sunday added what a press release cannot fit. Who the patients were. What happened to them month by month. Which side effects showed up and how often. The details behind the averages.

Buried in there is one chart that changes how you should read the whole program, and I have not seen anyone write about it yet.

2. The chart that matters

Patients got four injections, spaced three months apart, at Months 0, 3, 6 and 9. The trial then measured its main result at Month 12.

Sit with that timing for a moment. Month 12 is three months after the last shot. That is the point in the cycle when the drug has had the longest time to wear off, in the fourth cycle of the year, when any accumulating problem would have shown up.

It is, in other words, the point in the dosing cycle where you would expect the drug to look its weakest.

Every drug looks good right after you take it. The question that decides whether a once-every-three-months schedule actually works is what the patient looks like just before the next injection is due.

Here is the answer. At Month 10, triglycerides were down 84 percent in both studies. At Month 12, they were down 79 and 81 percent.

Roughly four points given back from Month 10 to Month 12, as patients reached the end of the three-month dosing interval in the fourth cycle of treatment. That is not meaningful wear-off. That is a remarkably flat curve through the end of the quarter.

That number does real work, because olezarsen is injected monthly. Twelve shots a year against four.

Before Sunday, the advantage of quarterly dosing was mostly a convenience argument, and a slightly hand-wavy one, since nobody had shown what happens at the end of the quarter. After Sunday, the durability needed to support that schedule is demonstrated. The drug holds at the exact point in the interval where meaningful waning should have been easiest to see.

3. Head to head with olezarsen

One fact has to sit underneath this entire comparison. Olezarsen was approved by the FDA for severe hypertriglyceridemia on June 24, six days ahead of its June 30 decision date. It is on the market for this condition right now, and any read of the SHASTA data that skips that is incomplete.

A caution goes with it. These two drugs have never been tested against each other. Everything below compares separate trials, run in somewhat different populations, and olezarsen measured its main result at six months where plozasiran measured at twelve. The gaps are large enough to be informative. They are not head-to-head evidence.

How do the two drugs actually stack up?

Triglyceride lowering: plozasiran, and it is the consistency that stands out. Olezarsen ran two pivotal trials as well. In the first, its two doses lowered triglycerides 63 and 72 percent more than placebo. In the second, the same two doses managed 49 and 55 percent. Plozasiran produced 79 and 81 percent across its two trials.

Look at what happened to olezarsen’s higher dose between studies: 72 percent, then 55 percent. That is a seventeen-point swing in the same drug at the same dose. Plozasiran moved two points. Whatever explains the difference, and trial populations and placebo performance can account for a good deal of it, the contrast is striking. Plozasiran’s replication across its two studies is unusually clean.

Getting patients to a safe number: plozasiran. Percentage reduction tells only part of the story. What a doctor actually wants to know is how many patients ended up below the danger line. At Month 12, 91 and 93 percent of plozasiran patients were under 500 mg/dL, the threshold that defines severe hypertriglyceridemia. Olezarsen reported 86 percent.

More striking is the normal range. Over half of plozasiran patients got below 150 mg/dL, which is a normal triglyceride level. In one of the two placebo groups, 2 patients out of 98 managed that. Two.

Pancreatitis: olezarsen looks slightly better on paper, and I would not make much of it. Both drugs cut pancreatitis attacks sharply. Olezarsen reduced them about 85 percent, plozasiran about 78 percent. The ranges around those two estimates overlap heavily, and olezarsen enrolled roughly 1,100 patients against Arrowhead’s 757, which buys you a tighter estimate regardless of how good the drug is. The honest read is that both drugs prevent pancreatitis and neither trial can tell you which does it better.

What plozasiran did produce is a striking number in the sickest patients. Among those who had already suffered a pancreatitis attack, close to 4 in 10 on placebo had another one within the year. On plozasiran it was roughly 1 in 25. That subgroup was small, 35 placebo patients against 60 treated, so the precise figure is soft. The direction is not.

There is one matched comparison worth having, in the sickest patients of all, those above 880 mg/dL with a prior attack. Ionis reported that four such patients would need treating for a year to prevent one attack. Arrowhead reported no events at all in that group. The caveat travels with it: the subgroup was small enough that the company did not publish the underlying numbers, so the direction is more informative than the figure.

Dosing: plozasiran, and Sunday is what turned it into an argument. Olezarsen is monthly. Plozasiran is quarterly, and the Month 10 to Month 12 data show the interval genuinely holds rather than merely being claimed. Four injections a year instead of twelve is a meaningful difference in a group of patients who are already managing a lot. Between 54 and 63 percent of the people in these trials were already diabetic, and roughly two thirds were taking two or more other cholesterol drugs before they enrolled. Every additional appointment is another chance to fall off treatment.

Liver enzymes: plozasiran. Olezarsen’s label lists liver enzyme elevations among its most common side effects. SHASTA showed no meaningful liver enzyme changes compared with placebo.

Figure 1. Every figure is as reported by each sponsor. The two programs were never compared directly.

4. Two places the data are thinner than they look

Two findings deserve more scrutiny than the coverage has given them. Both happen to sit exactly where Arrowhead would most want strength.

Liver fat. The press release says a planned MRI substudy found no meaningful increase in liver fat, with a p-value of 0.70. That reads as a clean result, and it has been repeated everywhere.

The substudy had 36 patients in it. Thirteen on placebo, 23 on plozasiran, at whichever trial sites happened to have the right scanner. Liver fat went up 1.0 percent on the drug and down 0.5 percent on placebo.

The p-value was 0.70, meaning the substudy did not detect a statistically significant difference between the groups. What that number cannot tell you is whether the study was large enough to confidently rule one out.

A p-value of 0.70 in 36 patients does not establish that there is no effect. It says the study did not find one, and with a sample that small, considerable uncertainty remains around the estimate.

This matters more than it might appear. Liver fat was supposed to be the clean differentiator against olezarsen, which showed increases of roughly 2 to 4 percent that grew with dose. Arrowhead’s own chief medical officer said in June that if plozasiran turned out to show something similar, both drugs would be in the same boat.

Sunday did not settle that question. It left it open, with a number that sounds like it settled it.

Blood sugar. Side effects related to worsening blood sugar control were reported in 14.3 percent of plozasiran patients against 8.7 percent on placebo. That is the first real imbalance this program has produced.

The defense is reasonable and it is in the data. Between 54 and 63 percent of enrolled patients were already diabetic, with average HbA1c, the standard measure of blood sugar control over the preceding months, between 6.4 and 6.6 percent. This is a population already at substantial risk of worsening blood sugar, which helps put the 8.7 percent placebo rate in context. When you look at the actual measured HbA1c rather than the reported side effects, it barely moved over twelve months in either group.

A side effect somebody wrote down and a lab value that actually changed are different things, and the lab values are reassuring. Even so, a 5.6-point imbalance in a population with this much baseline diabetes is conspicuous enough that regulators and clinicians are likely to ask about it.

One more figure belongs here, since this section exists to look at the uncomfortable parts. Three deaths occurred among plozasiran-treated patients, two cardiovascular and one from chronic myelomonocytic leukemia. Investigators attributed all three to pre-existing disease and judged them unrelated to treatment. Serious side effects overall were actually lower on drug than on placebo, 8.3 percent against 10 percent, and investigators found no treatment relationship for any of the three deaths. There is no evident mortality signal here, but the events are worth stating anyway.

5. What the call added

Management restated Sunday for most of the hour. The genuinely new material came from the independent discussant, and it did not point the way Arrowhead would have chosen.

Borge Nordestgaard presented unpublished registry data from Denmark covering 3.4 million people between 2008 and 2021, none of whom had cardiovascular disease at baseline. Within them he identified roughly 29,000 with severe hypertriglyceridemia. That group produced 400 cases of acute pancreatitis and 2,000 cardiovascular events. On an incidence basis, 2 per 1,000 patient-years against 18.

Five times as many cardiovascular events as pancreatitis attacks, and nine times the rate once you account for how long people were followed, in patients who had no cardiovascular disease when the clock started. His conclusion was not that the pancreatitis work is misdirected. It was that he would like to see studies going after both diseases, and that the long-term need in this population is cardiovascular.

Arrowhead put an independent expert on its own investor call, and he used the time to point out that these patients are roughly nine times more likely to suffer a cardiovascular event than the event the label is being built around.

That cuts in both directions. On the bearish side, if payers price plozasiran purely on pancreatitis prevention, the addressable market is narrower than headline patient counts suggest. Arrowhead’s own slide identifies roughly one million high-risk patients within the roughly three million Americans with the condition, and the initial commercial focus is that high-risk segment. Management nonetheless put a three to four billion dollar annual US opportunity on the same call.

On the bullish side, plozasiran reduced remnant cholesterol by 72 to 76 percent in these trials. If the drug ever runs a cardiovascular outcomes study and that reduction translates, the opportunity is a different order of magnitude than a pancreatitis label. That remains entirely hypothetical. SHASTA was not designed to demonstrate cardiovascular benefit and does not. Nordestgaard did not say otherwise. He simply pointed at where the events actually are.

What the glycemic number actually counted. An analyst asked what the imbalance actually consisted of, and Watts answered it. The 14.3 percent was not a single measurement. It pooled several loosely related endpoints, among them impaired glucose tolerance and the need to increase antidiabetic medication. On that basis he said it is difficult to make much of a five-point difference. He described the HbA1c change as very minor, not clinically significant, and something that resolves once treatment is intensified, adding that patients typically finish these studies with better control than they started with. Nordestgaard called the safety profile excellent against the risk these patients carry.

How the strongest numbers are constructed. The high-risk numbers arrive in three tiers, and the tiers matter. Across patients with triglycerides at or above 880, or above 500 with a prior attack, the number needed to treat is nine. Among those with a prior attack regardless of triglyceride level, it is three. In the narrowest group, above 880 with a prior attack, no events occurred at all. Watts called that last analysis exploratory and said plainly that the numbers are small. The direction is more reliable than any single figure until the publication lands.

The question management would not answer. The most useful exchange on the call came from Jefferies. Maury Raycroft said his back-calculation showed an imbalance among patients without a prior pancreatitis history, with three to four events in the plozasiran arm against none on placebo, and asked whether there was anything distinctive about those patients.

Management declined, citing the pending publication, and redirected to the point that the pooled endpoint was prespecified and hit statistical significance across the whole population. Both things are true. It is also true that a reader who wants to understand where the benefit concentrates, and where it does not, will have to wait for the manuscript.

A class effect, in his words. One more thing worth recording. Nordestgaard told the call that all five drugs in this class, across every study run so far, have produced roughly an 80 percent reduction in acute pancreatitis. His word was extremely consistent. That is the strongest available argument that neither company should be claiming an advantage on this endpoint, and it came from the independent discussant rather than from either sponsor.

The question nobody asked. Watts described the result as very reassuring, Arrowhead’s commercial lead described it as no liver fat elevation relative to placebo, and the size of the study went unmentioned by anyone on the call or in the questions that followed.

The switching question, answered by the wrong people. Bank of America asked the two physicians whether they saw any barrier to switching a patient from olezarsen to plozasiran. The answers were not the ones the switching argument wants.

Watts said switching happens in practice and that the quarterly interval is a patient preference matter, allowing that it leans in plozasiran’s favor. He also predicted the more likely response to inadequate control on olezarsen is a dose increase rather than a switch, while noting that the higher olezarsen dose carries its own problems.

Nordestgaard was blunter and less helpful to the thesis. Patients who get used to a drug and are having no trouble with it, he said, tend to stay on it, absent clearly more side effects or a real price difference. He then said what he had said twice already, which is that he would rather both companies spent their effort finding the enormous number of untreated patients than fighting over the ones already on therapy.

Management took the same line, framing severe hypertriglyceridemia as an untapped market with room for both drugs rather than a share contest. That is the diplomatic answer and it may also be the correct one. It is not, however, the answer that supports a thesis built on converting a competitor’s patients.

6. The longer route

Here is where this leaves things.

Arrowhead has the better drug on triglyceride lowering, on repeating that result across two trials, on getting patients into the safe range, on dosing schedule, and on liver enzymes. It has a comparable drug on preventing pancreatitis, which is the outcome that actually matters to a patient. It gives four injections a year where the competitor gives twelve.

What it does not have is permission to sell. Olezarsen has been approved for this condition since June. Arrowhead plans to file a supplemental application by the end of 2026, expanding the label on a drug the FDA has already approved rather than seeking a first approval. It will use a priority review voucher bought on August 4, which changes the FDA’s review goal from roughly ten months to six. Filing in December on that timeline points to a decision around the middle of 2027.

Call it a year of a competitor selling into a market before you can enter it. In a specialty field with a few thousand prescribing physicians, a year is enough time for habits to form.

That concentration cuts both ways, though, and the second edge is the one people forget. A small prescriber base lets Ionis establish habits quickly. It also means Arrowhead has a finite and identifiable audience to reach when it arrives, whether by converting patients already on therapy or, as management would prefer, by bringing untreated ones into it. This is not primary care, where changing behavior means reaching tens of thousands of physicians who have never heard of the disease.

Chess has a word for what happens next. A transposition is when two games reach the same position by different move orders. One player gets there down one path, the opponent down another, and once they both arrive, the order stops mattering. What is left on the board is the position.

The analogy is imperfect in a way worth naming. In chess both players arrive at the same moment. Here, Ionis got there a year early and has been using the time.

Pharmaceutical history offers plenty of reminders that arriving first is not the same as staying ahead. Lipitor was the fifth statin to market. Keytruda entered behind Opdivo. Neither case is proof of anything about this one, since market leadership turns on far more than which molecule performs better. What travels across all of them is that physicians can switch when the product difference is real. Nordestgaard’s answer on the call is a useful warning against assuming that dosing frequency alone will move a patient who is doing perfectly well. For a patient who is inadequately controlled, unhappy with monthly injections, or starting therapy for the first time, four injections a year instead of twelve gives Arrowhead an unusually simple conversation to have with a physician.

What Sunday did was hand Arrowhead the material for that conversation. What it could not do was change the order of arrival.

Ionis got there first. Arrowhead got there better. The position on the board is what settles it, and Arrowhead simply took the longer road to reach it.

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This note is published by BioBoyScout and is intended for informational and educational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. SHASTA-3 and SHASTA-4 figures come from Arrowhead's August 30, 2026 release and the slides presented at the ESC Congress Hot Line session the same day. Olezarsen figures come from the CORE and CORE2 results published in the New England Journal of Medicine and from sponsor disclosures. Comparisons across separate trials are directional only; the two programs measured their main results at different timepoints in somewhat different populations. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss. All financial projections, acquisition price estimates, and valuation analyses herein are hypothetical frameworks for analytical purposes and do not represent predictions of actual outcomes. Readers should conduct their own due diligence and consult a registered investment advisor before making investment decisions.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

On August 24, Arrowhead confirmed that the twelve-month results from SHASTA-3 and SHASTA-4 will be presented in Munich on Sunday, August 30. The topline came out on July 22 and the stock has already digested it. A scheduling announcement is not usually worth writing about.

This one is, because two of the details in it were decided by the European Society of Cardiology rather than by the company, and both say something about how the field intends to receive this trial.

The market already has the headline. Sunday is about validation, and validation is awarded by people who do not work for Arrowhead.

Hot Line is not the same as late-breaking

The presentation is in a Hot Line session, in the Munich Auditorium, Hall B3, at 17:30 on Sunday. The session is numbered nine, which is a scheduling detail and nothing more. The two words that carry weight are Hot Line.

Congresses run a great deal of late-breaking science. Hot Line is the tier above it, and it runs alongside a separate and larger late-breaking science track. By the society’s own July announcement, this year’s Hot Line program spans twelve sessions and 59 trials. Arrowhead’s slot is in the Munich Auditorium, Hall B3, which is where the Hot Line sessions are held.

The society describes the selection in its own words. Professor Tomasz Guzik, who chairs the ESC Congress Program Committee, said this year brought a record number of late-breaking submissions, and that the committee, in his phrase, rigorously selected the studies with the greatest scientific quality and potential clinical impact.

That is an editorial judgment made by cardiologists reviewing submitted data. It is not a slot a sponsor can buy. The inference worth drawing is bounded but real: a committee that saw a record volume of submissions looked at what Arrowhead sent and put it on the main stage.

The discussant is the tell

Every Hot Line presentation is followed by an assigned discussant whose job is to place the trial in context for the field and say plainly whether it should change what physicians do.

The discussant here is Borge Nordestgaard of Copenhagen University Hospital.

That name deserves explanation for anyone who does not follow lipid research. For decades he has led the Copenhagen population studies. Much of the modern evidence that high triglycerides actually cause heart disease, rather than simply appearing alongside it, comes from that work. When guideline committees debate whether triglycerides are worth treating, his data are central to the discussion.

The society did not assign a drug-development specialist to discuss this trial. It assigned the researcher whose work established that lowering triglycerides should matter in the first place.

That is a choice about framing. It signals ESC is treating SHASTA as evidence bearing on the triglyceride hypothesis itself, not simply as a registration trial for a rare disease drug.

The presenter reinforces the same reading. Gerald Watts of the University of Western Australia has chaired international guideline work on inherited lipid disorders. Between the presenter and the discussant, the society has put two people with real influence over treatment guidelines on the same stage.

Worth noting separately: Arrowhead has both of them on its investor webcast the following morning at 8:00 Eastern, alongside management, taking questions. That does not mean the company knows what Nordestgaard will say. He is independent, and the point of a discussant is that his assessment is his own. What it does mean is that whatever he says, favorable or critical, investors will hear it directly rather than filtered through a press release.

What actually lands on Sunday

The July topline reported median triglyceride reductions of 79 and 81 percent in the two studies, a 78 percent reduction in acute pancreatitis events across the broad severe hypertriglyceridemia population, and a 100 percent reduction in the highest-risk subgroup. Both trials met their primary endpoint and all pre-specified secondary endpoints.

Sunday brings the full dataset behind those numbers, across approximately 750 randomized patients, and the specific thing worth watching is durability.

The primary endpoint is percent change in fasting triglycerides from baseline to Month 12. Patients received four doses, one every three months. Which means the twelve-month measurement is taken at the end of the fourth dosing cycle, when drug effect is at its weakest point before the next injection would be due.

Any drug can look good at peak effect. A quarterly regimen is only real if the effect is still where it needs to be at the end of the quarter, four cycles into a year of treatment. That is what this endpoint measures, and it is the number that determines whether quarterly dosing is a convenience claim or a clinical fact.

Two things not in the release

Liver fat. James Hamilton, Arrowhead’s chief medical officer, confirmed in June that liver fat data would accompany these results, and the competitive stakes are specific.

The rival drug is olezarsen, from Ionis. Both drugs switch off the same gene, APOC3, but they do it with different molecular machinery. Olezarsen is an antisense oligonucleotide. Plozasiran is an siRNA. Same target, different tools.

That distinction is the whole question. Olezarsen showed liver fat increases of roughly 2 to 4 percent that grew with dose. Plozasiran showed none at its commercial dose in mid-stage testing. If the effect comes from suppressing APOC3 itself, both drugs should eventually show it. If it is a property of the antisense chemistry, only olezarsen will. Hamilton has pointed out that another antisense drug against a different lipid target showed the same pattern, which argues for chemistry, and he has also said openly that it may be a combination of both, and that if plozasiran shows a similar increase the two drugs are in the same boat.

Sunday, across 750 patients, is where that question gets a real answer.

Pancreatitis events, case by case. Triglyceride reduction is the primary endpoint. Pancreatitis is the outcome that matters to a patient, and it was pre-specified and pooled across both studies rather than found afterward. It is also the strongest clinical claim in the program, and it rests on a process most investors never see.

A patient in one of these trials turns up at a hospital with abdominal pain. Is that an attack of pancreatitis, or something else? The answer decides whether the event counts toward a pre-specified clinical outcome, and the sponsor cannot be the one deciding. An independent committee of physicians therefore reviews each suspected case and rules on it, separately from the sponsor. The process is called adjudication, and the committee that performs it exists precisely because the company has an interest in the answer.

The full presentation should show that process, the individual events, and the statistical range around a reduction reported as 100 percent in the highest-risk group, where the total number of events is necessarily small. A 100 percent reduction on four events is a different fact from a 100 percent reduction on forty.

The presentation nobody is watching

Monday morning at 9:00 Munich time, in a session titled Beyond statins: the next wave of lipid-lowering therapies, a Phase 3 trial of zodasiran in Chinese adolescents and adults with homozygous familial hypercholesterolemia will be presented by Zhuang Tian of Peking Union Medical College Hospital.

It appears in the ESC program under the designation vsa003 rather than any name Arrowhead uses in its own materials, which is one reason it is easy to overlook.

Homozygous familial hypercholesterolemia is genuinely ultra-rare, with global prevalence estimated between one in 250,000 and one in 360,000. It is hard to treat for a specific reason. Statins and most cholesterol drugs work through a receptor on the surface of liver cells. That receptor pulls cholesterol out of the blood. These patients inherited two broken copies of that receptor, so the usual drugs have little to work with. Zodasiran switches off a different gene entirely, one that does not depend on that receptor functioning.

This is a second late-stage asset presenting late-stage data at the same congress, in a named session, and it has attracted almost no attention. Which is the smaller version of the same point this note began with. The information that moves a company is not always the information the market is looking at, and it is frequently sitting in a program listing that nobody reads.

What this week is

Nothing presented in Munich is new information in the sense that the market has not seen the headline. The topline was July 22.

What happens on Sunday is different from a data release. It is the moment a trial stops being a company announcement and becomes part of the medical literature, presented by a guideline author, assessed in public by the researcher whose own work created the question the drug was built to answer.

Approvals determine whether a drug can be sold. Congresses like this one determine whether physicians believe it should be.

Chess used to settle unfinished games the same way. When a game ran past its time limit it was adjourned, and in many competitions the result could be decided by adjudication, in which an appointed master examined the position and ruled on what it was worth. Both players had already made every move. Nothing on the board could change. What remained was a judge, appointed by the federation rather than chosen by either side, declaring in public what the position was worth.

Arrowhead has made its moves. The data are locked and the topline is five weeks old. One set of adjudicators has already done its work, quietly, ruling case by case on which hospital admissions counted. Munich supplies a different kind, who rules in public on what the whole thing means. Neither side picked either of them.

Regulators have already said plozasiran can be sold in familial chylomicronemia syndrome, the rarest form of this disease. Sunday is about the much larger population behind it, and whether cardiologists believe the drug belongs there. ESC has chosen who tells them.

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This note is published by BioBoyScout and is intended for informational and educational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss. All financial projections, acquisition price estimates, and valuation analyses herein are hypothetical frameworks for analytical purposes and do not represent predictions of actual outcomes. Readers should conduct their own due diligence and consult a registered investment advisor before making investment decisions.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

Let me save you some time. If you open the earnings release and see a big loss, do not panic, and do not celebrate the revenue jump either. This quarter ended June 30. That is before the huge SHASTA trial results, before the launch really got going, before everything that actually moved this stock. The numbers you are looking at are a photograph of a company that has already changed, so we are not going to spend much time on them.

Here is what I actually care about today, in plain terms.

1. They just paid to make their biggest approval come faster

This is the headline, and most people will walk right past it. Arrowhead bought something called a priority review voucher. Think of it as a fast-pass at the FDA. Normally the agency takes about 10 months to review a drug application. This voucher cuts that to 6.

They are going to use it on plozasiran, their triglyceride drug, to expand it to the much larger group of patients with severe hypertriglyceridemia. Here is why that matters to you as an owner: that bigger approval is by far the most valuable single thing in this company. On the call today management put a number on it, saying the broad indication could drive peak sales in the $3 to $4 billion a year range. The analysts who put a price on Arrowhead give that one approval far more weight than the small rare-disease version already on the market.

How much did they pay? The filings show $215 million for the voucher, in cash. That is a real number, not a rounding error, and they spent it to shave four months off the review of the one approval that matters most. On the call the finance chief said that moving the launch forward those four months is worth, by their own math, more than three times what they paid for the voucher, before you even count the edge of beating a competitor to market.

You do not spend $215 million to speed up an approval you are worried about. Companies hedge when they are nervous. Arrowhead just did the opposite of hedging. That tells you how they feel about their own data.

There is a quieter signal here too, for those who have followed the SHASTA story with me. People kept asking whether Arrowhead would have to wait for one more trial, SHASTA-5, before filing. Buying a fast-pass to file now is your answer. They are not waiting. On the call, asked directly whether they would shut SHASTA-5 down now, management said no, they are keeping it running to help shape the label, not because the filing needs it. That is the definition of a backup, not a gate.

2. The launch is not just starting, it is speeding up

Prescriptions for REDEMPLO roughly doubled in three months. More than 400 different doctors have now prescribed it, mostly heart-prevention and hormone specialists, and the big insurers are covering it. They also got approved to sell it in Europe and Australia during the quarter.

On the call they connected this to the bigger prize. The rare-disease launch is a dry run. The team said the broad triglyceride launch would roughly quadruple the doctors they need to reach, from about 5,000 to more than 20,000, and that they are onboarding the extra salespeople now, ahead of a possible broad launch in the second quarter of next year. In other words, they are staffing up for the big label before they even have it, which is another way of saying they expect to get it.

Why does a simple investor care about launch numbers for a small rare-disease drug? Because this is the floor under the whole stock. The exciting part of Arrowhead, the brain program, has not reported yet. While we wait for that, it matters enormously that there is a real, growing, actual business selling actual medicine in five countries underneath it. A launch that doubles in its first full quarter is that floor getting stronger.

3. Another partner is paying to use Arrowhead’s technology

This one is not today’s news, it was struck earlier in the quarter, but its revenue shows up in these numbers so it is worth a word. Arrowhead licensed one of its earlier-stage liver programs to Madrigal Pharmaceuticals. Madrigal paid $25 million up front and could pay up to $975 million more down the road, plus a cut of sales.

Forget the exact numbers. Here is the pattern that matters, and it is the same one Novartis and Sarepta showed before with much bigger checks. Other drug companies keep paying Arrowhead to use its technology, while Arrowhead keeps its best programs for itself. That is the single hardest thing to see on an earnings statement and the single hardest thing for a competitor to copy: a machine that other people will rent. One detail I enjoyed: Madrigal already licensed similar liver technology from a Chinese competitor, and it came to Arrowhead anyway.

4. The pipeline behind it kept moving

One genuinely fresh item beyond the headline. Their cholesterol drug zodasiran finished enrolling its big trial, and demand was strong enough that they raised the target from 60 to 70 patients, with results expected in mid-2027. It is a small thing on its own, but it is one more program moving forward on schedule while the main event waits in the wings.

5. The one thing I was waiting for: a date on the brain

Now the big one, and the call delivered it. Management gave a date for the first look at ARO-MAPT, the brain program: topline data in September. That is not the vague second-half-of-the-year language we had before. It is next month.

Be clear about what this readout is and is not. This first look is from the healthy-volunteer part of the study, so it is a proof-of-concept test, does the drug reach the brain, silence its target, and stay safe, rather than a result in Alzheimer’s patients showing they got better. The patient part of the study is enrolling separately. September is the moment we find out whether Arrowhead can do the thing no one has done: reach a brain target with a simple injection under the skin, instead of a needle in the spine. If that works, it does not just matter for this one drug. It validates the whole delivery platform behind a stack of other brain programs, including ones partners have already paid for.

That is the readout that could genuinely re-rate this company, and it is now weeks away, not quarters.

A quieter thing I noticed on the call

This one is a read on tone, not a fact, so take it as one investor’s ear rather than anything the company said outright. When you listen to how management talks now, they are not really asking you to value a triglyceride drug. The CEO closed by saying, in so many words, of course look at plozasiran, but also look at the engine we have built and the dozens of medicines it can produce. That is a company telling you, and telling anyone else listening, to price the factory, not the one product coming off the line.

The tell that stuck with me was on the brain program. Management noted that a good September readout would not just help this one drug, it would validate the delivery platform behind a set of other brain programs, including ones that partners have already licensed. Read that again with a big drugmaker’s deal team in mind. It says the moment this platform is proven, the partners who signed early look smart, and the window to get in before proof is closing. Companies do not usually spell that out unless they want the right people to hear it.

I want to be careful here, because it is easy to talk yourself into a takeover story, and I am not doing that. There is nothing in these remarks about a sale, a process, or a banker. What I hear is a company deliberately raising the value of its platform in the minds of both investors and potential partners, right before the event that could prove that platform is real, while keeping every option open, including going it alone. That is posture, and it is smart posture. It is not a deal. I would not want you reading it as one.

What I make of all this

Strip it down and the quarter did four good things: it made the biggest approval come faster, it showed the launch speeding up, it booked revenue from another partner paying for the technology, and it moved the pipeline forward. None of that is the brain readout, which still decides how big this story gets.

That is the setup I want heading into the fall, and I mean setup in the chess sense. A strong player does not win by grabbing a piece early. They spend the game quietly improving their position, and then, when the pieces are where they need to be, one move decides it. Arrowhead has spent this year building the position: an approved drug, a launch that works, a balance sheet that lets them wait, partners paying to use the platform. That built-up position is the base under the stock. What comes next is the move that resolves it.

September is when the pieces start to move. First data on ARO-DIMER-PA, their two-genes-in-one drug, and, more importantly to me, that first look at the brain. The brain readout is the move I am watching, because if it lands, it does not just win a piece. It changes what kind of game this is.

The quarter itself was never the point, and a recap of moves already made rarely is. The point is that the position is ready and the decisive move is finally on the board. It is next month, and I will be watching.

A Note on Supporting Independent Research

If this reaction note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909

PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This reaction note is published by BioBoyScout and is intended for informational and educational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss. All financial projections, acquisition price estimates, and valuation analyses herein are hypothetical frameworks for analytical purposes and do not represent predictions of actual outcomes. Readers should conduct their own due diligence and consult a registered investment advisor before making investment decisions. All data cited herein were sourced from publicly available company disclosures, SEC filings, press releases, and peer-reviewed literature as of August 2026. Numbers from Arrowhead's Q3 FY2026 release, quarter ended June 30, 2026. Cash and investments about $1.57 billion.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

Every argument for Arrowhead eventually rests on one claim: the platform works. That is an execution claim, and execution can be measured. This note measures it.

The headline, from Arrowhead’s own filings: 19 company-discovered drug candidates now in clinical trials, spanning Phase 1 through Phase 3, on a platform proven to deliver to 7 distinct cell types. The company spent $607 million on research and development in fiscal 2025 to run that engine. Alnylam spent roughly $1 billion. Ionis spent $916 million. Both are excellent companies, and by the estimates of their disclosed pipelines used here, neither reaches as many tissues.

In chess, development means bringing your pieces off the back rank into active play. The player who develops more pieces in fewer moves controls the board. It is the same word drug developers use, and it means very nearly the same thing.

1. Tissue breadth is the number that matters

Program counts flatter whoever runs the most trials. The harder measure is how many different tissues a company can actually deliver medicine to, because each new tissue is not one drug. It is permission to attempt every disease in that tissue.

Arrowhead’s disclosed clinical programs already span five tissues: liver, lung, muscle, adipose, and the central nervous system. The company has also disclosed that it is extending the platform into two more, ocular and cardiomyocyte, its sixth and seventh tissues, though it has not yet named targets in either. Most of the field, including the two larger peers, remains concentrated in the liver, which is the easiest destination in the body to reach and the one everyone solved first. Getting anywhere else is the hard part, and it is where Arrowhead has spent its moves. Cardiac tissue alone, once the cardiomyocyte work reaches patients, would open one of the largest untouched territories in medicine.

Figure 1. Tissue breadth against annual research spending. Bubble size is the number of clinical-stage programs. Arrowhead reaches more tissues, with a larger pipeline, on less money than either larger peer. Arrowhead is shown with 19 clinical-stage programs and seven tissues: the five in which it has disclosed clinical programs, plus ocular and cardiomyocyte, which it has disclosed it is entering. Targets in those two have not been named. Peer program and tissue counts are estimates drawn from company disclosures.

2. Tempo: the pace of getting to the clinic

Breadth is one half of the execution claim. Speed is the other, and it is the half the chess metaphor points at. In the opening, the player who develops pieces fastest dictates the game, forcing the opponent to react rather than build. Arrowhead develops quickly.

The company describes its discovery engine, in its own filings, as capable of generating multiple new clinical candidates every year, and the record bears that out: the clinical count has climbed from roughly 10 candidates a few years ago to 19 today. For context, the industry benchmark from hit identification to a nominated candidate averages 33 to 36 months, before the further stretch of studies required to reach human testing. An engine that adds multiple clinical candidates a year is running well inside the field’s typical cadence.

The most telling evidence is that a competitor pays Arrowhead for its speed. Under the Sarepta collaboration, Sarepta nominates targets and Arrowhead delivers investigational-ready constructs across six programs spanning muscle, cardiac, and central nervous system tissue. A sophisticated partner chose to outsource the distance from target to clinic to Arrowhead rather than cover it itself. That is the market pricing Arrowhead’s tempo directly, and it is the same tempo that produced ARO-033 in the registry before the market knew the program existed.

3. Why a tissue is worth more than a drug

The case for tissue expansion is usually made as a matter of ambition. It is better understood as a matter of structure. Four reasons make it the variable that decides this field.

The liver is commoditized. Every serious company in this modality cracked liver delivery years ago. That is precisely why the fight between plozasiran and olezarsen is being waged over percentage points on the same gene in the same organ: two good drugs, one destination, competing on margins. When everyone can reach a place, arriving there stops being an advantage. The only exit from that kind of competition is a tissue no one else has reached.

Most disease is outside the liver. A company that can only deliver to one organ has a ceiling on what it can ever treat, no matter how elegant its chemistry becomes. Each new tissue does not add a drug. It adds every lowerable disease in that tissue at once, which is why the list of targets Arrowhead could credibly pursue runs to hundreds rather than dozens.

Breadth is a hedge, and this is the reason most often missed. In a single-tissue company, every program shares one point of failure: if the delivery mechanism disappoints, the whole pipeline disappoints together. 7 validated tissues mean 7 substantially independent delivery problems already solved, so a setback in one does not travel to the others. That is a lower risk of ruin, not merely a wider set of chances, and it is why a broad platform deserves a different valuation framework than a deep one.

Each tissue makes the next one cheaper. Every conquest leaves behind reusable knowledge: ligand chemistry, molecules that tune how the drug moves through the body, safety experience with regulators, and a manufacturing plant whose cost is spread across everything that follows. Tissue expansion is not a series of equally expensive conquests. It gets easier as it goes. An engine that becomes more efficient the longer it runs does not converge with its competitors over time. It separates from them.

The honest objection is that focus has value too. Alnylam concentrated on the liver and has six approved products to Arrowhead’s one, which is a serious argument that depth converts to revenue sooner than breadth does. It is correct about the past decade. The question this paper raises is which approach owns the next one.

4. The cost picture, stated honestly

Divide research spending by clinical-stage programs and you get a rough cost per program: roughly $34 million at Arrowhead, and, using estimated peer program counts, on the order of $40 million at Alnylam and $46 million at Ionis. Arrowhead is leaner, though not dramatically so, and that distinction matters more than the direction of it.

The proxy is crude, and it deserves the caveats. Spending is lumpy. Programs sit at different stages, and a Phase 3 trial costs many times what a Phase 1 does. Partnered programs have some of their costs carried by Takeda, GSK, Sarepta, Amgen, Novartis, and Sanofi, which lowers Arrowhead's reported spending for reasons the counter-case takes up below. Smaller companies such as Silence and Wave spend far less in absolute terms, but they run a handful of programs across one to three tissues. Cheap alone is not the achievement.

What the numbers support is narrower and more durable than a claim of dramatic cost advantage. Arrowhead occupies the productive middle: more breadth and throughput than the small players, less spending than the large ones. It is the best combination of the two on the board.

5. Why it costs less, mechanically

Efficiency without an explanation is a coincidence. Arrowhead’s annual report supplies the mechanism. The design philosophy is to begin with a structurally simple molecule and add only the chemistry strictly necessary to achieve the required knockdown and duration. The company states plainly that its platform is built for simplified manufacturing and reduced costs. Simpler molecules take fewer synthesis steps, which makes each batch cheaper and faster to produce.

Two further structural advantages compound it. Arrowhead identifies potent RNA sequences rapidly using proprietary selection rules, which shortens the distance from target to candidate. It also manufactures in its own facility rather than queuing for slots at a contract manufacturer, which removes a bottleneck that routinely costs competitors months.

6. The proof that is audited rather than asserted

Any company can claim it executes well. Milestone payments are different, because the counterparty sets the bar, verifies the result, and pays in cash. In fiscal 2025, Arrowhead earned $300 million in milestones from Sarepta alone: $100 million when it hit the first enrollment target and won authorization to escalate dosing in the ARO-DM1 study, and $200 million when it cleared a safety committee review and reached the second enrollment target. Nobody pays $200 million for a good slide. They pay because the trial enrolled and the review cleared, on time.

Novartis then paid $200 million up front, with up to $2 billion in milestones, for a program that had not yet entered human trials. That is a sophisticated buyer pricing the engine rather than the asset.

There is a quieter piece of evidence as well. In June, a new Arrowhead candidate called ARO-033 appeared in the clinical trial registry, a placebo-controlled first-in-human study in roughly 42 healthy volunteers dosed subcutaneously. While Arrowhead has not yet officially disclosed the program’s target, research indicates it is an ocular program, most likely aimed at dry age-related macular degeneration. A candidate reached human testing before most of the market noticed it existed, which is what a running engine looks like from the outside.

On that basis the commercial logic is considerable. Dry age-related macular degeneration is a market generally sized at $3 to $5 billion, and it is underpenetrated because the approved therapies require an injection directly into the eye every one to two months. The mechanism is telling as well, since the complement proteins that drive the disease are made largely in the liver, which raises the possibility of treating an eye condition with a subcutaneous injection rather than a needle in the eye, and which fits the two complement programs Arrowhead already runs. The company has not formally confirmed the indication, so it should be held as a strong inference rather than a fact. What does not depend on it is the execution point: the engine put another candidate into humans before the market knew it existed.

7. The engine pays for itself

Here is the fact that separates Arrowhead from nearly every company running a pipeline this size. In fiscal 2025 it reported $829 million in revenue, $98 million in operating income, and $30 million in net income. It was profitable. Most companies running 19 clinical programs burn hundreds of millions and return to shareholders for more money. Arrowhead ran one of the broadest pipelines in the field, across more tissues than either larger peer, and finished the year in the black.

8. Quality, not just volume

Throughput proves the machine runs. It does not prove the output is good. For that, look at the cases where Arrowhead and a competitor pursued the identical target, which controls for the possibility that Arrowhead simply chose easier problems.

In alpha-1 antitrypsin deficiency, Arrowhead’s fazirsiran and Dicerna’s belcesiran went after the same gene. Fazirsiran published in the New England Journal of Medicine, showed a 94 percent reduction in the accumulated disease protein in the liver, produced fibrosis regression in a majority of biopsied patients, and advanced into Phase 3 with Takeda. It got further, faster. In severe hypertriglyceridemia, plozasiran and olezarsen target the same gene, and plozasiran has just delivered replicated 79 and 81 percent triglyceride reductions with a statistically significant reduction in acute pancreatitis, dosed four times a year against twelve.

One more marker of capability rather than volume: ARO-DIMER-PA is, by the company’s account, the first clinical candidate designed to silence two genes with a single molecule. The engine is not only fast. It does things the other engines have not done.

9. The honest counter-case

Four objections deserve a hearing, and one of them lands.

Alnylam has six approved products. Arrowhead has one. On cost per approval, which is the metric that ultimately matters, Arrowhead loses today and it is not close. The rebuttal is that approvals lag the engine that produces them, and Arrowhead only reached commercial stage in November of 2025. That is a real answer, but it is an answer about the future, and readers should weigh it as such.

The other three objections are weaker. Alnylam’s larger spending partly reflects a commercial organization supporting six marketed drugs, which is a different cost, not a worse one. Some of Arrowhead’s speed comes from RNAi biology in the liver rather than from management. Partnering also genuinely offloads late-stage costs, so the claim that Arrowhead would be cheaper standing alone remains unproven. That last point deserves a caveat of its own, though. Persuading Takeda, GSK, Sarepta, Amgen, and Novartis to fund your trials, pay you milestones for hitting them, and leave the wholly owned cardiometabolic, obesity, and brain programs untouched is not an accounting artifact. It is a deliberate strategy, and executing it is itself a form of efficiency.

10. What it means, and what to watch Tuesday

An acquirer buying Arrowhead is not buying 19 programs. Programs can be licensed one at a time. It is buying the machine that produced them, and machines of this kind have proven very hard to build from scratch. Novo Nordisk understood this in 2021 when it paid roughly $3.3 billion for Dicerna, acquiring an RNAi platform rather than any single approved drug, and notably paying that price for the platform even though the head-to-head program discussed above was lagging Arrowhead’s. Every large pharmaceutical company facing the patent expirations of the coming decade needs replacement revenue, and the fastest route is to buy an engine that is already running.

Arrowhead reports fiscal third quarter results on Tuesday, August 4. The quarter closed on June 30, before the SHASTA readout and before the first look at the brain program, so the financial statements are history. The engine is what to watch instead: the research spending line and what it bought, the pace of programs moving between phases, the launch of Redemplo, and above all the guidance on when the tau readout arrives. The numbers describe a quarter that has already ended. The commentary describes the machine that determines every quarter after it.

Arrowhead has developed more pieces, onto more squares, in fewer moves than anyone else on this board. Development is not the same thing as winning. It is what makes winning possible, and it is the part that cannot be improvised later.

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This note reflects the author’s personal opinions, is for informational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. Financial figures are drawn from audited annual filings. Peer program and tissue counts are estimates from public disclosures and are approximate. Cost per program is an indicative proxy, not a precise measure of development cost. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

Going back through Arrowhead’s recent public comments changed my read on one important point from my last note, enough that it deserves its own write-up. The company spoke directly about the pancreatitis question, the one everyone is watching in the coming SHASTA results, and what management said shifts how that result should be understood. Everything here comes from those public comments.

What management has said

In two public investor appearances, the RBC Capital Markets and Jefferies fireside chats, Arrowhead’s Chief Medical Officer, James Hamilton, addressed the acute pancreatitis endpoint directly, and the transcripts are on the record. He said the company is cautiously optimistic that SHASTA-3 and SHASTA-4 will actually prove a reduction in pancreatitis to the standard scientists treat as proof, and that the trials are large enough to do it based on the number of pancreatitis cases showing up so far. A quick word on what that means. To prove an effect on something, a trial needs enough of those events to occur during the study, otherwise there is too little to measure. Hamilton gave the number on those calls, the RBC Global Healthcare and Jefferies fireside chats in mid-2026: if roughly nine or more pancreatitis events occur, at rates like those seen in the company’s earlier CORE studies, that is enough to give a reliable answer. He noted, too, that the events seen so far have not fallen far outside what they expected. A word on how a company knows anything while blinded: treatment assignments stay hidden, but the company can still see the total number of adjudicated pancreatitis events piling up across the whole trial. That aggregate count, without revealing which arm the events landed in, is enough to gauge whether the trial is likely to have the statistical power it needs.

How that reframes the endpoint

This puts pancreatitis in a more precise light than the market conversation, mine included, has generally allowed. Here is the cleanest way to hold it. Triglyceride lowering is the main thing these trials were built and sized to prove, and it is widely expected to come through. Pancreatitis is a second thing they track, and whether they can prove it depends on one variable: how many pancreatitis events actually occur during the study. If enough occur, the trials can prove it. If too few occur, they cannot, no matter how well the drug works. Management is saying it believes enough will occur, and that proof on pancreatitis is genuinely within reach, not out of the question the way my first note implied.

Squaring this with the sell side

This is worth squaring with the sell side, because there is a real tension in how the pancreatitis endpoint is being described. Pancreatitis is not a vague hope hanging off these trials. It is a formally named secondary endpoint in both SHASTA-3 and SHASTA-4, an adjudicated count of pancreatitis events and related hospitalizations, assessed by an independent committee against pre-set criteria. It was built into the trials on purpose.

Against that, JPMorgan’s July 17 note, the same one that raised its price target to $95 while valuing the entire brain platform at a single dollar, carries a one-line caveat that the trials are not powered to show a pancreatitis reduction. Both things can be true, and the reconciliation is the whole point. The trials are powered first for triglyceride reduction, which is the primary endpoint. Pancreatitis is a secondary endpoint, and whether it reaches statistical significance depends on one thing: whether enough pancreatitis events happen during the study to measure a difference. The honest statement is not that the trials cannot show pancreatitis, it is that they will show it only if the event count cooperates. Management, watching the blinded event rate, is guiding that it expects it will.

There is a strong reason to take that guidance seriously, and it is the piece the sell-side framing tends to skip. Plozasiran has already hit statistical significance on pancreatitis once, in the Phase 3 FCS trial, where the reduction in adjudicated events came in at an odds ratio of 0.17 with a p-value of 0.03. The drug has demonstrably moved this endpoint in a pivotal setting before. The open question in SHASTA-3/4 is therefore not whether the drug can reduce pancreatitis, which is already on the record, it is whether the larger and somewhat less severe sHTG population will generate enough events for the effect to clear significance again. That is a question about event counts, not about whether the biology works.

Which is what makes JPMorgan’s own scenarios worth reading closely. Its best case, worth 15 to 30 percent upside, is built on proving a statistically significant pancreatitis reduction, and its middle case treats a result that falls short of significance as, in the bank’s words, perceived negatively at first, with buyers stepping in depending on the magnitude. The point is not to guess at what the analysts privately believe. It is simpler and entirely on the page: JPMorgan’s own valuation framework assigns real additional upside to a significant pancreatitis result. Whatever the caveat about powering, the endpoint plainly remains an important determinant of value in the model itself. That is consistent with what management is guiding.

Worth adding on that dollar: valuing the brain platform at a single dollar, up from the zero it carried before, concedes the platform is worth more than nothing while still pricing it at a rounding error, a tacit admission of the point I made in Zero.

Why it raises the stakes

There is a cost to management raising expectations this way, and it should not be glossed over. Guidance sets the bar, and by guiding to proof on pancreatitis, management has raised the standard the readout will be judged against. The comfortable reading from my first note, that a pancreatitis miss would just mean the trials were too small to prove it and could be shrugged off, does not survive the company itself saying it expects to prove it. The result now carries real weight in both directions: proof would be a genuine win the market is primed for, and falling short would sting more than an underpowered endpoint otherwise would, because it would miss a bar the company set for itself. Higher expectation, higher stakes.

What it clarifies about SHASTA-5

It also corrects a piece of the surrounding debate that has the logic backwards, and this part cuts in Arrowhead’s favor. SHASTA-5 is not a fallback that exists because SHASTA-3/4 cannot demonstrate pancreatitis. Per Hamilton, it is a separate, dedicated outcomes trial in high-risk patients, those with prior pancreatitis events, designed to provide even stronger, confirmatory evidence, particularly for payers. The framing that treats SHASTA-5 as the consolation study for an endpoint the main trials cannot reach is mistaken. The main trials may reach it, and SHASTA-5 is built to reinforce the case rather than to rescue it.

The real question into the readout

Strip it down and the question was never whether SHASTA-3/4 can show pancreatitis. Management has publicly guided that it believes they can. The question is whether enough pancreatitis events actually occurred during the study, which no one will know for certain until the final data is unblinded and analyzed. That is the single thing the result turns on, and it is the one to watch. Everything else, the triglyceride result almost certainly coming through, the underlying biology, the real-world case, sits on firmer ground. This is what makes the coming readout more than another triglyceride study. It is a direct test of whether Arrowhead’s confidence in the pancreatitis endpoint was warranted, a test the company chose to invite by telling the market it expects to pass.

The discipline of this work is separating what a trial can prove from what the market assumes. This update tightens exactly that line on the pancreatitis question, and it is on the record straight, ahead of the results rather than after them.

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909

PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This note reflects the author’s personal opinions, is for informational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

Robert Toczycki, JD, MBA
bioboyscout.com
bioboyscout@gmail.com
847.227.7909
X: @BioBoyScout

A pivotal readout is coming for Redemplo in severe high triglycerides, the SHASTA-3 and SHASTA-4 topline, expected within days, with the full 12-month data set for a Hot Line presentation at the European Society of Cardiology Congress in Munich in late August, the slot the congress reserves for its most practice-changing trials. Before it lands, it is worth separating what the trial was designed to measure from what the market has decided to judge it on, because those are not the same thing, and the gap between them is where the stock is most likely to be mispriced in the first hour after the results.

What the trial is built to show

One piece of vocabulary makes the whole thing clear, so here it is in plain terms. When statisticians say a trial is powered to prove something, they mean it was built big enough, with enough patients and enough time, to give a reliable yes-or-no answer on that specific question. A trial can measure a hundred things, but it is only powered to prove the one or two it was sized around. Power depends largely on how often the event happens and on how many patients are enrolled: when an event is uncommon, even a drug with a substantial effect may require thousands of patients or years of follow-up before statistical significance can be demonstrated. Measuring something is not the same as being able to prove it, and that single distinction is the entire point of this note.

The primary job of this trial is triglyceride reduction, and on that measure the bar is not really in doubt. Investors look for something above roughly 60 to 70 percent. The earlier SHASTA-2 study already delivered about 74 percent, and the main competing drug has shown triglyceride reductions in a comparable neighborhood, roughly 55 to 72 percent across its trials. Triglyceride lowering is the mechanism, it is what the drug is designed to do, and it is what this trial is powered to demonstrate. On the thing the trial was built to prove, expectations are high and, by most reckoning, likely to be met.

What the market has decided to grade

The number investors are actually fixated on is different. It is the reduction in acute pancreatitis events, the dangerous real-world consequence of very high triglycerides. The benchmark in everyone’s mind is the competitor’s headline of an 85 percent reduction in those events. That figure, worth understanding, came from a trial run in a pancreatitis-prone population and built around pancreatitis events, not from a triglyceride-sized study like this one, which is precisely why it makes an unfair yardstick for SHASTA. The reflex on results day, then, will be to compare Redemplo’s pancreatitis number against that bar and grade the drug a winner or a loser on the spot.

Here is the problem with that reflex, and it is not a subtle one. Pancreatitis is not an afterthought in these trials. It is a formally tracked outcome, the studies count pancreatitis events, related hospitalizations, and emergency visits, and they were described from the start as designed to look at whether the drug lowers both triglycerides and the rate of pancreatitis. The events are measured, in other words, and measured carefully.

What the trial can prove is a different matter, and this is the crux. The trial was sized around triglycerides, roughly 750 patients over a single year, which is enough to give a clean answer on triglyceride lowering. Pancreatitis, though, is a rare event. In a group that size over one year, only a small number of pancreatitis cases will occur at all, and that is simply too few to produce a statistically reliable result, the kind that clears the bar scientists and regulators treat as proof. The drug can genuinely reduce pancreatitis and the trial can still be unable to prove it to that standard, purely because it was not built to. Measured, yes. Powered to prove, no. Much of the print-day risk lives in that gap.

There is a clean piece of evidence that this is deliberate, and it is the most convincing detail of all. Arrowhead built a separate trial, SHASTA-5, for the specific purpose of proving a reduction in pancreatitis, enrolling only high-risk patients who have already suffered multiple pancreatitis attacks, and running for up to three years rather than one. A company does not construct a dedicated, years-long trial to prove something its main trials could already prove. The existence of SHASTA-5 is the clearest possible confirmation that SHASTA-3 and SHASTA-4 were never meant to settle the pancreatitis question. That job was handed to a different study, on purpose.

Why the distinction matters on print day

Follow that through to print day. If the pancreatitis numbers do not reach that bar of statistical proof, the quick, headline-reading reaction will be that the drug missed. That reading would be wrong, or at least badly incomplete, because you cannot miss a bar the trial was never built to clear. A pancreatitis result that falls short of formal proof, in a trial sized for triglycerides, is a feature of how the study was designed, not a verdict on whether the medicine works. What actually matters in that case is the size of the pancreatitis reduction and which direction it points, not whether it crossed a proof threshold the trial was never meant to reach.

The medical reality and the market reaction are likely to split here, and even the Wall Street analysts have quietly admitted it, noting that doctors will lean on the established biology, lower triglycerides mean fewer pancreatitis attacks, even where one trial cannot prove the reduction to a statistical certainty. Doctors treat the mechanism. Headlines grade the statistics. Those are two different audiences drawing two different conclusions from the very same result.

Figure 1: Powered to prove one thing, graded on another

The trial is sized to demonstrate triglyceride reduction, where the bar is expected to be cleared. The market will grade it on acute pancreatitis reduction, an outcome the trial is not powered to prove statistically. A significance miss on the second is a design feature, not a drug failure. Illustrative framing of the powering distinction.

How to read the result without being whipsawed

Hold three cases in advance, so the headline does not set the interpretation for you. If triglycerides clear the bar and pancreatitis shows a large reduction that also reaches significance, that is an unambiguous win, and the market will treat it as one. If triglycerides clear the bar and pancreatitis reduction is large in magnitude but short of significance, the headline may read negative for an hour, and it should not, because that is the trial doing exactly what a triglyceride-powered study does with a rare event. The number to read in that case is the size and direction of the pancreatitis effect, not whether it earned a stamp of statistical proof. Only the third case, a triglyceride result that falls short of the expected range, would be a genuine disappointment on the terms the trial was actually built to test.

The tie to the larger thesis

This is the same distinction that runs through everything I have written on this company. Separate the question a study was designed to answer from the question the market wants answered, and the mispricing usually lives in the gap. On results day the gap will sit between a triglyceride result the trial can prove and a pancreatitis result it cannot, and the first reaction is likely to judge the second as if the trial had been built to settle it.

Chess has a precise word for this situation. A player can hold a winning position, material up, the outcome not in doubt to anyone who actually reads the board, while the scoreboard still shows the game as undecided, because checkmate has not yet been forced. The impatient spectator glances over, sees no mate, and assumes nothing has happened. The player knows the win is already on the board and simply has not been delivered yet. Lower the triglycerides and you have the winning position. The forced mate, statistical proof on pancreatitis, was assigned to a different game, SHASTA-5, on purpose.

When the results land, do not ask whether Redemplo delivered checkmate in a trial that was never set up to force one. Ask whether it is winning. On triglycerides, it almost certainly is, and a winning position converts. The market may spend a headline or two confusing an undelivered mate for a lost game. That confusion is not a verdict on the drug. It is the buying opportunity.

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This note reflects the author’s personal opinions, is for informational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

Every so often an argument arrives fully assembled, made by someone with no interest in making it. This is one of those. JPMorgan published a note last week reiterating an Overweight rating on Arrowhead with a price target of $88. Inside that note is a sentence that should stop any careful reader, and a table that contradicts it.

The sentence says the brain program is the first asset in Arrowhead’s pipeline aimed at crossing the blood-brain barrier to reach the clinic, and that management expects a substantial expansion of the entire central nervous system pipeline if its first readout is encouraging. The table says that program is worth nothing.

Where the $88 comes from

A price target is not a slogan. It is arithmetic, and the arithmetic is published. Here is how JPMorgan builds its $88.

Figure 1: What JPMorgan’s $88 is made of

The stated components of JPMorgan’s December 2026 price target for Arrowhead, per share. The brain platform, the company’s most differentiated asset, appears nowhere. Composition from JPMorgan’s published note, July 2026.

Roughly $43 a share for the approved triglyceride drug in its larger indication. About $4 for the same drug in the rare disease where it is already approved. Around $5 for a second cardiometabolic drug, about $10 for the obesity programs, and roughly $12 for potential milestone payments from partners. The rest is cash, tax assets, and an unspecified remainder labeled pipeline value.

Read that list again and note what is missing. The delivery platform that lets Arrowhead put gene-silencing drugs into tissues nobody else can reach carries no line. The brain program, ARO-MAPT, carries no line. The bench of central nervous system targets behind it carries no line. The platform is not modeled conservatively. It is not modeled at all.

The contradiction, stated plainly

Hold the two halves of that note side by side. In the text, JPMorgan tells clients that the brain readout is important derisking, that it is the first blood-brain-barrier asset the company has put into humans, and that a good result triggers a substantial pipeline expansion beginning at the end of 2026. In the model, the same firm assigns that asset, that platform, and that expansion a value of zero.

Both cannot be right. Either the platform matters, in which case the price target is missing its most important input, or it does not matter, in which case the note should not describe it as a major derisking event. What JPMorgan has actually published is a valuation of Arrowhead as a cardiometabolic company that happens to own a brain platform for free.

This is not a criticism of the analyst. It is how sell-side models work, and it is precisely the mechanism I have been describing for months. A discounted cash flow can only value what it can forecast, and it cannot forecast a platform whose first human data does not exist yet. Faced with an unproven asset, the model does the only thing it knows how to do. It assigns zero and waits. The result is a price target that captures the company Arrowhead is today and none of the company it is becoming.

Zero is not the conservative answer

The defense an analyst would offer is that a model cannot value what has not read out. Set that defense against the same analyst’s own arithmetic. Roughly $10 of the $88 sits on the obesity programs, which is the right call, since those programs have already produced human data, meaningful reductions in visceral, total, and liver fat, and doubled weight loss in combination with tirzepatide. About $12 sits on milestone payments that hinge on other companies’ trials. Both are estimates of things not yet certain, and the analyst is right to make them, because making them is the job. The model is entirely willing to price an early clinical asset on a probability, right up to the moment it reaches the brain platform, where it suddenly assigns nothing. That is not caution. It is selective, and the selection lands on the single most valuable asset in the company.

The point cuts deeper than one note, because risk-adjusting unproven assets is not something biotech analysts occasionally do. It is the job. In most industries an analyst forecasts revenue that already exists. In biotechnology almost nothing exists yet, so the entire discipline is built on putting numbers on things that have not happened. Probability of technical success, phase-by-phase attrition rates, risk-adjusted net present value, probability-weighted peak sales: these are not exotic instruments. They are the daily vocabulary of the profession, and analysts rightly take pride in wielding them. Assigning a defensible number to a deeply uncertain asset is the craft itself.

A zero, in any case, is not a number the model produced. It is the number that appears when nobody enters one. There is a difference between running the calculation and arriving at something small, which is rigorous, and never creating the line item at all, which is an absence wearing the costume of an estimate. A conservative analyst would take a low probability of success, apply a modest value, and publish a small figure. That is defensible and it is honest work. Zero is not conservatism. Zero is the only output that requires no analysis whatsoever.

There is a cost to that absence, and it is not merely academic. A price target is supposed to be a forecast, which means it should already carry the probability-weighted value of events that are foreseeable. The brain readout is about as foreseeable as an event in this business gets. It is scheduled, the company has said when to expect it, the bar for success is public, and the consequences of clearing that bar are estimable within a range. A model that carries no expectation for it is not forecasting the future. It is photographing the present and putting a future date on the frame.

Notice the date on that frame. The price target runs to December 2026. The readout arrives in the fall. The target is therefore dated after the single most important event of Arrowhead’s year, and priced as though that event will not occur.

To be clear about what is and is not being argued. A stock should move sharply when a great deal is learned, and a large repricing after a genuine binary readout is the correct outcome, not a failure. What should not happen is that the repricing comes as news to the model. The purpose of risk-adjusting an unproven asset is to hold, today, a considered view of what tomorrow might bring, so that when tomorrow comes the analyst is updating a number rather than inventing one, and is not blindsided by an event that was on the calendar all along.

The fair objection is that sell-side convention often does keep early-stage and preclinical assets out of a formal discounted cash flow, handling them qualitatively in the text instead. That convention is real, and in most cases it is harmless. It stops being harmless when the excluded asset is the most valuable thing the company owns, and when the same analyst, in the same document, calls it major derisking. At that point the convention is not prudence. It is the reason the mispricing exists.

Recognize what a zero actually asserts. It is not a shrug, and it is not caution. Written down, a zero is a specific and aggressive claim: probability of success multiplied by value equals nothing. Not small. Not uncertain. Nothing. To hold that view of Arrowhead’s brain platform, an analyst must believe either that ARO-MAPT has essentially no chance of working, or that a proven subcutaneous route into the human brain would be worth nothing once it did. No analyst would say either sentence out loud, and yet the model says both.

The minimum honest answer is not a zero. It is a range. Take a probability of success, take a value if it works, multiply, and publish the number. That is the ordinary machinery of sell-side valuation, applied everywhere else in the very same note. The anchors for that estimate are not hard to find. What informed buyers have actually paid for brain access, examined below, sets a floor, and discounting those prices aggressively still does not get you to zero.

The asset is not undifferentiated guesswork either. Arrowhead has spent years removing risk from this program in ways an analyst can actually see: primate data showing roughly 50 to 60 percent knockdown in the brain sustained for months, an approved trial enrolling patients today, a partner who paid real money for a piece of the platform, and a patent estate built around the delivery route itself. The target has now been derisked as well, by someone else’s capital. Biogen’s diranersen has shown that lowering tau in the human brain produces measurable clinical benefit, which removes the most fundamental question hanging over ARO-MAPT: whether the thing it is aimed at is worth aiming at. The platform is more derisked today than it was on the day the price target was published. The valuation assigned to it has not moved.

Why this is the strongest evidence yet

For months these white papers have argued that the market prices Arrowhead’s drugs and ignores its platform. That was an assertion. This is a receipt.

Consider the source. This is not a bearish analyst reaching for reasons to be negative. It is a bulge-bracket firm that rates the stock Overweight, that recommends buying it, and that in the same document praises the brain program in the warmest terms available. Even in the mouth of a bull, the platform is worth nothing. If the most enthusiastic sell-side model in the room carries a zero in that line, ask what is actually inside the roughly $72 a share the market is paying today.

The answer is: the triglyceride franchise, the obesity programs, some milestones, and the cash. That is the whole stock. Everything these white papers have called the crown jewel, the delivery technology, the brain pipeline, the strategic scarcity that makes three large pharmaceutical companies pay attention, is being handed to buyers at no charge.

What the platform is worth to someone who has to buy it

Set the models aside and look at what strategic buyers actually pay, because they cannot afford the luxury of a zero. Novartis committed $200 million upfront and as much as $2 billion for a narrow slice of Arrowhead’s neurology work, and it did so while already owning its own liver-targeted RNAi drug and while cheap liver-focused licensing deals were freely available. It was not buying the cardiometabolic pipeline that makes up the whole of JPMorgan’s price target. It was buying access to the brain.

BioArctic makes the point sharper still. With a blood-brain-barrier delivery technology but no approved drug of its own riding on it, it has signed four separate agreements in about two years, with Bristol Myers, Novartis, Lilly, and Eisai, each worth from hundreds of millions to well over a billion dollars, for nothing more than a way across the barrier. Four large pharmaceutical companies have paid, repeatedly and in public, simply for the right to try. Arrowhead has the only platform of its kind already in the clinic, a brain drug dosing humans today, and a partner that has committed as much as $2 billion to one corner of it. Whatever the right number is, the observed evidence says it begins in the billions. Zero is not a conservative estimate of it. Zero is a placeholder for a number the model cannot generate.

Sarepta is the third data point, and it tests a different claim than the other two. Novartis and BioArctic price the value of reaching the brain. Sarepta prices the value of the platform itself, its capacity to keep producing licensable programs across tissues. In late 2024 Sarepta licensed a suite of Arrowhead’s clinical and preclinical programs spanning muscle, lung, and the central nervous system, including central nervous system targets in Huntington’s disease and the spinocerebellar ataxias. It paid $825 million immediately, $500 million in cash plus a $325 million equity stake taken at a 35 percent premium, committed a further $250 million over five years, and put up to roughly $10 billion in milestones behind the collaboration, with the right to commission six more targets from the platform on demand.

Read what that structure actually says. A sophisticated partner did not buy one drug. It bought standing access to the factory, the right to keep pulling new programs off Arrowhead’s delivery platform for years. That is the precise asset JPMorgan labels pipeline value and scores at nothing. Sarepta named the reason itself, calling Arrowhead’s approach to crossing the blood-brain barrier with a subcutaneous shot a potential paradigm shift for the central nervous system programs it was licensing. The acquiring partner identified, by name, the capability the model refuses to value. Note the honest limits: several of these programs are early, the headline figure is milestone-heavy rather than banked, and Sarepta has had its own turbulence, so the realized total will depend on execution. None of that touches the point, because the point is not what Sarepta will eventually pay. It is what an informed party agreed the platform was worth paying for in the first place, and that number was not zero. It was among the largest platform-licensing commitments in the sector.

The event that removes the excuse

Here is why this matters now rather than in the abstract. A model can carry a zero only while the asset remains unproven. The moment human data exists, the zero becomes indefensible, and every analyst carrying one has to replace it with a real number.

Arrowhead’s first human brain readout is expected late in the third quarter or early in the fourth. The bar is public: diranersen, the competing intrathecal drug, lowered tau in the spinal fluid by roughly 50 to 60 percent, and Arrowhead management has said it is looking for a comparable reduction in its own study as the mark of success. Its primate data already sits in that range, and its modeling projects sustained knockdown of 50 to 70 percent on quarterly dosing.

Consider what a positive result would do to a model like JPMorgan’s. It would not adjust an assumption. It would force the creation of a line item that does not currently exist, in a valuation where the largest single component is a triglyceride drug. Analysts do not re-rate gently when they have to build a new section of the model from nothing. That is the mechanical path from $88 to something that starts with a different digit.

What would make this wrong

Honesty requires the obvious caveat. The zero is only wrong if the platform works. If the brain readout disappoints, if the knockdown comes in well below the 50 to 60 percent bar, then the models were right to assign nothing, and the stock is roughly worth what the cardiometabolic franchise is worth. That is the risk, stated without varnish.

Note the asymmetry, though. If the platform fails, the market was correct and the stock is priced about right. If the platform works, the market is carrying a zero on the most strategically scarce asset in the sector, and it has to fix that in a hurry. Losing is being right about the price you already paid. Winning is a repricing that no model in the room is currently prepared for.

The hanging piece

Chess has a word for this. A piece is hanging when it sits on the board undefended, fully available for capture, and the player who should be watching it simply has not noticed. The piece has lost none of its value. Nobody is counting it.

That is what a zero in a valuation model actually describes. It does not say the brain platform is worthless. It says nobody has been forced to put a number on it, so the line stays empty and the position looks quieter than it is. The asset sits there in plain sight, undefended, worth exactly what it was worth before anyone bothered to look.

The trouble with a hanging piece is that it does not stay hanging. Somebody eventually looks at the board and counts it. It might be an analyst, obliged to build a line item after a readout leaves no excuse for the zero. It might be a strategic buyer who has been counting all along, which is what Novartis was doing when it wrote a check for the brain while the models were writing nothing.

What it all means

The most valuable thing Arrowhead owns does not appear in the arithmetic of the bank that recommends buying it. That is the entire thesis in a sentence, and this time it is not a claim from a letter with a position. It is published, sourced, and reiterated with an Overweight rating.

The market is not wrong about the triglyceride drug. It is not wrong about obesity, or the milestones, or the cash. It is simply not counting the road into the brain, because nothing has yet compelled it to. A price target is a bet on the company you can already see. The whole argument for owning this one rests on the company nobody has priced yet.

In chess, a piece that nobody defends is not a piece without value. It is a piece about to change hands.

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This note reflects the author’s personal opinions, is for informational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. Figures cited from JPMorgan’s published research note dated July 2026 and from company disclosures. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

Biogen presented the full Phase 2 CELIA results for diranersen at AAIC today, and by tonight every summary will have converged on the same question: does lowering tau treat Alzheimer’s disease. That is a fair question. It is not the one that moves the most value, and the gap between those two questions is where this note lives.

Two things were tested in that trial, not one, and only one of them is being talked about.

Two questions were on trial, not one

Think of a drug as a package that has to reach an address. The first question is whether the package arrives and does its job once it gets there. The second is whether that job actually helps the patient.

Those questions are worth very different amounts. A delivery answer travels. Prove that you can get a gene-silencing drug into the human brain and switch off a gene there, and you have opened the door for every drug that follows down the same road, whatever it aims at. An efficacy answer does not travel. Prove that lowering tau helps in Alzheimer’s, and you have proved exactly that, and nothing about the next target or the next disease. One answer opens a portfolio. The other adds a drug.

The market will grade the second question and shrug at the first. It has that backwards, and the rest of this note explains why.

What the data actually showed

Start with what was already public. In May, Biogen reported that CELIA missed its primary endpoint. The trial was supposed to show that higher doses worked better than lower ones, and it did not. Everything else, though, worked. Tau came down in the spinal fluid and, more impressively, tau came down in brain scans, at every dose, and it stayed down. Patients declined more slowly at every dose. The oddity: the best result came at the lowest dose, 60 mg given every 24 weeks, while the most serious side effects showed up at the highest dose. Biogen is pushing ahead to final-stage trials anyway.

Today’s presentation filled in the numbers, and they are better than the May summary implied. Tau in the spinal fluid fell by 50 to 65 percent across the dose arms by week 72, and tau also came down on brain scans in every brain region they looked at. No tau drug had ever moved both of those measures at once in a study this size. On the patient side, the winning dose slowed the decline of the disease by 26 percent, a difference of 0.54 points, on the main scale doctors use to track cognition and daily function, and by 42 and 50 percent on two pure memory-and-thinking tests. For scale, Leqembi, the amyloid drug already approved and on the market, slowed decline by 27 percent on that same main scale. A tau drug just matched an approved Alzheimer’s drug, and beat it on the thinking tests.

Then comes the detail almost no one will write about. Diranersen is injected into the spinal canal, a lumbar puncture, the same procedure people call a spinal tap. The three most common side effects in the whole trial were pain from the procedure, post-puncture syndrome, and confusion in the days right after dosing. Two of those three are the needle rather than the medicine, and the cleanest evidence for that is the placebo group: 57.9 percent of the patients who received no drug at all still had an adverse event attributed to the injection procedure. Fifty-eight percent, from the needle alone.

The third one, confusion, is more interesting, and it is not procedural. Every arm in the trial received an intrathecal injection every 12 weeks, drug or placebo, so the number of punctures was identical no matter which group a patient landed in. Confusion nonetheless grew more common the more drug a patient received. A side effect that tracks the dose cannot be caused by a procedure that does not vary with the dose. It is not the puncture. It is what the puncture delivers, and the concentration spike a bolus into the spinal fluid creates. Biogen also confirmed that this class does not carry the brain swelling and small bleeds that come with the amyloid drugs, because that risk belongs to the amyloid approach, not the tau one.

The full safety table adds something the May topline concealed. Harm climbed with dose while benefit did not. Side effects that Biogen’s own investigators judged related to the treatment affected 24.6 percent of the placebo group, then 37.7 percent at the winning low dose, 40.9 percent at the middle dose, and 57.8 percent at the highest dose, rising at every step. Serious side effects judged related to treatment ran from zero on placebo to 10.3 percent at the top dose, though not in a straight line, since the middle dose came in slightly below the low one. Set the exception aside and the shape is unmistakable. The most harm was concentrated in the arm that received the most drug, and Biogen’s own words for what that arm delivered in return were a lower effect size at the higher dose levels.

Figure 1: Level on the global scale, ahead on cognition, absent on function

Slowing of decline versus placebo at 18 months, as compiled by Biogen. Diranersen figures are the 60 mg every-24-weeks arm from the Phase 2 CELIA study (nominal significance, 60 patients); lecanemab and donanemab figures are from their Phase 3 trials (roughly 900 patients each). NR indicates the endpoint was not reported for that trial. Cross-trial comparisons are illustrative, not head-to-head. Source: Biogen AAIC 2026 investor presentation, July 14, 2026.

How it stacks up against the amyloid drugs

The comparison everyone will want, and almost no one will run properly today, is diranersen against the approved amyloid antibodies. Run it carefully, because the honest version is more interesting than the cheerleading one.

Take the main scale first, the one regulators weigh most heavily, which measures cognition and daily function together. Diranersen slowed decline by 26 percent at its best dose. Leqembi slowed it by 27 percent. Kisunla, the other approved amyloid drug, managed 29 percent. The tau drug therefore landed level with both approved drugs on the measure that matters most. On the pure thinking-and-memory tests, the picture tilts. Diranersen slowed decline by 42 percent where Leqembi managed 26 percent and Kisunla managed 20 percent, and it produced a 50 percent effect on a standard memory test where Kisunla managed 16 percent. On the two composite scales that blend cognition and function, diranersen scored 23 percent on ADCOMS against Leqembi’s 24, and 30 percent on iADRS against Kisunla’s 22, the only scales on which each of those drugs reported. On cognition alone, the tau drug looks better than the drugs already on pharmacy shelves. Everywhere else, it looks like a peer.

There is one column where it does not look like a peer, and Biogen printed it without comment. On the standalone measure of daily functioning, the ability to manage money, drive, keep up hobbies, diranersen showed zero separation from placebo. Leqembi showed 36 percent on that instrument. Aducanumab, in the trial that worked, showed 42 percent. Zero is not a small number. Daily functioning is what families actually feel, and it is a large part of what regulators are buying when they approve an Alzheimer’s drug.

Biogen’s answer to that, and it is a real answer rather than a dodge, is that the functional subdomains inside the main scale did move. Community affairs slowed by 21 percent, home and hobbies by 24 percent, personal care by 29 percent. Two instruments measuring roughly the same thing disagreed, and the one Biogen highlighted is the one that agreed with the drug. That may be noise in a 60-patient arm. It may be a real gap between what a clinician observes and what a caregiver questionnaire captures. It cannot be waved away, and it is the single largest hole in the registrational case.

Four further caveats keep this from being a victory lap. This is a mid-stage result resting on 60 patients in the winning group, the smallest arm in a study that put nearly twice as many patients in each of the others, against late-stage trials with roughly 900 patients each, and effects of this kind shrink more often than they grow when the trial gets bigger. The brain-scan substudy at the winning dose rested on 19 patients at baseline and 16 at the end. The statistics behind diranersen’s numbers are softer, too, held to a looser standard than the approved drugs were. The winning arm also entered the trial carrying less amyloid and fewer double copies of the highest-risk Alzheimer’s gene than the arms it beat, which is the kind of imbalance that can flatter a result. In fairness, it cuts both ways: that same arm started with worse cognition and more advanced disease, which would ordinarily predict faster decline, not slower. Randomization did its job imperfectly in both directions, which is what happens when an arm has 60 people in it. No single trial settles a question like this.

The safety comparison runs firmly the other way, and it is the more durable advantage. The amyloid drugs can cause brain swelling and small brain bleeds. That risk brings the FDA’s strongest warning label, repeated brain scans to monitor for it, and a genetic test before treatment even starts. The tau approach does not carry that risk, and this trial confirmed it. Nothing in diranersen’s safety profile is a mechanism attacking the brain’s blood vessels. Its burden is the route and what the route delivers. Put those together and the strategic picture is clear. Tau is now a proven target rather than a theory, and the drugs competing to hit it will be separated by how they are delivered and how safe they are, not by whether the idea works. That is precisely the ground Arrowhead built ARO-MAPT to fight on.

The endgame is a combination, and that changes everything

Look at those two columns again. The amyloid drugs did better on daily functioning. The tau drug did better on thinking and memory. Those do not look like two drugs competing to do the same job. They look like two drugs doing different halves of one job.

The biology says the same thing. Alzheimer’s is a two-protein disease. Amyloid builds up first, tau follows, and tau is the one that tracks most closely with symptoms, the protein that tangles inside brain cells in the places where memory actually fails. Clearing amyloid alone treats the trigger and leaves the bullet in flight. Almost everyone in this field now expects the eventual answer to be both, an amyloid drug and a tau drug together, and Biogen happens to own one of each.

Here is what almost no one is saying about that. If combination therapy is the destination, then how a drug is delivered stops being a matter of convenience and becomes the thing that decides whether the destination is reachable at all. Build that combination out of the standard of care as it stood until this week and you get an intravenous infusion in a clinic every two weeks for eighteen months, then an infusion every four weeks after that, plus a lumbar puncture every six months, for the rest of a patient’s life. Burdens do not simply add when you combine therapies. They compound, because the patient has to accept all of it, the doctor has to schedule all of it, and the payer has to fund all of it. Two clinic-bound drugs is not twice as difficult as one. It is disqualifying.

The timing here is almost too neat. One day before this presentation, the FDA approved Leqembi Iqlik, a once-weekly subcutaneous autoinjector, as a starting dose for early Alzheimer’s, which makes lecanemab the first anti-amyloid therapy a patient can take at home from the first dose through maintenance. The Alzheimer’s Drug Discovery Foundation said out loud what the approval means: a step toward the scalable care model the disease will need as the field moves from single drugs toward combinations. The amyloid half of the future combination just left the infusion center. The tau half is still in it.

Now picture the combination built out of what exists after this week: an at-home autoinjector for the amyloid drug, alongside a tau drug given as a shot under the skin once a quarter. There is exactly one tau program in clinical development that fits that description, and it is Arrowhead’s ARO-MAPT. Diranersen cannot be that drug, because a spinal tap does not happen at home. Every anti-tau antibody that might have been that drug has already failed. The regimen an ordinary neurologist can prescribe and an ordinary patient can live with for years is amyloid by autoinjector plus tau by subcutaneous injection, and Arrowhead owns the only candidate for the second half of it.

Readers of my first paper, The Needle Wins, will recognize the argument, because this is that argument arriving in a new disease. The thesis there was that the auto-injector had already normalized self-administration for tens of millions of people, and that any therapy which could migrate into that format would capture a market that clinic-bound competitors could not reach. Alzheimer’s crossed that line yesterday. The needle wins in neurology too, and the drug positioned to benefit most from it is not the one that just won the tau argument.

Be honest about the caveats. No one has run the combination trial, so the benefit is a hypothesis rather than a result, the costs of stacking two branded biologics will meet real resistance from insurers, and the safety of combining them has to be established rather than assumed. ARO-MAPT has also not yet shown a single human data point. Grant all of that, and the strategic point still stands. The moment the field decides the future is combination therapy, the drug that can be given as a simple shot is not merely the more pleasant option. It is the only version of the future that actually works, and Arrowhead is the only company holding a tau asset built for it.

The finding nobody else will write about

The strangest result in the trial is the one most likely to be glossed over. The lowest dose worked best. Diranersen was tested at three dose levels, and the smallest one, given twice a year, beat both of the bigger ones on essentially every measure of patient benefit. That is why the study technically failed its main goal, which was to show that more drug produces more benefit. More drug did not.

The full data sharpens this into something stronger than the topline allowed. More drug did not merely fail to help. More drug did more of everything except help. The highest dose lowered tau the furthest in the spinal fluid, drove tau down the furthest on brain scans, produced the most treatment-related side effects, produced the most serious ones, and delivered the worst clinical result of the three. The lowest dose lowered tau the least of the three and helped the most. That is not a flat dose-response curve. That is an inverted one, running through both benefit and harm at the same time.

Figure 2: Harm scaled with dose. Benefit ran the other way.

Treatment-emergent adverse events assessed by the investigator as related to study treatment, by randomized arm, from Biogen’s CELIA safety table (data cut 11 March 2026). Treatment-related adverse events rose at every step of the dose ladder. Serious treatment-related events rose from zero on placebo to 10.3 percent at the top dose, with a small non-monotonic dip at the middle dose. Clinical benefit ran the other way: the 60 mg every-24-weeks arm produced the largest slowing of decline on CDR-SB, and Biogen reports a lower effect size at the higher dose levels. Source: Biogen AAIC 2026 investor presentation, July 14, 2026.

There are two ways to read that, and the whole tau field turns on which one is true.

The first reading is biological. Tau is not purely a villain. Healthy brain cells use it for ordinary jobs, so stripping out too much of it may carry a cost of its own, and the curve turns down because the target itself has a floor. If that is right, the ceiling belongs to tau, and it applies to every drug that lowers tau, including Arrowhead’s.

The second reading is the needle. Harm rose monotonically with intrathecal exposure in Biogen’s own safety table, from zero treatment-related serious events on placebo to 10.3 percent at the top dose, with confusion specifically growing more common at higher doses. A drug that is helping a patient and injuring him at the same time will show exactly this curve, and the injury here is concentrated in events that trace to the route and to the peak concentrations a bolus into the spinal canal creates. If that is right, the ceiling belongs to the delivery, not to the target, and a route that reaches the brain gently and evenly does not inherit it.

Today’s data cannot separate those two readings, and any analyst who tells you otherwise is selling something. What it does establish is that the ceiling is real, that it arrived well below the doses Biogen tested, and that at least part of it is attributable to the way the drug gets in. Both readings converge on the same commercial conclusion. The winning technology in tau is not the one that hits hardest. It is the one that can hold a steady, moderate, precisely controlled reduction without paying an escalating toxicity toll to get there, which happens to be a description of what a quarterly injection under the skin is built to do.

The read-through to ARO-MAPT

The data landed on the most favorable branch available, and it landed on two of them at once. The mechanism worked and the route hurt.

Start with the mechanism. Deep tau knockdown produced a real cognitive signal, which validates tau as a target and, with it, the premise beneath Arrowhead’s ARO-MAPT. Someone else spent the capital to de-risk the target. Arrowhead inherits the benefit. The competitive question now narrows to delivery burden, and that is precisely where a subcutaneous injection has an obvious advantage over a repeat spinal tap.

Then the route. The winning regimen, 60 mg every six months, means two lumbar punctures a year, for life. Two of the three most common adverse events in the trial are the puncture itself, and the third is the concentration spike the puncture delivers. Every one of them is an argument for changing the route rather than changing the drug. The subcutaneous case no longer needs to be argued in the abstract. It is written into Biogen’s own safety table.

Steelman the other side, because there is a real counterargument and it appeared in this deck. Ninety-four percent of the patients who finished the study chose to continue into the extension, which means they signed up for years of further spinal taps. Patients tolerate the needle better than the delivery thesis assumes. Two honest responses. Clinical trial volunteers are the most motivated patients in the disease and are not the population that decides whether a drug reaches millions of people. Twice-yearly dosing is also genuinely less frequent than a quarterly subcutaneous injection, so the argument for a shot under the skin cannot rest on how often, only on what kind and where. The case is invasiveness and setting, not arithmetic, and it should be argued on those terms.

Where the route stops being a preference and becomes the whole game

Alzheimer’s is the largest tau market. It is not the market where delivery decides the winner, because in Alzheimer’s the two routes cover roughly the same ground. Tau pathology in Alzheimer’s begins in the entorhinal cortex and hippocampus and spreads through the association cortices, and those structures sit reasonably close to the fluid spaces that a spinal injection can reach. Diranersen’s 50 to 65 percent reduction in spinal fluid tau is evidence that intrathecal delivery gets to the places Alzheimer’s lives.

Now consider what today’s result opens up. CELIA validated tau lowering as a mechanism, not as an Alzheimer’s drug. The same mechanism points at a set of rarer diseases where tau is not one of two proteins but the only one: progressive supranuclear palsy, corticobasal degeneration, and the inherited frontotemporal dementias caused by mutations in the tau gene itself. None of them has an approved disease-modifying therapy. All of them are now more investable than they were yesterday, because the target has been reached and lowered in a human brain with a cognitive signal attached.

These are also the diseases that live in exactly the wrong part of the brain for a needle in the spine. Progressive supranuclear palsy is a disease of the subthalamic nucleus, the substantia nigra, the red nucleus, and the brainstem nuclei, including the structure whose degeneration produces the vertical gaze palsy that defines the illness. A drug injected into the lumbar spine travels up the fluid column and diffuses inward from the brain’s outer surfaces, so the structures nearest the fluid see the most drug and the structures buried deepest see the least. That gradient is a property of the route, not of the molecule, and no amount of chemistry improvement repeals it.

Look at what Biogen has published from its own animal work, and then at what it has not. Its intrathecal tau drug produced 77 percent knockdown in the frontal cortex and 74 percent in the hippocampus, which are precisely the structures the spinal fluid bathes most easily, and those are strong numbers. There is no published figure for the substantia nigra, and none for the brainstem. A program this far advanced, in a field this competitive, does not leave favorable data unpublished. The silence is the gradient. Arrowhead’s drug travels through the bloodstream instead, using a receptor expressed on the lining of brain blood vessels everywhere. Across 14 brain regions in primates, drug accumulation ran from 0.47 micrograms per gram in the substantia nigra to 1.55 in the motor cortex, a spread of roughly threefold, with the lowest region still above the threshold that produces knockdown. Arrowhead’s own slide put it plainly: the distribution overcomes the intrathecal limitation in deep brain delivery.

Hold the caveat firmly. That is a monkey, not a person, and the human distribution data does not exist yet in any program. Grant the caveat and the strategic shape is still unmistakable. In Alzheimer’s, the route is a commercial advantage. In the rare tauopathies, the route is the difference between a drug that reaches the disease and one that does not, and those are the indications with no competition, orphan pricing, and an accelerated regulatory path.

One more thing the route argument gains today. Arrowhead is not the only company that concluded the failures in tau were about getting there rather than about tau. Denali’s DNL628 uses the same class of receptor-mediated brain transport, delivered intravenously, with its first patient data expected in the first half of 2027. A third serious player betting on brain-crossing tau knockdown is corroboration of the thesis rather than a threat to it, and on the current timelines Arrowhead reads out first and is alone in the subcutaneous lane.

The number to grade the autumn on

The most useful thing to take from today is a bar, and it is now a precise one. Diranersen lowered total tau in the spinal fluid by 50 to 65 percent across the dose arms, and the arm that produced the clinical benefit sat at the shallow end of that range. Arrowhead’s management has said it is looking for a comparable reduction in its own healthy-volunteer study as the mark of success. The autumn readout now has a number rather than a mood, and the number is roughly half.

Arrowhead’s animal data already sits there. In primates, ARO-MAPT produced roughly 50 to 60 percent reductions in tau in the spinal fluid, holding for up to four months after the last dose, and its modeling projects sustained knockdown of 50 to 70 percent on quarterly dosing. My own translation framework, published before today, was more conservative than the company’s: 40 to 55 percent in humans at an optimal loading dose, with anything above 55 percent exceptional and anything below 30 percent a translation failure. That conservatism used to be a concession. Today it is a fit. Since the arm that produced the benefit sat at the shallow end of the band, a 40 to 55 percent human result for ARO-MAPT is not a disappointing near-miss of the benchmark. It lands in the range that worked.

Be clear-eyed about the flip side, because this is the real risk and it is quantitative rather than binary. The advantage of a shot under the skin only counts if the knockdown lands in the right range. Convenience does not rescue a weaker drug. If ARO-MAPT reaches the brain but silences only a fraction of what a spinal injection achieves, the delivery win is real and the commercial case is not. What today changed is the shape of the target. Arrowhead no longer has to beat diranersen on depth of knockdown, because depth of knockdown is not what won this trial. It has to land in the band, hold it steadily, and then win on everything else.

Set expectations correctly on what the autumn actually delivers. The readout coming in late September or October is the healthy-volunteer portion of the Phase 1/2a study. It answers whether a subcutaneous injection crosses into the human brain and lowers tau, and how much. It does not answer whether patients decline more slowly, because it does not enroll patients. Alzheimer’s patient data comes later, in 2027. Anyone expecting a cognitive result this autumn is going to be disappointed by a study that was never designed to produce one, and anyone who understands what is actually being tested will recognize it as the only question that has ever mattered for this program.

One practical note on timing

Expect the readthrough to be a slow burn rather than a same-day move. Arrowhead has its own topline coming in severe hypertriglyceridemia, the SHASTA readout, and that is the nearer and louder catalyst. JPMorgan made the point plainly: full credit for the tau work may only be realized on the back of that cardiometabolic topline. A tape focused on one readout does not price a second one that belongs to a competitor. The derisking today is real, and it will still be real in the autumn, when Arrowhead’s own brain data arrives and the market finally has to price it directly.

The gambit

Chess has a word for what Biogen just did. A gambit is a deliberate sacrifice, material given up on purpose to gain position. The player who offers it accepts a visible, immediate loss in exchange for something harder to see on the board: open lines, freer pieces, a position that pays out later.

Biogen sacrificed the endpoint. It gave up the clean win, a met primary and an unambiguous headline, and what it purchased with that loss was position for the entire field. Tau is now a target that has been reached, engaged, and lowered in the human brain, with a cognitive signal attached that matches the approved amyloid antibody. That knowledge did not exist in a randomized trial before today, and Biogen paid for it with a missed primary, an invasive route, and a dose curve that turned out to argue against its own higher doses.

Look closely at what Biogen is now proposing to do with the position. Its final slide says the data supports moving diranersen into registrational studies. Its next-steps slide commits to nothing firmer than continued engagement with regulators on Phase 3 planning, with no start date and, tellingly, no declared dose. The company intends to take the lowest dose, from the smallest arm, in a trial that failed the prespecified test of whether dose matters at all, into a program that will cost it hundreds of millions of dollars. That is the second half of the gambit, and it is the half that has not been paid for yet.

Here is the thing about a gambit, though. The player who sacrifices is not always the player who collects. A gambit opens a line, and whoever has a piece already trained on that line is the one who benefits from it. Biogen opened the tau file with a drug that has to go into the spine. Arrowhead is aiming down the same line with a shot under the skin, and it did not pay a dollar for the position it just inherited.

What it means

Today was a delivery win dressed up as an argument about tau. A drug reached the human brain, found its target, and cleared out tau, which is what this field has been chasing for a decade. Whether tau is the right thing to chase is a separate question, still open, and it will be settled in years of late-stage trials, not in a conference room in London.

The lesson for a platform investor is the one I keep returning to. Bet on the road, not on the destination. Targets fail, and they fail often. A validated way into the brain does not, and it can be pointed at the next target, and the one after that. Arrowhead’s own first human brain readout arrives later this year, and it should be judged on exactly the terms this note has laid out: can it get there, how much drug it takes, and how precisely the knockdown can be controlled. Whether it cures anything is a question for a different year.

Biogen made the sacrifice. The position is open. Watch who plays into it.

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909

PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This note reflects the author’s personal opinions, is for informational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

The hottest worry in biotech right now is China. Chinese drug companies are rising fast, copying proven Western medicines cheaper and quicker, and selling them to big pharma. A reader asked me a fair question: does this hurt Arrowhead? The honest answer is not a simple no. China is real, it has reached Arrowhead’s field, and it does threaten part of the business. What it cannot touch is the part that actually matters, and this note explains where that line is, in plain terms.

First, take the threat seriously

Any answer that just brushes China off is worthless, so let me give the threat its due. Chinese drug companies signed a record $137.7 billion of licensing deals in 2025, and 2026 is on pace to beat it. Chinese medicines now make up about half of all the big licensing deals in the world. The reason is simple: Western drug giants have huge products losing patent protection, and they can fill the gap by buying Chinese drugs for a fraction of what it costs to buy a Western company. This has already reached Arrowhead’s corner of medicine. Earlier this year, a U.S. company, Madrigal, signed a deal worth up to $4.4 billion with a Chinese firm called Ribo for liver-disease drugs of the same type Arrowhead makes.

These Chinese companies are not amateurs, either. Ribo has raised about $250 million and even runs a lab in Sweden. Another, Sirnaomics, has been at this since 2007. A third, Argo, was started by a scientist who used to work at Arrowhead. The skill is real, then, and some of it has walked right out of Arrowhead’s own door. Any honest look starts by admitting that.

What China can copy, and what it can’t

Here is the key idea, and it is simpler than it sounds. Think of one of these drugs as a package that has to be delivered to a specific address in the body. The medicine itself is the package. The organ it needs to reach, the liver, the muscle, the lung, the brain, is the address. The hard part was never making the package. It was always the delivery.

Delivering to the liver is like dropping a package at a house on a busy main road. Everybody knows how to get there, the route is published, and it is no longer a secret. That is why the liver drugs, the ones for cholesterol and triglycerides, are the copyable part. China is strong at exactly this kind of copying, so over time cheaper Chinese look-alikes can chip away at prices in that area, and that touches a slice of Arrowhead’s income. That much is fair to admit, and admitting it is what makes the rest believable.

The real edge is delivery, and it grows the farther from the liver you go

Beyond the liver, everything changes. Getting a drug into muscle, lung, or brain is not a matter of copying a known route. It is a hard problem that takes years of trial and error to solve, and this is where Arrowhead is ahead. By its own count, and it is a fair one, Arrowhead has spent more than a decade learning to make these drugs potent, long-lasting, and safe, and it now has drugs in human testing across seven different parts of the body. Reaching one hard organ is impressive. Reaching seven is a different league.

Figure 1: The farther from the liver, the fewer competitors

How crowded each part of the body is with companies testing this kind of drug. The liver is crowded and easy to copy, and it empties out as you move away from it. No one has followed Arrowhead into the brain yet. Numbers are a rough illustration; Arrowhead reports drugs in testing across seven parts of the body.

Be fair about what this edge is, though. It is a head start, not a locked door. The leading Chinese companies already have their own delivery methods and are working on organs beyond the liver, and talent moves around, as the ex-Arrowhead scientist at Argo shows. The honest claim, then, is not that no one can ever follow. It is that Arrowhead is years ahead, and the further you get from the liver, the wider that lead becomes.

The brain is where the lead is widest

At the far end sits the brain, and here Arrowhead’s lead is not just wide, no one has reached it the easy way at all. Every RNAi drug ever approved works only in the liver, Arrowhead’s own approved drug included. Getting this kind of medicine past the brain’s natural wall, with a simple shot rather than surgery or a spinal tap, has never been done in people by anyone, Western or Chinese. The Chinese brain work that exists is early lab research in animals, not a real human program. Arrowhead’s brain drug, ARO-MAPT, is on track to be the first to show it can switch off a target gene in the human brain, with early results expected in 2026. Say that plainly: it has not happened yet. That readout is the hinge the whole brain case turns on. If it confirms Arrowhead can reach the brain, being first is not a slogan, it is the whole advantage, because a proven way in works for every drug that follows. If it disappoints, the brain lead is a promise, not a fact. Whether this one drug then goes on to beat the disease is a further question, harder and years away.

Why being first in the brain matters so much

Suppose the readout lands. Being first is often overrated, but in the brain it is unusually powerful, and it snowballs. Here is why it is different from being first with a liver drug.

Figure 2: The head start that keeps growing

Why a rival lands years behind. It has to crack brain delivery first, the very thing that has stalled the field for years, before it can even begin the long testing process. The timeline is a rough illustration; the order is not.

The delivery problem comes before the clock even starts. A competitor cannot begin the long years of brain-disease trials until it has first figured out how to get the drug into the brain, which is the very thing that has stalled the whole field for a decade. A rival is therefore not one step behind Arrowhead. It is a whole delivery breakthrough plus a full round of trials behind, and brain trials are among the longest in medicine. The head start is measured in years before anyone else even reaches the starting line.

The lead also feeds on itself. By going first, Arrowhead grabs the best targets: it already has drugs aimed at the proteins behind Alzheimer’s, Parkinson’s, and Huntington’s. Being first attracts the big partners who pay to fund the next round, Novartis has already committed up to $2 billion for the brain platform, and that money buys the next drugs, which produce the data that lands the next partner. The first approved brain drug also becomes the standard everyone else is measured against. Each of these advantages makes the next one bigger. That is why a company that reaches the brain first is far harder to catch than one that is merely first in a crowded liver market.

Then comes the part that outlasts all of it. Once a brain drug is actually being prescribed, it digs in. Brain specialists are a small, careful world, and doctors who have learned one treatment, watched it work, and grown comfortable with its quirks do not switch on a whim. Treatment guidelines get written around the drug that got there first. Insurers put it in the preferred slot and make every latecomer fight for coverage. Patients doing well on a long-term medicine are rarely moved off it. A rival showing up years later with a slightly better drug still has to pry all of that loose, one doctor and one insurer at a time. Being first also makes the next drug easier: every brain program teaches Arrowhead something about delivery it can reuse, so its tenth brain drug costs less and moves faster than its first, while a competitor is still struggling through its first.

The patents are hard to get around

There is a legal layer on top of all this, and being first shapes it too. A patent can only protect something new, something no one has done before. In a crowded field, where a lot of similar work already exists, a company can patent only narrow slivers, because everything else is already taken. In a brand-new field, where almost nothing came before, the first company in can patent broadly. Arrowhead is first into the brain, so there is very little earlier work to box in its claims, which means its patents can cover wide ground. It also runs its own in-house patent team, building that protection from the start.

This matters most where the money is. A rival that wanted to sell a copycat brain drug in the United States, the market that counts, would not just have to match the science. It would have to invent a completely different route around a wide wall of Arrowhead patents. Patents are not a magic shield, and a determined competitor can sometimes design around them. Doing so is slow and expensive, though, and it often leaves the copycat a step behind with a weaker drug, while Arrowhead keeps pulling further ahead.

Why China’s rise actually helps Arrowhead

Put the two halves together and something surprising happens. If the brain bet pays off, China’s rise raises Arrowhead’s value instead of lowering it. When everything that can be copied gets copied and turns cheap, the one thing that cannot be copied becomes rarer, and rare is exactly what makes something valuable. This also sharpens the buyout case rather than weakening it. A big drug company can now buy a cheap liver drug from China, which means the reason to buy Arrowhead was never its liver drugs in the first place. It is the delivery skill and the head start in the brain, and those are the two things no amount of money can buy from China. The proof is already on the table, and it is stronger than it first looks. Novartis already owns a liver drug of exactly this kind, called Leqvio, so it had no need of Arrowhead for the liver at all. It still paid Arrowhead $200 million up front and promised up to $2 billion, every dollar of it for the brain platform. Buyers have already shown which part they will pay up for.

What could go wrong

It is only fair to say how this could be wrong. The largest risk is the most basic one: the brain lead is not proven yet. Everything in the brain half of this note rests on the 2026 readout showing that Arrowhead can actually reach the brain. If that result disappoints, there is no first-mover position to defend and the brain advantage does not exist. Even if the delivery works, whether lowering the target treats the disease is a separate and harder question that will take years. The other risks are about how long the lead lasts rather than whether it starts: China is pouring money into reaching organs beyond the liver and learning fast, helped by talent that keeps moving, so the years-ahead lead could shrink quicker than expected, and the copycat pressure on the liver drugs could prove bigger than the modest hit described here. None of these turns the easy-to-copy drugs into the crown jewel. The honest posture is simple: the liver headwind is real and here now, and the brain prize is real but still unproven.

The move no one can copy

Chess has a useful idea here. Every serious player memorizes the openings, the published moves that begin a game. They are free for anyone to study and copy, move for move, which is exactly what the copycats do best. The real edge shows up later, in positions the book has never seen, where the memorized moves run out and only the player who arrived first knows what to do. The liver is the opening. Everyone has it by heart. The brain is a position with no book at all, and Arrowhead is about to make the first move into it.

Here, then, is the whole paper in a breath. China can copy the drug. It cannot copy the move no one has played yet, and the first move into the brain is the one that wins the game. The more the world fills with cheap copies of the openings, the more valuable the one player becomes who is writing a book everyone else will have to study. That player is Arrowhead, and it is the one thing a cornered buyer cannot buy from China at any price.

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This note reflects the author’s personal opinions, is for informational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

This note translates the game theory trilogy into plain numbers. The Forced Move series argues that three large drugmakers, Novartis, Lilly, and Roche, may each be pushed toward acquiring Arrowhead, not because they want to, but because the cost of letting a rival buy it first can be worse than the cost of buying it themselves. That is what a forced move means in chess: a move you make because every alternative is worse. This note shows how that idea looks once you attach real numbers to it, and how those numbers are built.

A quick word on the patent cliff

Every large drugmaker lives in fear of the patent cliff. A drug is protected by patents for a set number of years. When that protection ends, cheaper copies, generics for ordinary pills and biosimilars for the more complex biologic drugs, flood in, and the original medicine can lose most of its sales within a year or two. A company with a big drug going off patent has a revenue hole to fill, and filling it is urgent.

The three companies in this story face that cliff on very different clocks. Figure 1 shows the cumulative sales each one is set to lose to expiring patents over the next ten years.

Figure 1: The patent cliff arrives on three different clocks

Cumulative branded revenue each company is projected to lose to patent expiry, 2026 through 2035. Modeled from public sales and known expiry dates.

Novartis is bleeding now. Its heart-failure blockbuster Entresto, which sold roughly $7.7 billion in 2024, began losing United States protection in 2025, and the company has called 2026 its largest patent-expiry year ever. Roche faces a slower wave that builds mid-decade, led by its multiple-sclerosis drug Ocrevus losing protection around 2028 and 2029. Lilly barely bends, because its giant obesity and diabetes franchise, Mounjaro and Zepbound, is protected into the late 2030s, so its near-term hole is small.

The shape of those three lines is the first half of the story. Novartis needs a replacement engine today. Roche needs one soon. Lilly can afford to wait.

The one idea that changes everything

Arrowhead is attractive to all three because its platform works like a factory for new medicines, which is exactly what a company with a revenue hole needs. That much is ordinary. The idea that turns this into a forced move is less obvious, and it is the heart of the argument.

Most people weigh an acquisition as buy versus do not buy, where not buying simply saves the purchase price. That framing is wrong here. The real choice is buy it yourself versus let a rival buy it. Letting a rival win is not free. You still face your own patent cliff with no new engine to fill it, and now a competitor owns a platform it can turn against your business. Inaction carries a price tag, and once you see that, the math tips.

The payoff grid

Figure 2 puts that logic onto a single grid.

Figure 2: The three-way payoff grid

Net present value to each company (columns) under each possible winner (rows), in billions of dollars, at an assumed $120 billion acquisition price. Green is a gain from winning; red is a loss when a rival wins. Modeled base case.

Each row is one possible outcome, the company that wins Arrowhead. Each column is the result for one company. Every square then answers a single question: if the company on the left wins, what happens to the company named at the top?

The green squares run down the diagonal, where a company wins the auction itself, and those are gains. Every red square is an outcome where a rival wins instead, and those are losses. Here is the punchline. Pick any single column and read down it. You will find one green square and two red ones. No company has a comfortable do-nothing option, because if it stays out, one of the other two wins and it takes a loss. The only good outcome is the one you have to pay for. That is the forced move.

A few specifics are worth seeing. Novartis has the most to gain by winning, because its cliff is the most urgent. Roche faces the steepest single loss on the board, the $45 billion it would suffer if Novartis wins, because Arrowhead’s brain-delivery work sits right next to Roche’s own brain franchise, so a Novartis-owned Arrowhead would be a direct threat. Lilly’s squares are the smallest in both directions, because it is the least cornered.

Where the numbers come from

None of these figures are facts pulled from a filing. They are estimates, built from a few simple rules, and it is worth knowing exactly how, so you can judge them for yourself.

Start with the price. The base grid assumes a sale clears at about $120 billion, which sits in the middle of a realistic range for an asset like this.

Next comes the value of owning Arrowhead, which differs by buyer. It starts from a common baseline, the standalone worth of the platform and pipeline, built from the parts in the next section at about $90 billion, then adds an amount unique to each buyer for the synergies and cliff-filling it gains. Subtract the price from that total, and the result is the green diagonal number, the net gain of winning.

Then come the losses, and here a tempting mistake was avoided. It is natural to think a company that loses Arrowhead loses two things: the cliff-filling it misses and the competitive damage of a rival holding the platform. Counting both is wrong. Your patent cliff is unfilled whether Arrowhead stays independent or a rival buys it, so you never actually had that cliff-filling to lose; it belongs entirely to the gain from winning. The only genuine loss from a rival winning is the extra competitive damage that rival does with the platform, over and above the competition an independent Arrowhead already poses, so that is the single thing the red squares count. This keeps the same pipeline from being counted twice, once as a gain and once again as a loss.

What the platform is worth on its own

That $90 billion baseline is not a number borrowed from thin air, and it is worth building from the parts. Figure 3 does that.

Figure 3: Building the $90 billion standalone value

A modeled sum of the parts. The tangible floor rests on named programs and signed contracts; the platform option value is the contested estimate. Risk-adjusted and illustrative.

The tangible floor comes first. Arrowhead’s wholly-owned pipeline, led by the approved triglyceride-lowering drug plozasiran and its much larger late-stage program, alongside the obesity, tau, and complement candidates, carries the most identifiable value, on the order of $43 billion on a risk-adjusted basis. Its partnership streams, the milestones and royalties owed by Sarepta, Amgen, GSK, Novartis, and others, together with net cash, add roughly $12 billion. Those pieces give a tangible floor near $55 billion, the part grounded in named assets and signed contracts.

The platform option value is the rest, about $35 billion, and it is the real bet. This is the worth of the delivery engine itself, its proven ability to reach the liver, lung, muscle, fat, kidney, and now the brain, and to keep generating new programs not yet named. It is the hardest piece to pin down and the easiest to argue over, which is why Figure 3 shows it separately. Value the engine conservatively and the standalone value sits near $90 billion; value it the way a true believer in the platform would, and it climbs well past that.

Two things follow. The $90 billion baseline used throughout this note is a deliberately conservative reading, a solid tangible floor plus a restrained platform value, sitting at the low end of the wider sale range. The single largest source of disagreement about what Arrowhead is worth is therefore not the pipeline, which is fairly concrete, but how much credit to give the engine that keeps building it.

What the precedents say

Modeled numbers feel less abstract when set against real deals, and three precedents are worth knowing. In 2019, Novartis bought The Medicines Company for $9.7 billion, a premium of about 41 percent over the prior month’s average price, to acquire a single siRNA drug, inclisiran, which became its cholesterol medicine Leqvio. That deal put nearly $10 billion behind one asset, from the very company at the center of this analysis. Arrowhead is not one asset; it is a platform with roughly a dozen programs across the body, including the brain.

Two larger deals fill in the picture. In 2021, Novo Nordisk paid $3.3 billion for Dicerna, another RNAi company. In 2023, Pfizer paid $43 billion for Seagen to own an antibody-drug-conjugate platform, financing most of it with about $31 billion of new debt. Large platform deals happen, they clear regulators, and acquirers take on serious debt to do them.

Two lessons carry over. Biotech takeovers routinely price at premiums of 40 percent to 100 percent or more over the trading price, so a wide gap between Arrowhead’s roughly $12 billion market value and a strategic price is the norm, not a stretch. A buyer with an urgent need also pays up, as Novartis did with a double-digit premium for one cardiovascular siRNA when it wanted to anchor that franchise. The platform logic that justified $9.7 billion for inclisiran applies with far more force to an entire delivery engine.

How high would each company bid?

There is a clean way to put a floor and a ceiling on what each company should rationally pay, with the real bid landing somewhere between the two.

The floor is the denial value, the competitive damage a company avoids purely by keeping the most threatening rival from winning. A company should be willing to commit at least this much for defense alone, before counting a single dollar of owning the asset, because preventing that particular rival is worth exactly that avoided loss. For Novartis, letting Roche win would cost about $30 billion, so $30 billion is its floor. For Roche, letting Novartis win would cost about $45 billion, the steepest figure on the board, because a Novartis-owned Arrowhead would aim the brain-delivery platform straight at Roche. For Lilly, letting Novartis win would cost about $20 billion.

The ceiling sits far higher. The most a company should pay is that same denial value plus the full value of owning Arrowhead in its own hands. That works out to roughly $200 billion for Novartis, $205 billion for Roche, and $160 billion for Lilly. Every one of those ceilings towers over any realistic clearing price, which is precisely why a contested auction would run hot.

Put plainly: the floor is the loss avoided, the ceiling is that loss avoided plus the gain from owning, and the rational bid lives in the band between them, pushed upward by how hard the other two press. Folding the gain into the floor would be a mistake, because it would collapse the floor and the ceiling into one number and erase the band entirely.

One subtlety is worth getting right: the ceiling has two layers. The bottom layer is the plain value of owning Arrowhead, and it holds whether or not anyone else bids, because even an independent Arrowhead competes with these three in lipids, in metabolic disease, and in complement, and could partner with any of their rivals at any time. Owning it neutralizes that competitor either way, so part of the ceiling has nothing to do with a bidding war.

The top layer is the rival-control premium, the $30 billion for Novartis or the $45 billion for Roche, the extra harm of a specific, deep-pocketed rival seizing the platform and aiming it at you. That premium exists only while a live rival is actually bidding, and it falls away the moment the rival steps back. The forced move is sharpest in that top layer, yet the layer beneath still gives each company a standing reason to want Arrowhead off the board.

Notice that Roche carries both the highest floor and the highest ceiling, even though its patent cliff is less urgent than Novartis’s. What drives Roche is not its own revenue hole but the prospect of a rival seizing the brain platform, which makes its case a matter of defense rather than need.

Arrowhead’s walk-away: the $90 billion floor

Every walk-away price so far has belonged to a buyer. Arrowhead has one of its own, and it anchors the entire deal. A seller’s walk-away is the value of its best alternative to selling, which for Arrowhead is simply continuing to operate independently. That value is the standalone worth built in Figure 3, about $90 billion. It is the price below which Arrowhead should refuse any offer and stay independent, because below it shareholders are better off keeping the company than selling it. That single number is the floor under everything.

This floor is not a negotiating pose; it has real force. A public-company board owes its shareholders a duty, and accepting a bid beneath the company’s own standalone value would hand shareholders less than they already hold by doing nothing. No board can defend that, and few would survive trying. That makes $90 billion a line with teeth, not a wish.

What makes the floor robust is what sits inside it. The $90 billion is not a snapshot of today’s revenue; it already includes roughly $35 billion of platform option value, the future programs the delivery engine will keep producing. Staying independent means keeping all of that upside for existing shareholders. A buyer must therefore pay at least $90 billion simply to match what Arrowhead’s owners already possess by doing nothing at all. Anything less asks them to sell the future at a discount, and they should not.

Arrowhead also feels none of the pressure its suitors feel, and that is the heart of the matter. It is not a distressed seller. It has an approved drug generating revenue, a deep partnered pipeline throwing off milestones, and the runway to keep building. The whole thesis of this series is that the buyers are cornered by their patent cliffs; the seller is cornered by nothing. A party under a clock negotiating against a party with no clock does not set the price low. That asymmetry is precisely what lets Arrowhead hold its floor and push the final number up toward the buyers’ ceilings rather than down toward its own.

The floor is not even static. A successful first readout from the brain program would lift the platform’s standalone value, and with it the price below which Arrowhead refuses to sell. Time and data work for the seller. The same event that tightens the screws on the buyers raises Arrowhead’s walk-away, which is itself a reason a confident board would wait rather than take an early offer.

Put both sides on the table and the deal space is clear. Arrowhead should not sell below roughly $90 billion, while every buyer ceiling, the $160 to $205 billion figures from the bidding section, sits far above that floor. The zone of a possible deal is therefore wide, and with three motivated buyers competing inside it, the clearing price is pushed up through that zone rather than down to its floor. The realistic $90 to $150 billion sale range is simply where a rising seller floor and a contested set of buyer ceilings are most likely to meet. The $90 billion anchors the bottom of that range for one reason: it is the least Arrowhead should ever accept to give up its independence.

What changes if the price changes?

A fair question is how sensitive all of this is to the price. Figure 4 redraws the grid across the realistic sale range, at $150 billion, $120 billion, and $90 billion. Watch what moves and what holds still.

Figure 4: The grid across the realistic sale range

The payoff grid recalculated at $150 billion, $120 billion, and $90 billion. The red losses are identical across all three; only the green gains change as the price moves.

The red squares never change. The damage a rival does by owning the platform has nothing to do with what was paid for it, so the cost of losing is identical across all three panels. Only the green gains move, and watching them move across the range is instructive.

At $90 billion, the low end, every buyer wins handsomely: Novartis nets $80 billion, Roche $70 billion, even Lilly $50 billion. At $120 billion the gains shrink but stay clearly positive for all three. At $150 billion, the top of the range, something telling happens. Lilly’s own square turns red, because $150 billion now exceeds what Arrowhead is worth in Lilly’s hands. The instinct is to say Lilly should walk away, and the instinct is wrong. An overpriced win at $150 billion costs Lilly about $10 billion, while letting Novartis take the asset instead costs it $20 billion, so Lilly keeps bidding rather than accept the worse outcome. That red square is the winner’s curse made visible: a forced move can push a buyer past the point where winning makes sense on its own, purely because losing is worse.

That dynamic decides how an auction would actually end. As the price climbs past the top of the realistic range, the weakest-fit buyer drops out first, Lilly at its $160 billion ceiling, leaving the two most motivated, Novartis and Roche, to set the final price. The grid shows the outcome at each fixed price; how high each would actually go is the separate question answered by the floors and ceilings above.

Why not build, license, or buy someone else?

A fair challenge runs through all of this: if these companies need RNAi and brain delivery, why must they buy Arrowhead? They could build the capability themselves, license a single program, or buy a different company. The honest answer is that each alternative is weaker, and seeing why strengthens the case.

Building takes time the cornered companies do not have. Delivering RNA into tissues beyond the liver, and especially into the brain, has taken Arrowhead more than a decade of chemistry. A Novartis staring at its cliff in 2026 cannot wait out a ten-year internal program.

Licensing one program solves one problem, not the strategic one. A license gives a buyer a single drug on someone else’s terms; it does not hand over the platform, the delivery toolkit, the dozens of future programs, or the people who built them, the scientists who have solved one hard delivery problem after another, pushed RNAi into tissue after tissue beyond the liver, and engineered trigger chemistry at the leading edge of the field. A license leaves all of that, and the asset itself, on the table for a rival. The Sarepta and GSK deals with Arrowhead show that licensing happens, yet none of them removed Arrowhead as a target.

Buying a different RNAi company is the strongest objection, and the obvious candidate is Alnylam. Here the distinction matters. Alnylam is a finished franchise: profitable, with 2026 product revenue guided to roughly $4.9 to $5.3 billion, anchored by its heart drug, and valued near $42 billion before any premium. It is the better company to own outright, a mature and cash-generative business. It is the worse fit for this particular need, because its delivery is concentrated in the liver, it carries less of the brain and extrahepatic optionality a cliff-facing buyer is reaching for, and it is already entangled with two of the three buyers, since Novartis commercializes its Leqvio and Roche partners on another of its drugs. Arrowhead is the engine: broader tissue reach, a real path into the brain, a deep cardiometabolic pipeline, and far more future revenue still ahead of it. That does not make Arrowhead cheaper. Its market value is a fraction of Alnylam’s today, near $12 billion against $42 billion, yet the strategic price it would command, the $90 to $150 billion in this note, sits above what Alnylam would cost to acquire. A buyer pays more for Arrowhead precisely because it is buying the future and the breadth rather than a single mature franchise. Alnylam is the better company to own, Arrowhead the better company to acquire.

Can they actually pay, and clear the regulators?

A ceiling no one can fund or clear past regulators is not a real ceiling, so two practical checks matter. On the money, all three can write the check. Lilly, valued at over $1.1 trillion, has by far the most room. Roche is large and cash-generative across drugs and diagnostics. Novartis carries more debt, with net debt around $22 billion after recent moves, yet it has shown it will borrow for the right asset, and the Pfizer purchase of Seagen showed a buyer raising roughly $31 billion in fresh debt for a platform it wanted. A price in the range discussed here is large, yet within reach for each, especially with a mix of debt and stock.

On the regulators, the path looks clearer than for a typical mega-merger. Arrowhead’s only marketed product today is plozasiran, a therapy for a rare triglyceride disorder, and none of the three buyers sells a competing product in that small market, so a deal eliminates almost no existing competition, which is the usual antitrust trigger. The closest concern is overlap inside a single disease area, for instance Novartis already holding an RNAi cholesterol drug, and the standard remedy there is a narrow divestiture rather than a block. Pfizer cleared its Seagen deal by giving up one product’s United States royalties to satisfy the regulator. The lesson is that these deals get done, sometimes with a minor concession, rather than stopped.

How firm are these numbers

Honesty matters here. The patent-cliff figures behind Figure 1 are the most solid, drawn from public sales and known expiry dates, though they remain projections of how fast sales erode. The gains rest on two assumptions you can change: the $90 billion baseline value, whose softest piece is the platform option value broken out in Figure 3, and the price, which Figure 4 flexes across the realistic range. Both move the green numbers dollar for dollar. The competitive-damage figures in the red squares are the softest of all. Their relative size is well reasoned, with Roche losing most to a Novartis win, yet the exact dollars are estimates and should be read as approximate rather than precise. To make that concrete, the competitive-damage cells are best read with a band of roughly 30 percent either way, so Roche’s $45 billion loss to a Novartis win is better understood as a range from about $30 billion to $60 billion. One thing the model now gets right by construction: it counts each piece of value only once, never as both a gain and a loss.

What would break this thesis

Honest analysis names what would prove it wrong, and several things would. The clearest is the science. Arrowhead’s brain program, ARO-MAPT, has not yet shown that it works in people, and a clear failure at its first human readout would knock out the most valuable part of the platform and deflate the urgency for the brain-focused buyer, Roche above all.

A rival platform could leap ahead. If another company demonstrated cheaper or better delivery into the brain or other hard tissues, Arrowhead’s scarcity, the very thing that makes it worth fighting over, would erode.

The buyers could simply decline. A forced move is a claim about incentives, not a guarantee of behavior. Boards delay, balk at premiums, and sometimes choose to build despite the logic, so the thesis predicts pressure, not certainty.

Arrowhead could take itself off the table. A large financing, a transformational partnership, or a clear statement of intent to stay independent would signal that management does not mean to sell, which would defer the whole question. Watching for those signals is part of testing the thesis rather than merely asserting it.

The clock: when the move gets forced

A forced move needs a trigger, and the triggers are dated. Figure 5 lines them up.

Figure 5: Two clocks running at once

The cliff clock below the line and Arrowhead’s proof points above it. The shaded window is where a revenue hole and a platform proof point overlap.

Two clocks run at the same time. The cliff clock is already ticking for Novartis, whose largest expiries land in 2026, and it builds toward Roche as Ocrevus rolls off around 2028 and 2029. Arrowhead’s side runs hot in the very same window: the sHTG Phase 3 data land in 2026 and a plozasiran sHTG approval could follow in 2027, while the first human readout from the brain program, the event most likely to convert the platform from promise into proof, is also expected in late 2026. That readout is a gate, not a footnote: it opens a substantial CNS pipeline expansion that Arrowhead has slated to begin at the end of 2026 and run through 2027, so it does not add a single proof point; it opens a portfolio. When a cluster of proof points on Arrowhead’s side meets a revenue hole on a buyer’s side, the pressure stops being theoretical. That overlap, more than any single number in this note, is what would set a forced move in motion.

What it all means

One contrast ties it all together. Arrowhead trades near $12 billion today, yet each of the three buyers could rationally justify paying somewhere between $160 and $205 billion, well over ten times that, once the cost of letting a rival win is counted. That gap, between a market price set by today’s results and a strategic price set by tomorrow’s threat, is the entire point of the Forced Move thesis. When all three would pay far more than the asset is likely to clear for, the result is not a quiet negotiation. It is a bidding war.

The grid does not promise that any deal will happen. Real acquisitions turn on personalities, regulators, balance sheets, and timing that no model captures. What it shows is why the pressure exists, why no company can comfortably sit out, and how the squeeze falls differently on each: Novartis cornered first by the timing of its cliff, Roche most threatened by a specific rival, Lilly the most able to wait. Chess players have a name for the moment when every comfortable option has quietly vanished and only one move keeps you in the game. They call it the forced move. The board is nearly set, and the clocks are running. No one at this table wants to pay $100 billion for a company the market prices at $12 billion. That, precisely, is why one of them will.

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This note reflects the author’s personal opinions, is for informational purposes only, and is not investment advice. The figures shown are modeled estimates meant to illustrate a strategic argument, not forecasts of any specific transaction or price. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

A Clinical Evidence Analysis of Why Almost Every Step of ARO-MAPT's Journey Has Already Been Proven in a Human Being, Across the Five Drugs That Each Cleared One Link of the Chain, the Single Crossing That Remains, and the Subcutaneous Brain-Delivery Platform That a Clean Readout Would Unlock.

Why this matters

Most first-in-human brain drugs are close to a coin flip. The blood-brain barrier, the biological wall that keeps most medicines out of the brain, defeats the large majority of what is sent against it, and a first clinical readout usually carries enormous uncertainty. ARO-MAPT, Arrowhead’s first wholly owned brain program, is an unusual case, because by the time its first human data arrive in the third quarter of 2026, almost every individual step in how the drug is supposed to work has already been demonstrated in a living human being, just not all by the same molecule. This note walks through those proof points in plain language, shows them in a single picture, and then points to the one step that remains genuinely unproven, and what that means. That one step is the last mile, and the last mile is the hardest mile, short in the sequence, but the most demanding leg of the journey, and the stretch the fall readout exists to test.

The journey, in plain terms

ARO-MAPT is a gene-silencing medicine. At its heart is a tiny strand of genetic material, called an siRNA, that works like an off switch for a single gene. Here the gene it switches off is the one that makes tau, a protein that builds up in Alzheimer’s disease and other brain disorders. To do its job, the drug has to complete a short journey: get into the bloodstream from a simple injection, cross the blood-brain barrier into the brain, get inside brain cells, and switch off the tau gene, which brings tau levels down. The clever part is how it crosses the wall. The drug carries its siRNA on a molecular grip, a small antibody fragment known as a Fab, that latches onto a docking point on the surface of cells called the transferrin receptor, or TfR1, which the body uses to ferry iron into the brain. The drug hitches a ride on that same system.

The question every investor really wants answered is simple: how likely is this to work in people? The most useful way to answer it is to break the journey into steps and ask, for each one, has anyone already proven this step in a human? The answer, step by step, is the heart of the case.

Five human proofs

Five different drugs, made by five different companies, have each proven a piece of ARO-MAPT’s journey in actual human beings, with two of them clearing the single hardest step, the wall itself.

Roche’s trontinemab proved the hardest-sounding part: that the transferrin-receptor grip really can carry a large molecule across the human blood-brain barrier. In Alzheimer’s patients it crossed into the brain and rapidly cleared away the sticky plaques that mark the disease. The wall can be crossed using this exact docking system.

That proof is no longer alone. In March 2026 the FDA approved tividenofusp alfa, a Denali medicine that uses the same transferrin-receptor system to carry a working enzyme from the bloodstream across the human blood-brain barrier and into brain cells, where it does its job. It cut a brain disease marker in the spinal fluid by roughly eighty to ninety percent in patients. This matters for two reasons. It is the first medicine ever approved on the strength of crossing the blood-brain barrier by this route, so the approach is now not just demonstrated but regulator-endorsed. Unlike an antibody clearing plaques outside cells, the enzyme has to get inside brain cells and function there, a closer parallel to what a gene-silencing payload must do. Two different payloads, an antibody and an enzyme, made by two different companies, have now crossed the human blood-brain barrier through this exact system.

Avidity’s del-desiran proved the next piece: that a medicine injected into the blood, routed through the same transferrin receptor, can carry a gene-silencing payload into human cells and actually switch a gene off. It lowered its target gene by roughly forty-five percent in human muscle. The approach was convincing enough that Novartis agreed to buy Avidity for about $12 billion, largely on the strength of this platform.

Alnylam’s mivelsiran proved the piece inside the brain: that a gene-silencing medicine can get into human brain cells and shut a gene down, lowering its target in the spinal fluid by roughly seventy to eighty percent. It reaches the brain by a different route, a direct injection into the spinal fluid rather than through the bloodstream, but it settles the question of whether the silencing machinery works in human neurons. It does.

Biogen’s BIIB080 proved the destination: that lowering tau itself is achievable in people, cutting tau in the spinal fluid by up to roughly half. It uses a different silencing tool than ARO-MAPT, so it does not validate the exact mechanism, but it confirms that the target Arrowhead is aiming at is a real and reachable one.

Arrowhead’s own foundation

Underneath those five human proof points sits the most directly relevant evidence of all: Arrowhead has already run the entire ARO-MAPT journey, start to finish, in monkeys. A single injection under the skin, across the blood-brain barrier, into neurons, and deep-brain tau knockdown. The five human drugs prove the individual steps are each possible in people. Arrowhead’s own primate data prove the whole chain works when assembled into one molecule, in a living primate. The human question is whether that complete chain, demonstrated in monkeys, repeats in humans.

One more piece is worth understanding, because it gives a useful measuring stick. In its monkey studies, Arrowhead compared two ways of getting the drug to the brain: the older method of injecting it into the spinal fluid, the route drugs like BIIB080 use, and its own new method of a simple shot under the skin. The spinal route makes a good benchmark, because BIIB080 has already shown, in people, that lowering tau this way works and carries over from animals to humans. In Arrowhead’s monkeys, the under-the-skin route matched or beat that spinal route, and reached deep brain regions the spinal route could not. The new route therefore cleared, in animals, a bar that a real human drug has already set. This does not prove the new route crosses the human wall. It does show that, once the drug is inside, the silencing it produces holds up against the one tau drug already proven in people.

Humans and monkeys, side by side

The same chain, shown two ways. The left column is what has been proven in humans, step by step, by drugs already in the clinic or on the market, with one step still open. The right column is what Arrowhead has proven in monkeys with ARO-MAPT itself: every step, including the one still open in humans. The contrast is the whole thesis in a single view.

The one gap, and what it means

Look closely at the comparison above and a single honest gap appears. Every step has a human proof point except one precise junction: no one has yet shown that a medicine injected into the blood can carry a gene-silencing siRNA payload across the human blood-brain barrier and into neurons. Trontinemab carried an antibody across that wall in humans, and tividenofusp now carries an enzyme across it, approved and in patients, but neither is a gene-silencing payload. Del-desiran carried a gene-silencing payload through the blood into human cells using that same transferrin receptor, but into muscle, not across the brain’s wall. Mivelsiran silenced a gene in human brain cells, but reached them by injection into the spinal fluid, bypassing the wall entirely. The exact intersection, blood-borne delivery, across the blood-brain barrier, with an siRNA payload, has been shown in monkeys but not yet in a single human.

Notice how much narrower this gap has become. The two payloads that have already crossed the human wall, an antibody and an FDA-approved enzyme, are both far larger than an siRNA, so the carrier has proven it can haul heavier cargo than ARO-MAPT asks of it. The size of the cargo was never the problem. What remains unproven in humans is the very last part of the siRNA’s job: once across the wall and inside a brain cell, it has to slip out of the bubble that carried it in and switch the gene off. That final step has already been shown to work in people, just never in this one combination. Mivelsiran showed an siRNA can do it inside the human brain, reaching the brain by the spinal route. Del-desiran showed a blood-borne siRNA can do it through the very same transferrin receptor ARO-MAPT uses, though in muscle rather than brain. What no one has done yet is put the two together: a blood-borne siRNA, on the transferrin-receptor grip ARO-MAPT uses, doing its work across the brain’s wall. The gap is now as narrow as the human evidence can make it, one kind of cargo, at one barrier, with proof on every side of it.

There is one more piece, and for this exact step it may be the most reassuring of all. Until recently, the full journey by the new route, into the blood, across the wall, into brain cells, and the gene switched off, had been shown only by Arrowhead, in its own monkeys. That is no longer true. Independent groups have now reproduced it in monkeys, using the same transferrin-receptor system to drive gene-silencing deep into the brain: one team with an siRNA like ARO-MAPT’s, reported in a preprint, and another with a related oligonucleotide in a peer-reviewed journal. The exact route is no longer one company’s private result, though the siRNA version of it still awaits peer review.

What none of them has shown yet, Arrowhead included, is that same crossing in a human rather than a laboratory animal. These studies use animals engineered to carry the human version of the docking point, because the receptor differs from one species to the next. That is a strong stand-in for human biology, but a stand-in is what it remains, and whether the human receptor behaves in a real patient the way these animals predict is the one thing still left to settle.

It is worth knowing that Arrowhead is not the only company attempting this exact crossing. Denali, whose transferrin-receptor platform produced the approved brain-crossing enzyme described above, has its own program aimed at the same tau target, delivered from the bloodstream across the wall, and it has just entered the clinic. Newer entrants are converging on the same idea: Aerska, co-founded by a veteran of Alnylam’s early CNS siRNA delivery work, raised roughly $60 million across 2025 and 2026 to build the same kind of subcutaneous, transferrin-receptor siRNA shuttle, though its programs remain preclinical, years behind ARO-MAPT. That cuts two ways. It is validation, since serious players are convinced that reaching the brain from the bloodstream is real, and it is a reminder that the prize is contested. It does not change ARO-MAPT’s gap. It underscores that the gap is the field’s central open question, and that whoever crosses it first in humans establishes something genuinely new.

This gap matters more than its size suggests, because the blood-brain barrier is the hardest part of the whole journey, and the siRNA is the one cargo the human proof points have not yet carried across it. Within that single step, though, one half carries little doubt. The silencing that follows the crossing is the part of the process that carries over from animals to people most reliably of all, and Arrowhead’s platform has turned animal results into matching human results in the tissues it has taken into patients, so the deep monkey numbers are a fair guide to what humans would show once the drug is inside. The open question is therefore not whether the silencing works in people, but whether the drug reaches the brain to begin with. On that, the weight of evidence now leans in Arrowhead’s favor: the carrier already crosses the human wall, the silencing already carries over, and the full chain already works in monkeys, reproduced by more than one independent team. This is not a sure thing, the remaining step is genuinely the hard one and no human has yet taken it. It does mean that, for a first look at a brain drug, the odds sit better than they usually do, and on Arrowhead’s side of the line.

In the language of chess, Arrowhead has marched a pawn almost the length of the board and stands one square from promotion, the move that turns a foot soldier into a queen. A winning position, though, is not yet a win. The hardest game to win, players say, is a won one, and the conversion comes this fall.

What the readout will tell us

The first ARO-MAPT data, expected late in the third quarter of 2026, are in healthy volunteers given a single dose, and they will answer the one open question directly: did the drug cross the wall and lower tau in people, the way it did in monkeys and the way every surrounding step suggests it should.

The study is built to measure exactly that. After the injection, blood draws across the first 48 hours track the drug to confirm it reached the bloodstream and to chart how fast it peaks and clears. The brain signal comes from cerebrospinal fluid, sampled by lumbar puncture, a needle that draws fluid from the lower spine. Tau is the pharmacodynamic result everyone is watching for, the same cerebrospinal-fluid tau that fell in Arrowhead’s monkeys and that BIIB080 lowered in patients. The readout is therefore a direct measurement of the decisive step, not an indirect signal standing in for it.

That cerebrospinal fluid is sampled before dosing, for a baseline, and then at several points after, at roughly Day 75, Day 135, and Day 270. The practical meaning is worth sitting with. The first human read on tau knockdown arrives a couple of months after dosing, not on day one, and the full picture, how deep the knockdown goes and how long it lasts, is not complete until around nine months in. An early signal first, then a durability curve that fills in over the better part of a year.

One more feature of the design shapes how that signal arrives. The study is blinded: neither participants nor investigators are told who received the drug and who received the saline placebo, so the early cerebrospinal-fluid results come in as tau numbers without labels attached. Blinding hides who got what, though, not whether tau is moving. Placebo does not lower tau, so if the drug works as the monkeys predict, the data should split into two groups, a drug-sized set whose tau drops sharply from baseline and a placebo-sized set that stays flat, and that separation is itself a signal. A deep, clear knockdown would be hard to miss even before the code is broken. A weak or ambiguous one is where the blinding bites, since a small effect can hide in the noise until assignments are revealed. The clean, patient-by-patient attribution waits for that unblinding; the presence and rough size of an effect do not.

A clean result would close the last gap and turn a well-supported expectation into a proven fact. A disappointing result would say the gap was real, and that the wall, with this cargo, is harder to cross in humans than in monkeys. Either way, this is the test that matters, and it is narrow, specific, and close.

What is at stake

It is worth being clear about why a single early readout carries such weight. If ARO-MAPT crosses that last barrier in humans, the prize is not one drug. It is a proven, repeatable way into the brain. The same delivery that carries this siRNA across the wall, a simple shot under the skin, could then be aimed at one brain gene after another, which is why a clean result would validate a platform, not a product. The brain has been the hardest organ in the body to drug, walled off from exactly the gene-silencing medicines that have already proven themselves in the liver. A simple injection that reliably silences a chosen gene in the brain would turn a long list of once-unreachable targets into a pipeline. That is the real stake, and it rests on the delivery question the fall readout tests, not on any later one. The platform is validated the moment the crossing is, whether or not any single drug goes on to prove it treats a disease.

Tau itself is no small target. It sits at the center of Alzheimer’s and a family of related brain disorders driven by the same protein, an enormous unmet need and, if the biology holds, a commercial opportunity to match. That upside, though, rests on two separate questions, not one: whether the drug reaches and silences tau in people, which the fall readout tests, and whether lowering tau meaningfully changes the course of Alzheimer’s, which no one has yet proven and which years of patient data will decide. The delivery result would be a landmark on its own, and the platform it unlocks larger still. The therapeutic payoff is a further bet placed on top of both.

There is a market consequence worth naming. Arrowhead’s CNS pipeline is, for now, priced largely as option value: a promising route to the brain that no human result has yet confirmed. A clean readout would not re-rate one drug so much as the platform behind it, because proof of the crossing converts that option value into an expectation, and does so across every brain program the same delivery could carry. The size of any such move depends on what the stock already discounts, which is beyond the scope of this note. The direction, if the crossing is shown, is not hard to reason out.

The bottom line

Every step of ARO-MAPT’s journey has already been walked in a human being, just not all by the same molecule, and not yet across the one wall that matters most.

That is the whole case in a sentence. This is not a leap into the dark. It is a short step across a single, well-lit gap, onto ground that five other drugs have already proven can hold weight, with Arrowhead’s own monkeys having made the full crossing first. The science is no longer asking whether any of this can work, because each piece already does, in people. It is asking one question, and only one: can a molecule injected into the blood carry its silencing payload across the human blood-brain barrier and into a neuron? Monkeys have already said yes. This fall, humans will answer.

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This note reflects the author’s personal opinions, is for informational purposes only, and is not investment advice. Comparisons to other companies’ drugs are illustrative of scientific precedent and do not imply equivalence of outcome. Clinical figures are drawn from public company disclosures and peer-reviewed sources. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

The setup

Both Arrowhead Pharmaceuticals (ARWR) and Wave Life Sciences (WVE) are developing drugs that silence a liver gene called INHBE. Silencing INHBE lowers a hormone called Activin E, which in turn helps the body shed visceral fat, the harmful fat around organs that drives diabetes, fatty liver disease, and cardiovascular risk. Both companies are pursuing this as a new approach to obesity and metabolic disease, with twice-yearly subcutaneous dosing as the goal.

Until recently, the market viewed Wave as the clear leader in this race. That view formed on December 8, 2025, when Wave printed the first human data showing visceral fat reduction and lean muscle preservation from a single dose of its INHBE drug, WVE-007. The stock moved 147% that day. “Fat loss without muscle loss” became the headline thesis, and Wave became the consensus INHBE leader.

That consensus lasted just over three months.

On March 26, 2026, Wave released six-month follow-up data from the same patient cohort. The visceral fat number held: a 14% placebo-adjusted reduction (meaning 14% better than placebo). Lean mass was preserved. Activin E suppression was durable through seven months. But total body weight loss was just 1%. Waist circumference fell 3%. And the trial population had an average BMI of roughly 32, meaningfully leaner than the patients typically enrolled in obesity drug studies.

Wave’s stock fell nearly 50% that day, closing at $6.20. Bank of America cut its price target to $21. Wells Fargo cut to $13. The note language singled out “reduced conviction in the liver Activin E knockdown mechanism.”

Read that last sentence carefully. The market did not just punish Wave, it punished the INHBE monotherapy thesis itself.

That is the backdrop against which Arrowhead’s ARO-INHBE data, released at the EASL 2026 liver disease conference this morning, should be evaluated. The right question is no longer “who has the cleaner monotherapy headline?” The right question is the one Wave’s March miss raised: can INHBE silencing meaningfully move metabolic outcomes on its own, or does it need a partner drug (specifically, a GLP-1 like Mounjaro or Zepbound) to deliver?

ARO-INHBE’s EASL data is the cleanest answer yet to that question.

What the March repricing actually meant

The 50% drop in WVE was not just disappointment over a single weight loss number. It was a re-evaluation of the entire pharmacology.

INHBE silencing produces deep, durable suppression of Activin E. Wave proved that, but the downstream effect on the metrics the obesity market cares about (pounds lost, waist inches reduced, BMI change) came in well below the bar the December readout had set. A 1% placebo-adjusted weight loss does not compete with GLP-1s like Ozempic and Mounjaro, which routinely deliver 15-22% in late-stage trials.

This left two interpretations. Either the INHBE mechanism is intrinsically a “body composition” drug (reshaping where fat sits) rather than a “weight loss” drug (reducing total mass), and the December market reaction was overpriced, or INHBE silencing only delivers meaningful outcomes when layered on top of a GLP-1, not used alone.

Both interpretations lead to the same operational conclusion: INHBE-as-monotherapy is unlikely to support obesity peak sales models on its own. Either the asset needs to shift toward MASH (metabolic-dysfunction-associated steatohepatitis, a serious form of fatty liver disease) and broader metabolic dysfunction, where body composition matters more than scale weight, or the development path needs to run through combination with the GLP-1 class.

Wave is pursuing neither yet. Its planned Phase 2a multidose study, due to begin in Q2 2026, is still monotherapy in higher-BMI patients. The GLP-1 add-on trial is announced but unstarted. The MASH endpoint is exploratory in a protocol that has not yet begun enrolling. The bet Wave is making is that monotherapy will simply work better in heavier patients than it did in the leaner Phase 1 cohort.

That may turn out to be right, but it is a single-asset, single-strategy bet, dependent on a thesis the market already partially rejected.

The Zwischenzug

In chess, a Zwischenzug (literally “in-between move”) is an unexpected interjection in what appears to be a forced sequence. The opponent has played their move expecting a specific reply. Instead of responding directly, you play something else entirely, something that forces a reassessment of the whole position.

The ARO-INHBE data released this morning is that move.

The market was waiting for Wave to resolve the open question its March readout raised: whether monotherapy could work in higher-BMI patients. Arrowhead answered the question first, and from a completely different angle. Five data points stand out.

First, deeper target engagement. ARO-INHBE achieved an 85.3% mean maximum reduction in Activin E at the 400mg dose, with effect persisting beyond three months. Wave’s 240mg cohort hit roughly 78%. Deeper Activin E suppression directly addresses the sell-side concern about whether the liver INHBE knockdown mechanism reliably works.

Second, real GLP-1 combination data, in humans, today. ARO-INHBE has now produced clinical data in combination with tirzepatide 5mg (the active ingredient in Mounjaro and Zepbound) in two separate cohorts. The first included obese patients without diabetes. The second included obese patients with Type 2 Diabetes Mellitus (T2DM, the most common form of diabetes). Both were followed through week 24. The combination produced enhanced reductions in both visceral fat and liver fat compared to tirzepatide alone. This is the combination path Wave has yet to begin clinical work on.

Third, fatty liver disease data. ARO-INHBE produced a 44% placebo-adjusted reduction in liver fat content in the subgroup of patients with baseline liver fat above 8% receiving 200mg or higher of monotherapy (n=10, p<0.01). In the T2DM combination cohort, where baseline liver fat content was 16.9% (squarely in MASH territory), the combination produced substantially greater liver fat reduction than tirzepatide alone. In the cleaner week 24 readout from the non-T2DM combination cohort, ARO-INHBE 200mg plus tirzepatide reduced liver fat by approximately 45%, versus approximately 16% for placebo plus tirzepatide. That is a roughly 29 percentage point additive effect on top of what a GLP-1 alone delivers.

Fourth, durability. The longest-exposure data from ARO-INHBE shows visceral fat and liver fat reductions deepening from week 12 to week 24 within a single dose interval. Not waning, but deepening. This is the strongest possible support for a twice-yearly subcutaneous dosing schedule. Effects compound through the back half of the dose window, not the opposite.

Fifth, regulatory engagement. Arrowhead is now in active discussions with the FDA on Phase 2 study designs for both obesity and MASH, in parallel.

Every one of these data points addresses an open question raised by Wave’s March miss. The GLP-1 combination works. The mechanism engages the liver fat target deeply. The dosing interval holds. MASH is a credible second indication. T2DM patients respond.

The combination bet, reconsidered

The most consequential decision either company made in INHBE was structural: whether to run the combination program in parallel with monotherapy, or to sequence them: proving the standalone drug first, then layering on combinations later.

Wave sequenced. This produced the cleaner first headline in December. It also produced the harder second headline in March, because monotherapy on its own had to clear an obesity drug bar that increasingly favors percentage body weight loss, the metric Wave fell short on.

Arrowhead ran in parallel. Monotherapy and tirzepatide combination arms enrolled simultaneously, with T2DM patients included from the start. This produced a messier first data presentation (there is no single hero number in the EASL release), but a much more complete picture of where the asset actually works.

In retrospect, the parallel strategy was the right one. Not because monotherapy will necessarily fail; it may still succeed in Wave’s higher-BMI Phase 2a study, but the strategic value of an INHBE asset is dominated by its ability to layer onto the dominant GLP-1 class. The combination path is where the economics get decided. The company that shows combination data first will get the partnership first.

Wave’s GLP-1 add-on trial is scheduled for initiation sometime in 2026. The earliest that produces meaningful data is late 2027. By that time, ARWR will have Phase 2 combination data in hand, possibly Phase 2 MASH data, and could plausibly be in registrational discussions for the obesity-plus-MASH program.

The gap between the two programs is twelve to eighteen months wide. It is widening, and it is not yet reflected in either stock.

What this means for the acquirer thesis

If Eli Lilly (the obvious GLP-1-side buyer or licensor for an INHBE asset, given its tirzepatide franchise) were running a diligence process today, the operational read is unambiguous.

Wave offers a clean monotherapy lean-mass story, an unstarted combination program, and an exploratory MASH endpoint in a protocol that has not yet started enrolling. The development optionality is there but unproven.

Arrowhead offers deeper target engagement, demonstrated additivity with tirzepatide, in-hand liver fat data at MASH-relevant baseline values, a T2DM patient cohort with real combination data, week 24 durability, and active FDA Phase 2 engagement on both obesity and MASH. The development optionality is largely de-risked.

For an acquirer, de-risked optionality is worth more than narrative optionality. Always.

This does not mean Wave is uninvestable. The monotherapy thesis may yet work in higher-BMI patients. The company has real assets beyond WVE-007, particularly in RNA editing. The current valuation already reflects a damaged INHBE story, but the relative premium the market has historically assigned to Wave as the INHBE leader is not supported by the underlying clinical state of the two programs. If anything, that premium should have been migrating to Arrowhead for months.

What I expect from here

Three things to watch over the next two quarters.

First, ARO-INHBE 400mg plus tirzepatide week 24 data in the T2DM cohort, the single highest-impact pending data point from the current Phase 1/2a study (the 400mg combination week 24 data was not yet available for the EASL presentation). If that arm shows continued liver fat and visceral fat deepening at the high dose, the combination case is essentially closed for ARWR.

Second, Wave’s Phase 2a higher-BMI monotherapy data, with the first assessment expected three months after first dose. If placebo-adjusted body weight loss again comes in below 3-4%, the monotherapy thesis collapses entirely, and Wave’s path forward depends entirely on a GLP-1 combination trial it has not yet started.

Third, sell-side recalibration. Most analysts modeling the INHBE class still anchor on Wave’s December readout as the relative reference point, even after the March price target cuts. Expect models to start splitting INHBE valuation into “monotherapy obesity” and “MASH + GLP-1 combination” buckets, with ARWR taking the larger share of the second bucket. That repricing has not started in earnest. It will.

The narrative will catch up. Headlines win the day. Programs win the decade.

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This note is published by BioBoyScout and is intended for informational and educational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss. All financial projections, acquisition price estimates, and valuation analyses herein are hypothetical frameworks for analytical purposes and do not represent predictions of actual outcomes. Readers should conduct their own due diligence and consult a registered investment advisor before making investment decisions. All data cited herein were sourced from publicly available company disclosures, SEC filings, press releases, and peer-reviewed literature as of May 2026.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

The finding

In January and February of 2026, the United States Patent and Trademark Office granted Arrowhead Pharmaceuticals two patents covering the company’s central nervous system delivery platform. The first, US Patent 12,527,877 (Glebocka et al., granted January 20, 2026), claims a platform for delivering RNAi payloads across the blood-brain barrier and to skeletal muscle and heart tissues using antibody fragments that bind the transferrin receptor. The second, US 12,551,569 (Lazzara et al., granted February 17, 2026), claims a specific tau-targeting RNAi conjugate built on that platform, with named therapeutic indications including Alzheimer’s disease, frontotemporal lobar degeneration, progressive supranuclear palsy, and other tauopathies. Both patents are publicly available and run through 2045.

Read together with Arrowhead’s TIDES USA 2026 conference presentation on ARO-MAPT, the patent record reveals a feature of the TRiM SC architecture that public investor materials have not made explicit. The brain delivery platform Arrowhead has described publicly as a “chemistry-engineered targeting ligand” is fundamentally an antibody-fragment platform. The lead binder, identified in both patents as Fab0070, is a Fab fragment: the binding portion of an antibody, the piece that recognizes and attaches to a target on the surface of a cell. Antibody fragments are much smaller than full antibodies but retain the specificity that makes antibodies effective at homing in on particular targets. The transferrin receptor is a protein expressed on the surface of cells throughout the body and is the molecular doorway through which cells take up iron from the bloodstream. By engineering a Fab fragment that binds the transferrin receptor, Arrowhead has built a delivery system that uses that receptor’s natural transport machinery to ferry an RNAi payload into cells. ARO-MAPT, the company’s lead clinical-stage neurology program, is most likely the Fab0070-MAPT siRNA conjugate disclosed in the ‘569 patent claims.

This is a structural observation about the platform’s molecular architecture, not a discovery of hidden technology. The patents are public and the conference presentations have shown the structural imaging of the binder. What the public framing has not emphasized is that the binder is an antibody fragment. The “chemistry-engineered” language is technically accurate (Fab fragments are engineered molecules) but has not conveyed the antibody-fragment nature of the binding component to non-specialist readers.

The distinction matters. Fab-based architectures and small-molecule ligand architectures have different competitive moats, different manufacturing implications, different tissue distribution profiles, and different strategic value. The Fab choice itself is an engineering accomplishment worth understanding. Arrowhead’s scientists looked at how other companies had approached antibody-mediated brain delivery, recognized that the full-antibody approach forces intravenous administration, and engineered a Fab fragment instead. The remainder of this paper works through what the patent record reveals about that engineering choice, why it produces capabilities competing programs have not matched, and what the cross-tissue scope and pipeline breadth imply for Arrowhead’s strategic position.

What the patents and the TIDES presentation disclose

The ’877 platform patent claims an anti-transferrin receptor antibody fragment for delivering RNAi payloads to tissues that express the transferrin receptor. The patent specification describes a screening campaign in which Arrowhead generated and tested dozens of Fab candidates against the receptor, eventually selecting two lead clones called Fab0061 and Fab0070. A screening campaign like this is how antibody-based drugs are developed: a company generates a large library of candidate antibody fragments, tests each one for binding strength and specificity, and selects the best performers as the leads. The patent discloses the full amino acid sequences of both heavy and light chains for both Fabs, which is the level of detail at which the molecular identity of an antibody fragment is publicly established. The connection between the Fab and the siRNA payload is specified as a polyethylene glycol-based chemical tether, the chemistry that holds the antibody fragment and the RNAi payload together in a single drug molecule. The patent claims tissue coverage for the central nervous system, skeletal muscle, and heart muscle, with non-human primate data documenting subcutaneous knockdown across more than fifteen brain regions, both cardiac chambers and ventricles, and skeletal muscle including triceps and gastrocnemius.

The ’569 program patent claims the specific tau-targeting RNAi molecule and its conjugation to an anti-transferrin receptor Fab. The patent identifies the lead conjugate by molecular structure: Fab0070, the lead clone from the ’877 patent, joined through a defined linker chemistry to a specific MAPT-targeting siRNA sequence (MAPT is the gene that produces tau protein, which forms the toxic tangles inside neurons that drive Alzheimer’s disease and related tauopathies). The siRNA sequence is disclosed in the patent’s claims. The conjugation chemistry is the same as that disclosed in the ’877 patent. The therapeutic indications named in the claims include Alzheimer’s disease (Claim 26), frontotemporal lobar degeneration dementia, progressive supranuclear palsy, and other tauopathies (Claim 25). The patent specification frames the disclosure as addressing the historical failure of tau-targeting therapies due to blood-brain barrier penetration challenges, off-target effects, and limited efficacy.

The dual-patent structure (a platform patent and a program-specific patent for a clinical asset) is a meaningful escalation in Arrowhead’s intellectual property strategy. The company’s TRiM-liver franchise has historically relied on program-specific patents covering each clinical asset rather than on a platform-level patent claiming the underlying delivery chemistry. The foundational GalNAc-asialoglycoprotein receptor delivery technology used in the liver franchise is in the public domain and used across the RNAi industry, so platform-level patent protection was not available for that approach. The Fab-based brain delivery technology is different. Because no other company had built a subcutaneously-deliverable antibody-fragment-mediated RNAi delivery platform, Arrowhead was able to secure proprietary platform-level protection. The ’877 patent is the platform patent for the new technology; the ’569 patent is the program-specific patent for a tau program built on it. The ’569 patent provides direct documentary evidence that the antibody-fragment delivery architecture is not a research-stage exploration but a platform that has produced at least one specific clinical-stage molecule with named therapeutic indications, protected by granted intellectual property running through 2045.

The TIDES USA 2026 conference presentation, “Systemic RNAi Targeting MAPT: Advancing Tau Suppression Across the CNS with TRiM SC,” delivered by Kayal Madhivanan of Arrowhead, discloses the public scientific framing of ARO-MAPT. The presentation shows non-human primate data using a dosing regimen of three subcutaneous doses at 3 mg/kg administered weekly on Days 1, 8, and 15, with brain region knockdown of 70 to 80 percent measured at Day 29 across cortex, hippocampus, deep brain regions, and spinal cord, and up to 85 percent in some cortex regions. The durability data extends knockdown to Day 99 and shows tau protein suppression sustained out to Day 239 with a repeat dosing regimen of three weekly loading doses followed by four monthly maintenance doses. The presentation also shows a cryo-EM structure of the TRiM BBB ligand bound at the apical domain of the transferrin receptor (Cryo-EM is a structural imaging technique that uses cryogenic electron microscopy to produce three-dimensional images of biological molecules at near-atomic resolution). The cryo-EM image depicts the binder as a protein-sized molecule rather than as a small-molecule ligand.

The dosing regimen, brain region knockdown profile, durability data, and cryo-EM imaging in the TIDES presentation align with the ’877 and ’569 patent disclosures. The most consistent reading of the available primary-source evidence is that the TRiM BBB ligand publicly described in the TIDES presentation and the Fab0070 conjugate claimed in the ’569 patent are most likely the same molecule, and that ARO-MAPT is the Fab0070-MAPT siRNA conjugate disclosed in the ’569 patent claims.

Figure 1. Schematic of the TRiM SC molecular architecture. The Fab fragment (shown in blue) is the binding component of the delivery system. One end of the Fab binds the transferrin receptor (TfR1) on the surface of cells across the blood-brain barrier and on cardiomyocytes and skeletal muscle. The other end is conjugated to the siRNA payload through a chemical linker. The Fab format is approximately one-third the molecular weight of a full antibody, which is what makes subcutaneous administration possible. Once the Fab binds TfR1, the complex is internalized into the target cell, where the siRNA is released to silence the target gene.

Why the Fab format matters: subcutaneous delivery

The Fab-based architecture is an engineering accomplishment worth pausing on. The competitive landscape for antibody-mediated brain delivery has been dominated by full-antibody approaches that require intravenous infusion. Denali, Roche, JCR, and Alector each took this route. Arrowhead’s scientists studied that landscape and chose differently. In chess terms, the Fab choice was a hypermodern move: a deliberate rejection of the classical approach in favor of an indirect route that proves stronger over time. By engineering a Fab fragment rather than a full antibody, they solved for subcutaneous delivery at the molecular level. The choice was not obvious and the engineering was not trivial. Selecting a Fab that binds the transferrin receptor with the right affinity, conjugating it to an siRNA payload through a stable linker, and demonstrating that the construct produces durable target engagement across the brain at primate scale from a subcutaneous injection is the kind of work that takes years of iteration and represents a meaningful step beyond what the broader field has produced.

The size choice matters more than it might first appear. Full antibodies are large, roughly 150,000 daltons in molecular weight, and at therapeutic doses they require intravenous infusion delivered in a clinical setting. Fab fragments are roughly 50,000 daltons, small enough to be administered as a subcutaneous injection, the same way insulin or a GLP-1 weight-loss drug is administered. The choice between a Fab fragment and a full antibody as the binding component of a brain delivery platform is therefore not just a chemistry decision, it is a commercial decision about how the eventual drug will be administered, where it can be administered, and which patient populations can practically receive it.

Every clinical-stage competitor pursuing antibody-mediated brain delivery has used full antibodies and administered them intravenously. Denali Therapeutics develops enzyme replacement therapies for lysosomal storage disorders such as Hunter syndrome and similar inherited diseases, with its lead clinical programs delivered intravenously. Roche’s Brainshuttle program develops modified antibodies for Alzheimer’s disease and other neurology indications, including trontinemab in the Alzheimer’s space, all delivered intravenously. JCR Pharmaceuticals develops enzyme replacement therapies including pabinafusp alfa for Hunter syndrome, delivered intravenously. Alector develops antibody therapies for neurodegenerative diseases including frontotemporal dementia, delivered intravenously. One preclinical competitor, Dyne Therapeutics, has pursued the same Fab-fragment architecture for muscle delivery and disclosed preclinical NHP MAPT data at the 2026 ASGCT meeting. Dyne’s NHP study used intravenous dosing, with subcutaneous-to-intravenous equivalence demonstrated in mice but not yet in primates. Dyne’s program is preclinical and the company has explicitly framed it as exploratory and capital-efficient rather than as a prioritized clinical development path. ARO-MAPT, by contrast, was demonstrated in primates by subcutaneous administration and has been dosing patients since December 2025. The platform-level engineering required to deliver subcutaneous antibody-fragment conjugates to the brain at clinical scale has been demonstrated only once at the primate-subcutaneous and clinical stages, and that demonstration is Arrowhead’s.

Arrowhead has designed its molecules to do exactly that, and the patent record documents primate subcutaneous knockdown data for both the androgen receptor and tau in Examples 12 and 13 of the ’877 patent. The Day 99 durability data documented in the ’569 patent’s Figure 2 extends the demonstration further, showing tau protein knockdown sustained at approximately three months after the final subcutaneous dose. The TIDES presentation extends this further still with the Day 239 durability data showing tau protein suppression maintained at 16 weeks after the final dose of a three-loading-dose-plus-four-monthly-maintenance regimen. The combination of the patent disclosures and the public TIDES disclosures establishes that Arrowhead’s Fab-based architecture not only enables subcutaneous administration in principle but produces durable target engagement in primates at doses and intervals consistent with quarterly clinical dosing.

The format choice is what makes the platform commercially differentiated. A Fab-based antibody conjugate that crosses the blood-brain barrier from a subcutaneous injection administered every three months is a fundamentally different commercial proposition than a full antibody that requires monthly or biweekly intravenous infusions in a clinical setting. The patient experience differs: a patient with Alzheimer’s disease can receive a subcutaneous injection at home or in a brief outpatient visit, while an IV infusion typically requires hours in an infusion center with skilled nursing. The reimbursement profile differs: payers price subcutaneous therapeutics differently than infused therapeutics, and the lower delivery cost flows through to net economics. The addressable patient population differs because subcutaneous injection at home expands access to patient populations that cannot reliably travel to infusion centers, including elderly patients and patients in rural areas where infusion infrastructure is limited. The cost-of-goods profile differs. The competitive moat against current clinical-stage competitors is substantial, and that moat exists because of an engineering choice (Fab fragment instead of full antibody) that none of the competitors has made.

Cross-tissue scope and pipeline breadth

The transferrin receptor is broadly expressed across the cell types that require iron for normal cellular function. Iron is essential for energy production in cells, and cells with high metabolic demand (the cells that work hardest) express more of the transferrin receptor in order to take up more iron. Beyond the cells of the blood-brain barrier, the receptor is expressed at high density on cardiomyocytes (heart muscle cells, which have particularly high metabolic demand) and on skeletal muscle cells. The Fab0070 conjugate that crosses the blood-brain barrier through transferrin receptor binding also reaches cardiomyocytes and skeletal muscle through the same receptor. The ’877 patent demonstrates this directly. In the same non-human primate study that documented brain knockdown of androgen receptor, the patent reports knockdown across all four heart chambers (77 to 87 percent across atria and ventricles) and across skeletal muscle (with gastrocnemius reaching 72 percent and triceps reaching 33 percent after two subcutaneous doses of 3 mg/kg, given seven days apart). The single Fab architecture, administered subcutaneously, produces deep target engagement in three distinct tissue types from one molecule.

The cardiac delivery data is worth singling out. The androgen receptor is not a therapeutic target in heart disease; the patent used it as a demonstration target to show where the platform reaches. The therapeutically meaningful implication is what this knockdown profile means for other cardiac genes. Several inherited cardiomyopathies are caused by mutations in specific genes that produce proteins inside heart muscle cells. LMNA mutations cause laminopathies, a group of inherited heart muscle diseases that often progress to heart failure and require transplantation. MYH7 mutations cause hypertrophic cardiomyopathy, the most common inherited heart disease, affecting roughly one in every 500 people. PLN mutations cause certain dilated cardiomyopathies. These targets are intracellular structural and regulatory proteins that have resisted small-molecule and antibody-based drug development for decades because conventional drugs cannot reach inside cells to affect them. Transthyretin (TTR) is the closest commercial precedent for cardiac RNAi: Alnylam’s vutrisiran is an approved RNAi drug for transthyretin amyloid cardiomyopathy, though it works through liver delivery to reduce circulating TTR rather than through direct cardiomyocyte targeting. Ion channel genes underlying inherited arrhythmias are another category. None of these therapeutic cardiac target genes is enumerated in the patent claims the way the CNS targets are. The patent claims heart muscle as a tissue the platform reaches but does not list specific cardiac target genes. That gap is notable, and it may indicate either that Arrowhead is reserving cardiac program disclosure for separate patent filings or that the cardiac applications sit at an earlier exploratory stage than the CNS and skeletal muscle programs.

For the CNS, the patent enumerates a substantial target list. More than thirty CNS target genes are claimed by name, including the targets of greatest current commercial interest in neurology. Tau (MAPT) is the target of multiple Alzheimer’s disease and tauopathy programs across the industry. Alpha-synuclein is the target of Parkinson’s disease programs. LRRK2 is another Parkinson’s disease target. Huntingtin is the cause of Huntington’s disease. The ataxin proteins (ATXN1, ATXN2, ATXN3, and others) are associated with various forms of spinocerebellar ataxia, a group of inherited neurodegenerative diseases. SOD1 and FUS are both targets in amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. Each of these names a clinical-stage or near-clinical-stage program at one or more major neuroscience companies. The breadth of the disclosed target list, combined with the ’569 patent’s confirmation that program-specific patents follow as individual molecules advance, signals that the antibody-fragment delivery platform is intended to support a broad neurology pipeline rather than to serve a single program.

The intellectual property architecture confirms this reading. The ‘877 platform patent protects the delivery technology at the platform level: anti-transferrin receptor Fab conjugates with siRNA payloads for subcutaneous delivery across the blood-brain barrier and to muscle and heart tissues. The ‘569 program patent then protects the specific MAPT-targeting molecule at the asset level. This is a meaningful escalation in Arrowhead’s intellectual property strategy. Arrowhead’s TRiM-liver franchise has historically relied on program-specific patents covering each clinical asset (ARO-AAT for alpha-1 antitrypsin deficiency, plozasiran for severe hypertriglyceridemia and now approved as Redemplo, ARO-ANG3 for cardiometabolic disease, ARO-PNPLA3 for nonalcoholic steatohepatitis, and others). The foundational GalNAc-asialoglycoprotein receptor delivery chemistry is in the public domain and used across the industry, including by Alnylam and Ionis, so broad platform-level patent protection was not available for that approach. The Fab-based brain delivery technology is different. Because no other company had built a subcutaneously-deliverable antibody-fragment-mediated RNAi delivery platform, Arrowhead was able to secure proprietary platform-level protection. The ’877 patent secures proprietary platform-level intellectual property for the antibody-fragment brain delivery technology, the kind of foundational protection that did not exist for the publicly available GalNAc-liver delivery chemistry. Additional program-specific patents would be expected as additional CNS targets advance toward clinical development. The granted intellectual property is the kind that supports a commercial pipeline rather than a research project, and the platform layer means competitors cannot replicate the approach without licensing or working around the ’877 patent.

The scope is therefore broader than the disclosed clinical pipeline reflects. ARO-MAPT is the lead clinical-stage asset. The patent’s thirty-plus CNS targets and the demonstrated extrahepatic reach suggest a multi-program pipeline that current investor materials have not articulated at the level of detail the patents now disclose.

Strategic and valuation implications

The Fab-based architecture has different manufacturing requirements than a small-molecule chemistry-engineered platform would have. Small-molecule drugs are produced through chemical synthesis. Antibody fragments are produced through biological manufacturing, where engineered cells (typically mammalian cells, such as Chinese hamster ovary cells) are grown in large bioreactors and instructed to produce the desired antibody fragment. The cells then secrete the antibody fragment into the surrounding fluid, from which it is purified and conjugated to the siRNA payload. This is a fundamentally different manufacturing process with different capital requirements, different operational expertise, different quality control systems, and different regulatory pathways. The Fab-based architecture means Arrowhead’s manufacturing footprint includes biologics-capable production capacity, either in-house or through contract manufacturing partners, which carries different cost and operational implications than the small-molecule chemistry that the GalNAc-liver programs require.

The cross-tissue scope expands the addressable disease space beyond what current investor materials emphasize. The CNS franchise spans Alzheimer’s, Parkinson’s, Huntington’s, ALS, and the spinocerebellar ataxias. The skeletal muscle extension opens muscular dystrophies. The cardiac extension opens inherited cardiomyopathies and inherited arrhythmias. The platform’s reach across three tissue types from a single subcutaneous injection means an acquirer is buying a multi-tissue intracellular delivery system rather than a brain delivery technology.

The intellectual property protection running through 2045 anchors the long-term strategic value. The ’877 platform patent and the ’569 program patent are granted, defensible, and would require an acquirer to either license or work around if a competitor tried to enter the same space. The platform-plus-program patent architecture also signals that additional program-specific patents will follow as additional clinical assets advance, creating layered intellectual property protection that compounds over time. A platform of this kind, with multi-tissue scope, durable patent protection, and primate-validated subcutaneous delivery, is the kind of asset that justifies acquisition premium above what current sell-side comparable-transaction methodology produces. The Acquisition of the Decade argued that the eventual acquirer of Arrowhead will own the most strategically important platform in biotech this decade. The patent-record evidence developed in this paper strengthens that case. The platform is more sophisticated, broader in scope, and more durably protected than public framing has emphasized. Whichever pharma is currently modeling Arrowhead as an acquisition target needs to model these features as part of the asset they are bidding on.

What this means for the existing thesis

The Acquisition of the Decade argued that Arrowhead is the most strategically important acquisition target in biotech this decade, on the basis of what the company had already publicly disclosed. The patents reviewed in this paper add documentary depth to that case. The brain delivery platform that public materials describe as a “chemistry-engineered targeting ligand” is fundamentally an antibody-fragment platform built around Fab0070. The platform reaches the brain, skeletal muscle, and cardiomyocytes from a single subcutaneous injection. The patent claims protect the architecture and the lead clinical asset through 2045. The platform-plus-program patent structure is stronger than the program-only intellectual property that has historically protected Arrowhead’s TRiM-liver franchise, signaling that the platform is positioned to support a full pipeline of clinical assets behind proprietary platform-level protection.

None of this changes the conclusion of The Acquisition of the Decade. This paper sharpens the supporting evidence. The platform is more sophisticated than public framing has emphasized, broader in tissue scope, and more deeply protected in the patent record. Each of these features strengthens the case that an acquirer of Arrowhead is acquiring a complete operational franchise rather than a single drug or a pipeline of small-molecule conjugates. The strategic value of that franchise is what the prior paper described as the most consequential acquisition available in biotech this decade. The patent-record evidence developed here makes the strategic value more concrete and more difficult for a sophisticated acquirer to ignore.

The public framing told one story. The patent record tells the full one. The Fab-based architecture documented in the patents is a real engineering accomplishment, the kind of work that takes years of iteration. The hypermodern move was the choice. The years of execution between choice and clinic are what turn a choice into a moat. The Fab choice is also a data point in a pattern. The same scientific team that delivered GalNAc-mediated liver RNAi, then extended the platform to skeletal muscle, to inhaled lung delivery, to adipose tissue, and now to subcutaneous brain delivery, has built a track record of solving the delivery problems that define what RNAi drugs can do. Each extension required its own engineering work. The team has not yet failed to find a path. When the next hard delivery problem arrives, the same team will be working on it. Arrowhead made the move, did the work, and arrived at the clinic alone.

The Fab choice was the hypermodern move. The years of execution were the moat. The position is now Arrowhead’s alone.

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed;

• he was not compensated in any form for producing this note; and

• he has not received and does not receive compensation from Arrowhead Pharmaceuticals.

This note is published by BioBoyScout and is intended for informational and educational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss. All financial projections, acquisition price estimates, and valuation analyses herein are hypothetical frameworks for analytical purposes and do not represent predictions of actual outcomes. Readers should conduct their own due diligence and consult a registered investment advisor before making investment decisions. All data cited herein were sourced from publicly available company disclosures, SEC filings, press releases, and peer-reviewed literature as of May 2026. Factual claims about the patent record are sourced from US Patent 12,527,877 (Glebocka et al.) and US Patent 12,551,569 (Lazzara et al.) as published by the United States Patent and Trademark Office. Factual claims about ARO-MAPT scientific data are sourced from the publicly available TIDES USA 2026 conference presentation by Kayal Madhivanan of Arrowhead Pharmaceuticals. The architectural identification of TRiM-CNS as a Fab-based antibody-fragment platform is an analytical inference from the most consistent reading of the available primary-source evidence rather than a direct statement from Arrowhead.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

The claim

Whichever pharma company acquires Arrowhead Pharmaceuticals will own the most strategically important asset in biotech this decade. Not because Arrowhead has the most drugs in clinical trials. Not because any single program is the next Keytruda. Because Arrowhead has built, and is translating into human patients across more tissues than anyone else, the broadest RNAi delivery platform in the industry. Everything else follows from that.

This note explains what that means, why it matters more than a pipeline, and why the timing makes this acquisition uniquely valuable to whichever large-cap pharma is willing to act.

The background

RNAi (RNA interference) is a way of silencing specific genes inside cells. Most drugs today work by blocking a protein after the body has already made it. RNAi works one step earlier: it stops the protein from being made in the first place. The practical consequence is that RNAi medicines tend to last longer. A single injection can suppress a disease-causing protein for months, and they can be more precise, because they target a unique genetic sequence rather than a protein shape that may be shared across many parts of the body.

The problem with RNAi, for most of the last twenty years, was delivery. You can design the perfect RNAi molecule in a laboratory, but if you cannot get it into the right cells inside the body, it does nothing. For a long time, the only tissue that could be reached reliably was the liver. A sugar molecule called GalNAc could escort RNAi drugs into liver cells, and that single delivery solution is essentially what the leading RNAi company before Arrowhead, Alnylam Pharmaceuticals, built its business on. Everything beyond the liver remained largely preclinical across the industry.

Arrowhead’s TRiM platform (Targeted RNAi Molecule) changed that. TRiM is a chemistry system that lets Arrowhead design molecular keys for different tissues. The company has now advanced programs into human clinical trials in five tissue types: liver, lung, skeletal muscle, the central nervous system, and adipose. Two further tissues, ocular and cardiomyocyte, are at the preclinical stage, bringing the total platform footprint to seven cell types Arrowhead is actively engineering against.

It is worth being honest about where competitors are. Alnylam is no longer simply a liver company. Its mivelsiran program in central nervous system disease is in Phase 2. Alnylam has also disclosed preclinical delivery work in adipose, muscle, heart, and kidney. That work is real and credible. The gap is at the clinical-stage tissue breadth: Alnylam has clinical programs in two tissues; Arrowhead has clinical programs in five. Translating preclinical delivery into human data is the hard part, and Arrowhead has done it more times, more recently, across more tissues than anyone else.

Ionis Pharmaceuticals, historically the leader in antisense oligonucleotides has now entered the siRNA space as well, with its first clinical-stage siRNA candidate in 2025. Ionis is taking a multi-modality approach, picking ASO or siRNA per target. That sharpens the competitive picture but does not close the tissue-breadth gap, which is the dimension that matters most for an acquirer.

The antibody-oligonucleotide companies, which use a different chemistry to deliver oligonucleotides to specific tissues, are also expanding beyond their initial muscle focus. Dyne Therapeutics’s FORCE platform now targets muscle and the central nervous system, supporting its programs in myotonic dystrophy, Duchenne muscular dystrophy, FSHD, and Pompe disease. Avidity Biosciences extended into cardiology and immunology via partnerships with Bristol Myers Squibb and Eli Lilly, and was acquired by Novartis in a deal that closed in February 2026 at approximately $12 billion. We will come back to that transaction. Both AOC platforms remain narrower than Arrowhead in tissue breadth, but neither is a single-tissue play any longer.

That foundation is what makes the strategic case. The rest of this note develops four arguments that follow from it.

Argument 1: Modality leadership

When a pharma company buys a single drug, they buy a single drug. When they buy a small-molecule company, they buy a library of molecules. When they buy Arrowhead, they buy the most clinically advanced multi-tissue RNAi platform that exists.

This is the difference between buying a product and buying a category. The liver category in RNAi is competitive. Alnylam, Ionis, and several smaller players all have liver-targeting assets. The extrahepatic categories are not competitive in the same way. Arrowhead has advanced more tissues into human studies, in more disease areas, on a faster timeline than any other RNAi developer. Competitors are pursuing extrahepatic delivery; Arrowhead is doing it in patients, across multiple tissues, today. That gap is the moat, and gaps measured in tissues and years are not closed by a single positive data point from a competitor.

Breadth is the headline, but the head-to-head record matters as much. Where Arrowhead’s programs have competed directly against competitor programs targeting the same gene, alpha-1 antitrypsin deficiency, hepatitis B, lipoprotein(a), APOC3, Arrowhead’s molecules have consistently produced more potent, more durable, or better-tolerated profiles than the alternatives. That track record is developed in detail later in this note. For the modality leadership argument here, the point is simpler: Arrowhead is not only broader than its competitors; it is also better than them at the level of the molecule itself.

Modality leadership of this kind is what large-cap pharma pays premium prices for, because it cannot be replicated through licensing or partnership. You can license a drug. You cannot license a decade of accumulated chemistry know-how, screening infrastructure, manufacturing capability, and clinical translation experience spread across seven tissues.

Argument 2: Optionality compounds

This is the argument most investors miss, and it is the one that matters most.

When a company has a pipeline of independent drugs, the value of that pipeline is roughly the sum of the value of each drug, adjusted for the probability that each one works. Each drug stands or falls on its own.

A platform works differently. Each new tissue that Arrowhead validates is not just one asset, it is a permission slip to credibly pursue every disease in that tissue. Validating the lung is not worth one drug; it is worth every lung disease where silencing a gene could help. Validating the central nervous system is not worth one neurological program; it is worth every neurodegenerative disease where the right target exists.

And each validated tissue makes the next one cheaper and faster to validate, because the underlying chemistry, the screening systems, the regulatory precedent, and the manufacturing all carry over. The manufacturing point deserves its own emphasis. Arrowhead built integrated in-house oligonucleotide manufacturing, its Verona, Wisconsin GMP facility, completed at a final capital cost of approximately $300 million, at a time when most RNAi developers were dependent on a small handful of contract manufacturers for large-scale oligonucleotide synthesis and conjugation. The facility now produces GMP drug substance for clinical trials in the United States and, following a successful Qualified Person audit, in the European Union and the United Kingdom as well. That internal capacity is what makes the carryover from one tissue program to the next real rather than theoretical. The same plant, the same process scientists, and the same quality systems absorb each new program without renegotiating contract scope or competing for batch slots with another company’s drug.

Platform value scales super-linearly with the number of validated tissues. Pipeline value scales linearly with the number of drugs. That is a fundamental difference in how value grows, and it is why platform companies command premium multiples when they are acquired.

The compounding is sharpened by a second effect that is easy to overlook. Each new target Arrowhead picks up is not a coin flip on whether the drug works, it is a coin that has been weighted by years of chemistry know-how toward producing better triggers than competitors targeting the same biology. The platform compounds across tissues, and the trigger design capability compounds within each tissue. The acquirer is not just buying more shots on goal; the acquirer is buying shots on goal with a higher per-shot probability of producing a best-in-class molecule.

For the acquirer, the arithmetic is straightforward. The cost of buying Arrowhead today is dwarfed by the cost of trying to rebuild what Arrowhead has from scratch. Even with unlimited money, you cannot compress a decade of validation work and a fully built manufacturing footprint into a few years. The acquirer is buying time as much as technology.

Argument 3: The team is part of the platform

TRiM did not emerge from a single insight. It was built over a decade by a specific group of scientists who made a sequence of correct, non-obvious decisions in chemistry, target selection, clinical strategy, and manufacturing. That knowledge lives in people, in scientists’ instincts about which experiments to run and which to skip, in laboratory notebooks, in screening platforms the team built internally, in the process engineers who know how to make these molecules at scale, in institutional muscle memory that cannot be written down.

This matters because pharma acquisition history is full of cases where the buyer got the assets and lost the scientists within two or three years. Celgene’s drug discovery culture did not survive the Bristol Myers Squibb acquisition. Genentech’s preservation under Roche is the exception that proves the rule. When the platform is the people, retention is the deal.

The Arrowhead team has demonstrated four things consistently:

Pace

They have outproduced the rest of the RNAi field. While competitors were extending their liver franchises, Arrowhead was advancing programs across five tissues into the clinic and adding two more, ocular and cardiomyocyte, at preclinical stage. That cadence is not luck. It reflects an organization that has figured out how to run programs efficiently across multiple targets at once, and it is materially helped by the company having built its own manufacturing. RNAi clinical timelines across the industry have historically been gated by availability at contract manufacturers, where queuing for batch slots has slowed program advancement for everyone dependent on them. Arrowhead largely solved that problem by building Verona. Internal manufacturing is part of why the team’s output cadence outruns competitors who are otherwise scientifically capable.

Target selection

INHBE, the gene Arrowhead is now silencing for obesity and metabolic disease, was a non-obvious choice when the program began. Picking it before the wider scientific consensus caught up signals real biological judgment, not just chemistry execution. The same pattern holds for MAPT in tau-driven neurodegeneration, for the cardiometabolic targets, and for the breadth of programs the team has prioritized over time.

Translation discipline

Across program after program, what Arrowhead sees in preclinical animal studies has carried into human studies. That kind of consistency across many shots on goal is not statistical luck, it reflects a screening and selection process that works.

Trigger design

The fourth capability is the one that matters most at the chemistry level, and the one that distinguishes Arrowhead most clearly from competitors targeting the same biology. Designing an RNAi trigger, the actual silencing molecule that gets delivered to a tissue, involves trade-offs between potency, durability, and tolerability that are not solved by following a formula. The team has to predict, across millions of possible sequences, which specific design will silence the target gene most completely, last the longest in circulation, and produce the fewest off-target effects. It is craft as much as it is chemistry, and Arrowhead has consistently produced triggers that beat competitor triggers head-to-head against the same target.

Three head-to-head comparisons make the point concrete. In alpha-1 antitrypsin deficiency, Arrowhead’s fazirsiran produced deep and durable Z-AAT knockdown and advanced into registrational development with Takeda; Alnylam’s belcesiran program against the same target underperformed on the potency-tolerability balance and was discontinued. In hepatitis B, Arrowhead’s JNJ-3989, partnered with Janssen, produced more profound and more durable HBsAg reductions than competing programs from Alnylam and Dicerna, and the strength of that profile drove a partnership expansion to multiple additional targets. In lipoprotein(a), Amgen’s olpasiran, derived from Arrowhead chemistry, achieves greater than 95 percent Lp(a) reduction at 75 milligrams dosed every twelve weeks. Silence Therapeutics’s zerlasiran, the closest competitor program, requires 300 to 450 milligrams every sixteen to twenty-four weeks for a comparable reduction. That is roughly four to six times the milligram dose for an effect that is, at best, equivalent. Drug volume is not a footnote, it determines injection burden, manufacturing economics, and ultimately commercial competitiveness.

This pattern repeats across the pipeline. Arrowhead’s APOC3 program, plozasiran, demonstrated a cleaner clinical profile than Ionis’s olezarsen in the same disease space. The pulmonary triggers in the lung pipeline have shown deeper knockdown than what competing antisense approaches have delivered in airway tissues. The CNS triggers are producing durable knockdown of difficult-to-target proteins that have resisted other modalities for years. The pattern is not coincidence. It is what happens when a chemistry team that has been doing this work together for a decade keeps getting better at it.

These four traits, pace, target selection, translation discipline, and trigger design, are not independent capabilities that happen to coexist at the same company. They are four expressions of the same underlying culture, and that culture is the most fragile asset Arrowhead would bring to a deal. Christopher Anzalone has been chief executive since December 2007, an unusually long tenure for a biotech of this scale, and the senior scientific bench has stayed largely intact across more than fifteen years of platform development. The decision to build internal manufacturing rather than outsource it was itself a cultural choice, it reflects an organization that prizes operational ownership over short-term cost optimization, and that is willing to invest capital in capability-building when the payoff is years away. The team works as a team because it has been the same team, doing the same work, in the same place, for a long time. That continuity has built a team culture, a bond and a working atmosphere, that the rests of the industry has not been able to replicate.

The acquirer who lands Arrowhead has to recognize that they are buying a research and manufacturing organization, not a pipeline. That recognition actually narrows the list of natural acquirers. It favors buyers with a track record of preserving acquired science over buyers known for aggressive cost-cutting integration. That selection effect is itself useful, it tells you which large-caps will be willing to pay the premium this deserves, and which will not.

Argument 4: The post-cliff decade

The biopharma industry is approaching the largest patent cliff in its history. Between 2028 and 2030, drugs accounting for more than $200 billion in annual revenue are losing their patent protection. Keytruda, Eliquis, Opdivo, Stelara, Xarelto, and a long tail of secondary brands all come off-patent in roughly the same window. The acquirers facing this cliff need replacement revenue, and the standard playbooks, bolt-on small molecules, biosimilar-vulnerable biologics, me-too oncology, do not structurally solve the problem.

RNAi assets are different in ways that matter for this exact situation. The chemistry is patentable in ways small molecules are not, because the molecules themselves are complex and the manufacturing is genuinely difficult. Composition-of-matter patents are one wall against generic competition. The second wall is process know-how. Making oligonucleotide drugs at commercial scale, with the purity and consistency regulators require, involves hard-won operational knowledge that accumulates in plants and process scientists rather than in published methods. Arrowhead owns that know-how because it built and runs its own manufacturing. The regulatory pathway for follow-on or generic-equivalent oligonucleotide drugs remains undefined, which adds a third layer of durability that small-molecule franchises do not enjoy.

Dosing intervals are long, often quarterly or twice-yearly, which builds patient stickiness and creates real barriers to switching. The diseases being targeted, chronic metabolic, cardiovascular, neurodegenerative, are exactly the durable, large-population indications that produce decade-long franchises.

But the timing point is the one that makes this argument actually work. Arrowhead does not solve the immediate 2028 cliff. Plozasiran, now approved as Redemplo, is the only Arrowhead drug already contributing revenue in that window. Everything else, INHBE and ALK7 for obesity and metabolic disease, MAPT for neurodegeneration, the expanding cardiometabolic pipeline, the Sarepta-partnered neuro programs, contributes through the 2030s.

That is the right frame. The acquirer is not patching a 2028 hole. The acquirer is building the franchise that carries them through the post-cliff decade, when their existing blockbusters are off-patent and their pipeline needs to deliver. Arrowhead is the highest-quality answer to that problem in the entire industry.

A real-world reference point

In October 2025, Novartis announced its acquisition of Avidity Biosciences. The deal closed on February 27, 2026 at approximately $12 billion in total value, a 46 percent premium to Avidity’s prior closing share price, for an antibody-oligonucleotide platform with three late-stage muscle programs and an early-stage cardiology effort that was spun out as a separate publicly traded company before close.

The Avidity transaction is the closest recent comparable for what an Arrowhead acquisition could look like, and it makes the strategic logic of this note concrete rather than hypothetical. Novartis framed the deal explicitly as part of its xRNA strategy and as a way to support its 2025-2030 sales growth, with product launches expected before 2030. That is large-cap pharma using RNA acquisitions to position for the same post-cliff decade this note has been describing, and paying a premium to do it.

Arrowhead is broader than Avidity across every dimension that mattered in that deal. More tissues with active clinical programs. An already-approved commercial drug in Redemplo. Internal manufacturing capacity that Avidity did not have, and a longer pipeline runway through the 2030s. The strategic logic that justified the Novartis-Avidity transaction applies with greater force to Arrowhead.

What it adds up to

Four arguments converge on one conclusion.

1. The asset is differentiated. TRiM has the broadest clinical-stage tissue footprint in RNAi, with seven tissues now under active development and five already in human trials. Where Arrowhead has competed head-to-head against competitor programs targeting the same gene, it has consistently produced more potent or better-tolerated molecules. That combination gives the acquirer modality leadership rather than product leadership.

2. The asset compounds. Each validated tissue makes the next one cheaper, and the platform’s underlying chemistry, screening systems, manufacturing capacity, and regulatory experience all carry over. The team’s trigger design capability compounds within each tissue as well. Every new target benefits from a higher baseline probability of producing a best-in-class molecule. Platform value grows super-linearly. Pipeline value does not.

3. The asset cannot be replicated. The team, the manufacturing know-how, and the institutional knowledge are part of what the acquirer is buying, and the acquirers who understand this will pay accordingly.

4. The timing is right. Arrowhead’s value is concentrated in the 2030s, exactly when the rest of large-cap pharma needs replacement revenue to survive the post-2028 patent cliff.

These arguments are not independent. They reinforce each other. The platform is rare because the team built it. The team’s output is large because the platform compounds, and because manufacturing capacity removed the operational bottleneck that slows competitors. The molecules are better because the chemistry team has spent a decade getting better at designing them. The platform’s commercial value is durable because the chemistry, the process, and the regulatory pathway all favor incumbents. The durability matters most in the decade after the cliff.

This is why “the most strategically important acquisition of the decade” is not hyperbole. It is the straightforward consequence of facts about the asset, the team, the modality, and the calendar.

Whichever large-cap pharma acts on this, and the list of natural acquirers is shorter than it looks, because the integration question screens out the wrong ones, will reset its competitive position for the 2030s. The M&A cycle in RNA therapeutics is not hypothetical and not coming; it is already underway. Novartis acted on a narrower version of this thesis in October 2025 and closed on it four months later. Whichever large-cap pharma does not act on the broader version will spend the next ten years watching a competitor consolidate the modality, and wondering what the right price would have been.

In chess, the queen is the most powerful piece on the board. It controls more squares than any other piece, moves in any direction, and is the single piece whose capture changes a game more than any other exchange. Most acquisitions in biopharma are pawn trades and knight exchanges. Some are rook captures. Arrowhead is the queen. The acquirer who captures it acquires the single most consequential piece available on the biotech M&A board this decade. The acquirer who lets it be captured by a competitor spends the next decade playing without a queen.

There is a final point worth making, and then leaving for another day. Original research into Arrowhead's patent record has surfaced findings that materially strengthen the strategic case. A forthcoming note will lay out those findings in detail. The point for this note is narrower: the four arguments above are made entirely on the basis of what Arrowhead has already disclosed publicly, and the case is sufficient on that basis alone. What is coming only strengthens it.

The acquisition of the decade is not a prediction. It is a transaction waiting for its buyer.

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed; and

• he was not compensated in any form for producing this note.

This note is published by BioBoyScout and is intended for informational and educational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss. All financial projections, acquisition price estimates, and valuation analyses herein are hypothetical frameworks for analytical purposes and do not represent predictions of actual outcomes. Readers should conduct their own due diligence and consult a registered investment advisor before making investment decisions. All data cited herein were sourced from publicly available company disclosures, SEC filings, press releases, and peer-reviewed literature as of May 2026.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now

This morning I published a note on what TIDES revealed about ARO-MAPT. That note framed CELIA, Biogen’s Phase 2 trial of their tau-lowering drug diranersen (formerly BIIB080), as the upcoming question that would tell us whether reducing tau in patients actually slows cognitive decline.

Hours later, Biogen released the CELIA topline results. The question is now answered.

The answer is yes, with important nuances. This note works through what CELIA actually shows, why the headline “missed primary endpoint” framing misreads the data, and why the result is significantly positive for Arrowhead.

Before going further, a quick recap for readers who didn’t see this morning’s note. Alzheimer’s disease involves two abnormal proteins building up in the brain: amyloid (plaques) and tau (tangles inside neurons). The currently approved Alzheimer’s drugs (Leqembi, Kisunla) target amyloid. Tau is the next frontier because tau tangle burden, not amyloid, is what correlates with how fast patients decline cognitively. Diranersen and ARO-MAPT both aim to reduce tau, but through different delivery systems. Diranersen is injected into the spinal fluid via a needle in the lower back (intrathecal). ARO-MAPT is a quarterly under-the-skin injection (subcutaneous) that uses the body’s natural transport system to cross from the bloodstream into the brain. CELIA tested whether tau-lowering therapy works clinically in patients. The next test, ARO-MAPT’s first human readout, comes in late September or October. As Chris Anzalone clarified yesterday at the Bank of America Healthcare Conference, that readout is from the healthy volunteer portion of the Phase 1/2a trial. AD patient data comes later.

What CELIA actually shows

The headline most trading desks saw this morning was “CELIA did not meet its primary endpoint.” To understand why that headline misreads the data, it helps to know what a primary endpoint actually is.

Every clinical trial has one (or sometimes two) pre-specified primary endpoints, the main statistical questions the study is designed to answer. CELIA’s primary endpoint was unusual: it tested whether the three studied doses of diranersen produced a dose-response relationship on cognitive decline. In other words, did giving more drug produce proportionally better cognitive outcomes? The three doses tested were 60 mg every 24 weeks, 115 mg every 24 weeks, and 115 mg every 12 weeks. The answer was no, the dose-response relationship did not reach statistical significance.

But a trial’s primary endpoint isn’t the same thing as whether the drug works. Trials also measure secondary endpoints and pre-specified exploratory endpoints, additional questions designed into the study from the start. CELIA’s secondary and exploratory measures tell a very different story than the headline suggests.

On biomarkers, Biogen reported “robust reductions in both cerebrospinal fluid (CSF) tau and tau pathology, as measured by positron emission tomography (PET), across all studied doses, with reductions maintained throughout the dosing period.” Two of those technical terms matter. CSF tau is the level of tau protein in spinal fluid, a measurable indicator that the drug is working at the gene level to reduce tau production. Tau PET is a brain scan that lights up tau tangles inside the brain. PET reduction means the drug is actually shrinking the disease pathology, not just lowering numbers in a lab test. CELIA showed both, across every dose tested, and the effect held throughout the 18-month treatment period.

On cognition, Biogen reported “pre-specified analyses of cognitive endpoints demonstrated slowing of clinical decline across all studied doses, particularly in participants receiving the lowest dose of diranersen, 60 mg administered every 24 weeks.” Pre-specified means these analyses were designed into the trial before the data were unblinded, this is not data-mining after the fact. Slowing of clinical decline means patients on diranersen got worse more slowly than patients on placebo, which is the entire point of a disease-modifying therapy. The cognitive benefit was present at every dose. The strongest signal came from the lowest dose.

On safety, the side effect rates were similar across doses, but the highest dose produced more serious adverse events. This pattern explains why the dose-response primary endpoint missed. Higher doses didn’t produce proportionally better outcomes because they introduced safety problems that offset their benefit. The trial’s primary endpoint assumed more drug equals more benefit. That assumption was wrong, and that’s why the statistical test missed.

Biogen’s response to this data tells us how to read it. They are advancing diranersen to registrational Phase 3 development. Registrational means a trial designed to support FDA approval, not a smaller exploratory study. Biogen is a company that has been criticized for capital discipline, faces shareholder pressure on R&D spending, and has had a string of disappointing programs. That company is committing hundreds of millions of dollars to Phase 3 development despite the technical primary endpoint miss. They are doing this because the totality of evidence, including data the public hasn’t seen, is sufficient to justify the commitment. Companies do not greenlight expensive Phase 3 trials on weak signals.

Dr. Jeff Cummings of UNLV, one of the most prominent Alzheimer’s disease researchers in the world, characterized CELIA as “an important advance for the field, providing the first evidence that reducing tau, a hallmark of Alzheimer’s disease closely associated with neurodegeneration and cognitive decline, may meaningfully impact disease progression.” Cummings doesn’t endorse studies casually. His framing is that CELIA established a new fact about Alzheimer’s therapy.

Here is what the data actually shows: tau-targeting therapy works. Lowering tau produces measurable reductions in the disease pathology and slows the rate at which patients decline cognitively. The primary endpoint missed on a specific statistical test about dose-response, not on whether the drug works.

Why this validates the tau hypothesis clinically

For five years, the tau-targeting field has been waiting for proof that the underlying mechanism works in patients. Multiple anti-tau antibody programs from Roche, AbbVie, and others have failed in trials. The bear case argued that lowering tau wouldn’t translate to cognitive benefit because of a problem called species-selectivity.

Here is the species-selectivity problem in plain terms. Tau is a normal protein found in healthy brains, where it stabilizes the internal structure of neurons. The problem in Alzheimer’s is not that tau exists, the problem is that a subset of tau gets chemically modified in ways that cause it to misfold, clump up, and form the toxic tangles that kill neurons. The bear case asks: if you lower all tau indiscriminately, are you reducing the toxic version, or just depleting the healthy pool while the toxic version keeps accumulating?

CELIA answers this question. Diranersen lowers total tau, and the lowering produces cognitive benefit in patients. Whatever fraction of the tau being lowered includes the toxic version, the net effect on patients is positive. The mechanism works, despite the species-selectivity concern.

For ARO-MAPT specifically, this changes the structure of the upcoming readout. Before CELIA, ARO-MAPT was testing two things at once: does lowering tau help patients, and does Arrowhead’s specific approach work? Now the first question is answered. ARO-MAPT’s upcoming healthy volunteer data tests a more focused question: does Arrowhead’s subcutaneous delivery produce the foundational pharmacology, drug reaching the brain, target engagement, safety, that justifies advancing to patient cohorts?

This is a meaningfully lower-risk question. The biology is validated. The delivery system is the variable that the upcoming readout tests.

What the late-2026 readout will actually show

Chris Anzalone clarified the scope of the readout at the Bank of America conference yesterday. Worth quoting directly: “The data we will have this year is just in healthy volunteers. Let’s see if this translates from NHPs to humans, let’s see if we get good knockdown of tau. Let’s see if this is well tolerated.”

This is meaningful framing. Phase 1/2a trials for CNS drugs typically have a multi-part design. ARO-MAPT’s trial includes a single ascending dose (SAD) portion in healthy volunteers, where escalating doses are tested in non-AD participants to establish safety, drug exposure in the body and brain, and target engagement (tau reduction). It also includes multi-ascending dose (MAD) cohorts that include Alzheimer’s patients, where the drug is administered repeatedly over weeks to months to evaluate sustained effects.

The late-2026 readout is the healthy volunteer SAD data. It tests three specific questions:

• Does the drug cross into the brain in humans the way it did in monkeys?

• Does it produce target knockdown, meaning measurable reductions in tau, in human CNS tissue?

• Is it well tolerated at doses expected to be therapeutic?

The AD patient data, which will test cognitive endpoints and tau pathology imaging, comes later in 2027 from the MAD cohorts.

This is actually a cleaner read for the late-2026 catalyst than testing cognitive benefit in patients on the first readout. Healthy volunteers don’t have AD pathology, so the readout focuses on what matters analytically: does the drug do in humans what it did in monkeys? Spinal fluid tau reduction is the cleanest measurable endpoint for that question. The animal data and predictive model say 50% or greater reduction in spinal fluid tau is the expected number. Diranersen’s Phase 1b showed approximately 60%. If ARO-MAPT lands in that range in healthy volunteers, the platform translates as designed, and the AD patient cohorts have the foundation needed to test cognitive effects.

Why ARO-MAPT is the better-built version

This early morning’s TIDES note worked through the structural differences between intrathecal delivery (diranersen) and subcutaneous TfR1-mediated delivery (ARO-MAPT). The relevance of those differences just increased substantially.

Diranersen is delivered intrathecally, which means injected into the spinal fluid via a needle inserted into the lower back. The drug pools near the injection site and distributes mostly to the spinal cord and the surface of the brain. Arrowhead’s preclinical data shows intrathecal delivery produces a 22-fold differential between drug concentrations at the surface and concentrations in deep brain regions. The deep regions, including the hippocampus where Alzheimer’s pathology starts, get far less drug than the surface.

ARO-MAPT is delivered as a subcutaneous injection, meaning under the skin, similar to how insulin or a GLP-1 weight loss drug is administered. The drug travels through the bloodstream to the blood-brain barrier, where it hitches a ride on the transferrin receptor (TfR1), a natural transport mechanism the brain uses to bring iron in from the blood. Arrowhead engineered ARO-MAPT to bind to TfR1, which carries the drug across the blood-brain barrier and into the brain. The drug distributes evenly across all brain regions with less than 2-fold variation. Deep brain structures get comparable drug exposure to surface regions.

CELIA’s data adds a specific new dimension to this comparison: the inverse dose response. The lowest dose worked best. Higher doses produced more serious adverse events without proportional benefit. This pattern tells us something important about intrathecal delivery itself.

Think of it this way. Intrathecal delivery puts a concentrated dose of drug directly into the spinal fluid, where it has to spread out, reach the brain, and distribute. Increasing the dose increases the concentration at the injection site. The brain may only need a certain amount of drug to lower tau effectively. Beyond that level, the extra drug doesn’t help, but the higher local concentration can produce side effects. That is what the CELIA data is showing. The therapeutic window for intrathecal delivery, the range between too little and too much, appears narrower than the field assumed.

Subcutaneous TfR1-mediated delivery doesn’t work the same way. The drug enters the bloodstream gradually from the injection site under the skin. It crosses into the brain through receptor-mediated transit, which is a slower and more controlled process than direct CSF injection. The CNS exposure builds up gradually and stays within a narrower range. Arrowhead’s preclinical safety margin is more than 10 times higher than the effective dose, meaning the drug works at concentrations far below where any safety signals appear.

In other words, the dose-response problem that caused diranersen’s primary endpoint miss may be specific to intrathecal delivery. Subcutaneous delivery, by virtue of producing controlled CNS exposure rather than bolus injection, doesn’t face the same constraint. The very issue that complicated CELIA’s primary endpoint may not apply to ARO-MAPT.

There is a sharper version of this point worth making explicit. CELIA’s lowest dose worked best. That tells us less drug in the CNS at any given time produced better outcomes than more drug. The implication for ARO-MAPT isn’t just that subcutaneous delivery avoids the intrathecal-specific safety issue, the implication is that ARO-MAPT’s pharmacokinetic profile, the way the drug actually behaves in the body and brain, naturally operates in the favorable dose range CELIA identified.

Subcutaneous TfR1-mediated delivery produces lower CNS drug concentrations per dose than intrathecal bolus injection by design. The drug enters the brain gradually through receptor-mediated transit, not via direct injection into spinal fluid. The peak concentrations are lower. The exposure is spread over time rather than concentrated at the injection site. This is the dosing profile CELIA found to produce the best clinical outcomes.

Two practical consequences follow. First, ARO-MAPT doesn’t need to discover the right dose through Phase 2 dose-escalation the way diranersen will. Diranersen’s Phase 3 design will be complicated by needing to return to the lowest dose (60 mg every 24 weeks) after running higher doses that introduced safety concerns. ARO-MAPT, by virtue of its delivery mechanism, naturally operates in the favorable range without needing to discover it. Second, the clinical optimum (low CNS exposure, less frequent dosing) matches the commercial optimum (convenient delivery, infrequent administration). These don’t always align in drug development. For ARO-MAPT, they do.

This isn’t speculation. It follows from how the two delivery systems actually work biologically.

Why the first-mover advantage concern is overstated

The standard analytical instinct on competitive timing says diranersen is 4-6 years from potential FDA approval (Phase 3 design, enrollment, follow-up, NDA review, FDA approval process) while ARO-MAPT is 5-7 years away on the same timeline. Diranersen has roughly a 1-2 year lead. The standard framing would be that this lead matters because the first drug to market in a new category typically captures durable competitive advantage.

This framing misreads the dynamics of chronic disease therapy with structurally different delivery modalities. Several real-world examples explain why.

Look at GLP-1 obesity therapy. Wegovy (subcutaneous semaglutide) launched into a market with multiple existing weight loss approaches, including older pills that had been on the market for years. The structural advantage of the GLP-1 mechanism plus a self-injectable subcutaneous pen enabled rapid market displacement of less convenient options despite their first-mover status. Patients and physicians shifted to the better delivery profile once it became available. The earlier-approved drugs lost market share.

Look at biologic drugs for autoimmune disease. Adalimumab (Humira) went from monthly clinic infusions in early development to bi-weekly self-administered subcutaneous injections, and captured massive market share against earlier-approved options. Across multiple autoimmune disease categories, the same pattern: infusion-based therapies systematically displaced by subcutaneous self-injectable options as they became available.

Look at insulin therapy. Rapid-acting insulin analogs displaced regular insulin not because of first-mover advantage but because of structural improvement in patient convenience. Long-acting insulin analogs displaced earlier basal insulin options for the same reason. The structural advantage of better delivery wins, even against earlier-approved competitors.

The principle is consistent. In chronic disease therapy, the prescription decision isn’t a one-time event, it gets reconsidered constantly. As long as a structurally better option becomes available, patients and physicians switch. Brand loyalty doesn’t override structural advantages in delivery, convenience, or safety.

For Alzheimer’s specifically, this dynamic is especially powerful. Patients require chronic therapy over many years. The population is overwhelmingly aging adults managing complex medication regimens. Caregivers, often spouses or adult children, carry significant treatment burden. Geographic accessibility matters because most patients don’t live near a specialized neurology center. The difference between quarterly intrathecal procedures (requiring a clinic visit, a sterile environment, an interventional radiology team, and recovery time) and quarterly subcutaneous injections (administered at home by a patient or caregiver) is enormous.

Diranersen, if approved first, will compete with subsequent therapies on delivery, dosing convenience, safety profile, and clinical effect. ARO-MAPT’s subcutaneous quarterly dosing isn’t a marginal improvement over intrathecal, it’s a structural difference that matches how patients actually want to receive chronic therapy. The first-mover advantage that matters in chronic disease isn’t who launches first, it’s who matches what patients need over decades of treatment.

This same dynamic explains why ARO-MAPT is structurally suited to the rarer tauopathies (PSP, CBD, FTD-MAPT) that diranersen cannot economically address. These rarer diseases have patient populations too small to support intrathecal infrastructure (specialized clinics, trained interventional staff, dedicated procedure suites) but more than large enough to support subcutaneous home administration. Diranersen’s commercial reach is limited to Alzheimer’s disease. ARO-MAPT, if it works, addresses the entire tauopathy spectrum, including diseases where intrathecal therapy simply isn’t viable.

The CNS-mediated obesity opportunity

Chris made an explicit disclosure at the Bank of America conference yesterday that hasn’t been widely discussed but is worth understanding. The question was whether obesity could be partnered. His answer:

“We are positioned to take all these for ourselves, and that’s our posture right now. I think there’s a ton of value there. We really like blowing out obesity ourselves, not just INHBE and ALK7, not just the dimers that could be made with those two candidates, but other ones. I mentioned CNS. There are really interesting obesity candidates in the brain, and we’ll have data from ARO-MAPT, our first sub-q administered CNS drug. We’ll have data later this year, and if that’s positive, then that opens up a whole new area for obesity.”

This is a substantive new framing. The Q2 prepared remarks mentioned obesity alongside CNS but didn’t explicitly link the platform validation to obesity TAM expansion. Chris is now saying directly that ARO-MAPT validation opens up CNS-targeted obesity therapy.

Why does this matter? Obesity is one of the largest commercial opportunities in medicine. The current GLP-1 franchise (Lilly’s Mounjaro/Zepbound, Novo’s Ozempic/Wegovy) generates tens of billions of dollars in annual revenue. The market is still growing rapidly as treatment expands. The bottleneck for next-generation obesity therapy is finding combinations and mechanisms that produce additional weight loss, better fat distribution effects, and improved long-term outcomes beyond what GLP-1s alone can deliver.

CNS-mediated obesity therapy targets the brain pathways that regulate appetite, energy expenditure, and metabolic control. The brain is where hunger signals originate, where satiety is registered, where reward pathways drive eating behavior. Drugs that act on CNS pathways have historically been limited by delivery, the inability to selectively target brain receptors without crossing safety thresholds in peripheral tissues. Subcutaneous TfR1-mediated delivery solves this problem. The drug crosses the blood-brain barrier through the receptor mechanism, achieving CNS exposure at doses far below where peripheral side effects would emerge.

Chris elaborated specifically: “It’s inconceivable to me that an obesity therapy could be administered by intrathecal injection. It is certainly conceivable of an obesity therapy could be a simple subcutaneous injection at home, once every two or three months.”

This is the platform extension logic made commercially specific. ARO-MAPT validates that TRiM SC can deliver siRNA drugs into the brain at therapeutic concentrations using a quarterly subcutaneous injection. Once that’s validated, the same delivery system can carry siRNAs targeting CNS pathways relevant to obesity. The platform isn’t just for neurodegenerative diseases, it’s the gateway to centrally-acting therapies across multiple therapeutic areas, with obesity being among the largest commercial opportunities.

Chris’s framing here is decisive. Arrowhead has $1.8 billion in cash and is positioned to retain the obesity franchise wholly-owned. Plozasiran, zodasiran, ARO-DIMER-PA, and the obesity programs (ARO-INHBE, ARO-ALK7, dimer variants, plus the CNS-mediated obesity opportunity ARO-MAPT enables) are all explicitly off the partnership table. The strategic posture is to capture this value within Arrowhead, not distribute it to partners.

Updated probability framework

This early morning’s TIDES note outlined a three-biomarker framework for interpreting ARO-MAPT’s eventual full readout. The three numbers were spinal fluid tau reduction, plasma p-tau217 movement, and Tau PET signal direction. With the BofA clarification that the late-2026 readout is healthy volunteer data, the framework needs calibration to what’s actually measurable in healthy volunteers.

The cleanest healthy volunteer biomarker is spinal fluid tau reduction. Healthy volunteers don’t have AD pathology, so Tau PET reduction and p-tau217 movement aren’t expected at this stage, those biomarkers track disease-relevant tau in patients with established pathology. What healthy volunteers do have is normal tau production, which subcutaneous delivery should be able to suppress measurably.

The expected number from Arrowhead’s preclinical model is 50% or greater reduction in spinal fluid tau. Diranersen’s Phase 1b in patients showed approximately 60%. ARO-MAPT’s preclinical NHP data showed greater than 70% mRNA knockdown and 50-65% protein reduction. The healthy volunteer readout testing whether subcutaneous TfR1-mediated delivery achieves this benchmark in humans is the central question for the late-2026 catalyst.

Safety and tolerability data is the parallel question. Healthy volunteer studies test what doses the drug can be given at without producing meaningful side effects. The TRiM SC preclinical safety margin (more than 10x above the effective dose) supports the expectation that ARO-MAPT will be well tolerated. CELIA’s inverse dose response finding actually strengthens this expectation because it suggests the relevant safety constraint is delivery-specific to intrathecal, not a general property of tau lowering.

The AD patient cohort data, which will test cognitive endpoints and tau pathology imaging, comes later in 2027 from the multi-ascending dose portion of the trial. By that point, the platform translation question will have been answered by the healthy volunteer data. The patient cohorts will test clinical efficacy given that the underlying pharmacology has been validated.

Probability framework: the probability that ARO-MAPT shows positive healthy volunteer biomarker effects has increased meaningfully based on CELIA. The mechanism is clinically validated. The biomarker bar (50% or greater spinal fluid tau reduction) is established by diranersen’s intrathecal data. The structural delivery advantage suggests ARO-MAPT should meet or exceed those benchmarks. The safety expectation is reinforced by the preclinical margin combined with the inverse dose response evidence that intrathecal delivery, not tau lowering itself, is what constrains tolerability.

Chris Anzalone’s framing at BofA puts this in context: “If those are the case, you know, it opens up a lot of opportunities for us in CNS and beyond. And we’re preparing for that, we’ve got a number of CNS programs that should this initial readout be positive, we’re going to push as quickly as we can. I think you’ll see a number of new CNS candidates in clinical studies in 2027, and you might see the first one at the end of 2026.”

This is operational specificity beyond what Q2 disclosed. First new CNS candidate could enter clinical development at the end of 2026. Multiple candidates entering clinical studies in 2027. The pipeline expansion isn’t a single program launch, it’s a multi-program rollout queued and ready to execute on positive readout.

What this means for the broader thesis

CELIA’s clinical validation of tau-targeting therapy extends beyond the immediate ARO-MAPT readout question. Several specific implications worth thinking through.

The platform extension story gains commercial concreteness in two directions. First, validated tau lowering supports the broader tauopathy commercial opportunity. PSP (progressive supranuclear palsy), CBD (corticobasal degeneration), and FTD-MAPT (frontotemporal dementia caused by mutations in the tau gene) all become more concrete commercial opportunities for any drug that can reach the brain regions where these diseases live. ARO-MAPT can. Intrathecal therapies struggle to. Second, Chris’s explicit framing of CNS-mediated obesity as a downstream opportunity opens the platform to an entirely separate commercial vector. ARO-MAPT validation isn’t just about tau, it’s about establishing that the TRiM SC platform delivers therapeutic doses of siRNA into the brain via subcutaneous injection. That platform capability applies across CNS pathways relevant to obesity, addiction, mood disorders, and other indications.

The acquisition framework strengthens. The investment thesis I’ve been developing across The Setup and The Endgame argues that Arrowhead becomes a strategic acquisition target if ARO-MAPT validates the platform. For potential acquirers like Lilly and Roche, the validated tau hypothesis makes CNS franchise value more defensible. Synergy estimates for the CNS component become more concrete because the underlying mechanism is now clinically proven, not just preclinically validated. The CNS-mediated obesity opportunity strengthens Lilly’s and Roche’s strategic case specifically, given Lilly’s tirzepatide franchise and Roche’s CT-388 obesity drug in Phase 3, and the established combination logic with Arrowhead’s ARO-INHBE program.

The wholly-owned strategic posture is decisive. Chris made clear at BofA that Arrowhead intends to retain plozasiran, zodasiran, ARO-DIMER-PA, and the entire obesity franchise (including CNS-mediated obesity) within the company. This concentrates the commercial value within Arrowhead rather than distributing it across partners. An acquirer wanting access to these programs has to acquire Arrowhead. The $1.8B cash position supports the standalone posture and reduces pressure to partner from a position of weakness.

The pipeline expansion commitment gets more specific and credible. As I argued in last week’s Q2 reaction note, substantial CNS pipeline expansion within months of a readout requires that programs be IND-ready today, sitting in the queue waiting to be triggered. Chris’s BofA framing (first new CNS candidate at end of 2026, multiple candidates in 2027) is more specific operational detail. CELIA’s clinical validation of the tau hypothesis means those queued programs are now anchored to a validated mechanism, not just to platform hope. The operational commitment Arrowhead made in May becomes more economically defensible after today’s data.

The competitive landscape clarifies. Diranersen, mivelsiran (Alnylam’s drug targeting amyloid via intrathecal delivery), and other intrathecal CNS RNA programs are now competing in a category where tau-targeting therapy works but where intrathecal delivery has specific limitations. ARO-MAPT enters this category with structural delivery advantages and the clinical validation that the underlying mechanism works.

What I’m watching for next

The four to six months between now and ARO-MAPT’s healthy volunteer readout include several developments worth tracking.

CELIA detailed data presentations at AAIC 2026 (the major annual Alzheimer’s research conference) and other scientific congresses. The topline release covered the headline findings. Detailed data on specific cognitive subtests, biomarker correlations, and patient subgroup analyses will provide more granular insight into how tau-targeting therapy actually works. KOL (key opinion leader) commentary at these conferences will shape the longer-term interpretation.

Biogen’s Phase 3 trial design and FDA discussions. The regulatory pathway for tau-targeting therapy in early Alzheimer’s is being established by Biogen’s discussions with FDA over the coming months. Whatever framework emerges, dose selection, patient population definition, endpoint requirements, will inform how the agency eventually evaluates ARO-MAPT’s registrational program. Watch for specific FDA guidance, breakthrough designation discussions, and trial design precedents.

Arrowhead’s ongoing Phase 1/2a execution. Late September through October 2026 remains the healthy volunteer readout window. Multi-dose AD patient cohort data follows in 2027. The trial is well underway, with single-dose healthy volunteer enrollment nearly complete and multi-dose cohorts (including AD patients) beginning. The next several months will produce the data that resolves the central translation question.

The R&D Webinar Summer Series. Arrowhead committed on the Q2 call to three educational webcasts, including one specifically on ARO-MAPT and the blood-brain barrier platform. Timing wasn’t specified beyond “the coming months.” Each webcast represents an opportunity for management to share additional context ahead of the readout.

ARO-ALK7 data updates through the second half of 2026. Chris framed the ARO-ALK7 readout this year as a parallel platform validation event to ARO-MAPT, testing safety, target knockdown, and whether the activin E/ALK7 axis translates from animals to humans with effects on weight loss and fat distribution. Arrowhead’s obesity franchise has multiple data points coming.

EASL ARO-INHBE late-breaker on May 27-30. The next major data event for the cardiometabolic franchise specifically. Combination data with tirzepatide will inform the obesity strategy and reinforce the partnership value with Lilly.

European Commission Marketing Authorization decision for REDEMPLO in Europe. The CHMP (Committee for Medicinal Products for Human Use, the European equivalent of an FDA advisory committee) issued a positive opinion in April. The EC decision in June-July formalizes the approval. The continued international commercial trajectory adds standalone value independent of the CNS thesis.

Bottom line

CELIA validates the tau hypothesis clinically. This is the single most important fact for Arrowhead’s investment thesis since the company began ARO-MAPT trials.

The primary endpoint miss is real but secondary. The data Biogen reported, taken together, demonstrates that tau-targeting therapy produces both biomarker engagement and cognitive benefit in early Alzheimer’s disease. The mechanism works. The bear case that has constrained tau-targeting therapy for years is answered.

ARO-MAPT enters its healthy volunteer readout window with the underlying mechanism clinically validated, structural delivery advantages over intrathecal alternatives, evidence that the inverse dose-response problem affecting diranersen may not apply to subcutaneous delivery, and a platform extension story that gained commercial concreteness today, both in the broader tauopathy spectrum and in the new CNS-mediated obesity opportunity Chris disclosed at BofA.

The first-mover advantage concern that some investors will raise about Biogen’s lead misreads how chronic disease therapy with structurally different delivery modalities actually plays out commercially. Patients on years-long treatment for Alzheimer’s will prefer quarterly subcutaneous injection at home over quarterly intrathecal procedures at a specialized clinic. The category of tau-targeting therapy is large enough for multiple winners, and the structural advantage of subcutaneous delivery is durable.

The framework I established early this morning in “ARO-MAPT: The Last Open Question“ held up against Biogen’s data. The healthy volunteer readout in late September through October remains the binary catalyst for platform translation. The probability that ARO-MAPT meets the biomarker benchmarks has increased based on CELIA’s validation of the mechanism.

The platform extension implications, the CNS pipeline expansion commitment, the acquisition framework, the wholly-owned cardiometabolic and obesity strategic posture, the broader investment thesis, all of these become more economically defensible after today.

The data itself will tell, but CELIA changed the question ARO-MAPT has to answer.

A Note on Supporting Independent Research

If this note has been valuable to you, whether it shaped your thinking, validated your conviction, or simply saved you the time of doing this work yourself, a voluntary contribution is genuinely appreciated and directly funds the next paper.

For individual investors and readers

Any amount you feel reflects the value you received is welcome and meaningful. A contribution in the range of what you might pay for a single premium research report is a thoughtful gesture that makes a real difference.

For family offices, investment funds, hedge funds, and research platforms

This paper is the caliber of work that institutional research desks bill significant retainers to produce. If your team referenced it, distributed it internally, or used it to inform a position, a suggested contribution of $1,000 reflects the professional value of the analysis, though any amount is meaningful. Your support makes it possible to continue publishing at this level without a paywall that limits the reach of the ideas. If your organization requires an invoice to process a payment, please reach out directly at bioboyscout@gmail.com and one will be provided promptly.

There is no obligation and no expectation. This is purely a thank you for work that meant something to you.

Zelle: (847) 227-7909
PayPal: paypal.me/bioboyscout

Thank you for reading, and for being part of a community that takes this thesis seriously.

— Robert Toczycki | BioBoyScout

Important Risks, Disclosures, & Disclaimers

The author, Robert Toczycki (aka BioBoyScout), certifies that:

• all views expressed in this note accurately reflect his personal opinions about the topic discussed; and

• he was not compensated in any form for producing this note.

This note is published by BioBoyScout and is intended for informational and educational purposes only. It does not constitute investment advice, a solicitation to buy or sell securities, or a guarantee of future results. The author holds a long position in Arrowhead common stock. Arrowhead Pharmaceuticals (ARWR) is a publicly traded company; investments in its shares involve material risks, including the risk of total loss. All financial projections, acquisition price estimates, and valuation analyses herein are hypothetical frameworks for analytical purposes and do not represent predictions of actual outcomes. Readers should conduct their own due diligence and consult a registered investment advisor before making investment decisions. All data cited herein were sourced from publicly available company disclosures, SEC filings, press releases, and peer-reviewed literature as of May 2026.

About the Author

Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has a deep passion for financial analysis, particularly identifying valuation discrepancies and demonstrating them through rigorous, data-driven research and solid analytics.

Comments or questions: bioboyscout@gmail.com.

Copyright © 2026, BioBoyScout. All Rights Reserved.

Subscribe now